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“Our doubts are traitors, and make us lose the good we oft might win, by fearing to attempt.” 
William Shakespeare, Measure for measure. 
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I. Introduction 
 
I.1 History of measles 
 
Measles is a relatively recent disease for humans that probably evolved from an animal morbillivirus. 
MV most closely resembles the rinderpest virus, a pathogen of cattle (Norrby et al, 1985; 
Sheshberadaran et al, 1986) and it is postulated that measles virus (MV) evolved in an environment in 
which cattle and humans lived in close proximity. Rinderpest is likely to have evolved from a “young 
cow” disease in herds of ungulates large enough to maintain a continuous supply of susceptible and 
establish a pattern of endemic infection. Measles is thus a disease of civilization because its 
emergence has coincided with the domestication of cattle and the first settlements, where the densely 
populated regions in the Middle East and India were needed to maintain the disease (McNeill, 1976).  
 
The fi rst case descriptions of measles were attributed to an Arab physician, Abu Becr, known as 
Rhazes of Baghdad. During the 9th century of the Christian era, he first distinguished measles from 
smallpox. Rhazes refers to measles as hasbah, “eruption” in Arabic, and considered it as a 
modification of smallpox (Hirsh, 1883): He considered that “anxiety of mind, sick qualms and heaviness 
of heart, oppress more in measles than in smallpox” (Rhazes, 1748). It is also known that the Hebrew 
physician, Al Yehudi, had come across measles infection as early as in the 7th century (Plotkin and 
Mortimer,  1992) 
 
Repeated epidemics were recorded in European and Far Eastern populations between 1 and 1200 
A.D. During this period, european descriptions of the disease are limited,  but it appears that measles 
spread across the Pyrenees into France with the Saracen invasion of the 8th century. Measles is first 
mentioned as a childhood disease in 1224 (McNeill, 1976). Initially, measles was thought to be a 
diminutive form of the bubonic plague but the distinction between measles and smallpox became 
clearer by the beginning of the 17th century when the annual bills of mortality in London in 1629 listed 
the two diseases separately (Plotkin and Mortimer, 1992). 
 
Many of the basic principles of measles epidemiology and infection were recognized only during the 
19th century by Peter Panum (Panum, 1940) but already in 1757, Francis Home was able to transmit 
the disease to naïve individuals using blood from patients (Plotkin, 1967). In 1954, Enders and Peebles 
were the first to grow the virus in culture by inoculating human kidney cells with the blood from David 
Edmonston, a child with measles (Enders et al, 1957). Later, the virus was adapted to other human 
and non-human cell lines (Katz, 1958; Ruckle and Rogers, 1957). These studies led to diagnostic tests 
for measles as well as to the development of the first vaccine. 
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I.2 The measles disease 
 
Measles is transmitted primarily by aerosol originating from mucous membranes of the upper 
respiratory tract or by direct contact with nasal or throat secretions of infected persons. Measles is one 
of the most readily transmitted communicable diseases and probably the best known and most deadly 
of all childhood rash/fever illnesses. The incubation period is about 10 days, varying from 8-13 days 
from exposure to onset of fever and about 14 days until rash appears. Measles is most contagious 1-3 
days before the onset of fever and cough and is minimal after the second day of rash.  
 
 
Fig 1: Progression of measles clinical symptoms. Numbers are days after infection 
 
The first signs and symptoms of measles are the warning (prodromal) fever (>38.3°C according to 
CDC case definition), conjunctivitis (inflammation of the mucous membrane of the eye), coryza 
(swollen nasal tissue and runny nose), cough and Koplik's spots (tiny red patches with central white 
specks on the buccal mucosa in which characteristic giant syncytial cells containing viral proteins are 
identified) (CDC, 1983). After the diffuse secondary spread of the virus, the prodromal symptoms are 
intensified and the typical red, maculopapular rash appears on the 3rd to 7th day,  first on the head and 
face, and then on the extremities, before becoming generalized, lasting 4 to 7 days after the beginning 
of prodromal symptoms, and sometimes ending in branny desquamation.   
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Fig 2: Child with measles rash 
 
The rash is thought to appear as a result of immune T-lymphocytes interacting with infected cells.  
Children who are T-cell deficient, due to thymic dysplasia, do not develop a rash, but develop 
extensive giant-cell pneumonia. A reduced white cell count is common (immunodepletion). The 
disease may be more severe in infants and adults. Moreover, in some cases MV can establish 
persistent infections of the brain leading to severe neurological complications (Chen et al, 1994).  
 
Vitamin A administered to children acutely ill with measles has been shown to reduce mortality and 
accelerate recovery from pneumonia and diarrhea. Administration of antibiotics is recommended to 
prevent bacterial complications, and oral rehydration salts for preventing dehydration following 
diarrhea. Case-fatality rates can be lowered if cases reach health care facilities early enough. For 
uncomplicated cases, supportive fluids, antipyret ics and nutritional therapy may be required. Many 
children need increased food intake for four to eight weeks to recover their pre-measles nutritional 
status. Diarrhea and respiratory complications are undoubtedly the most frequent. Uncommon 
complications include nephritis, myocarditis, pericarditis, hepatitis, ileocolitis and appendicitis.  
 
Encephalomyelitis is the most serious complication, appearing 5-7 days after the rash.  This occurs in 
1:2000 cases and is more frequent in children over 10 years.  Th e mortality rate is 10%, with 
permanent mental and physical sequelae reported in 15% to 65% of survivors. With measles 
encephalomyelitis, the brain shows perivascular hemorrhage and lymphocytic infiltration early in the 
disease.  Areas of demyelination appear later in the brain and spinal cord.   
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Subacute sclerosing panencephalitis (SSPE) is a progressive, fatal but rare (1 case per 1,000,000 
patients) complication of measles.  SSPE is an example of a single virus inducing an acute disease 
and a chronic illness separated by a long interval during which there is restricted synthesis and 
expression of viral genes. Patients with SSPE display a degeneration of the cortex and the underlying 
white matter. Perivascular infiltration of plasma cells and lymphocytes, scattered degeneration of nerve 
cells, hypertrophy of astrocytes, microglial proliferation and demyelination are also evident.   
 
I.3 Epidemiology 
 
Measles occurs worldwide. It has a seasonal appearance and in the temperate climates, outbreaks 
generally occur in late winter or early spring. In tropical climates, the occurrence increases after the 
rainy season. 
 
Fig 3: Map of measles incidence in the world (Source: WHO). 
 
Measles is the most contagious disease in humans. With a basic reproduction number of 15, a single 
patient is able to infect 15 susceptibles individuals. The WHO estimates that over 40 millions cases still 
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occur worldwide each year, contributing to about 800.000 deaths. In large populations with low vaccine 
coverage, like many developing countries, measles may be endemic and is occurring within short 
intervals. The duration is depending on factors such as population size, crowding and immunization 
status. In countries with high vaccination coverage, measles has a 5 to 7 years periodicity and the case 
number remains small. As the number of susceptible children becomes large enough to sustain 
widespread transmission, explosive outbreaks may appear (PAHO, 1999). 
Prior to measles vaccination, the measles infection was nearly universal. In 1974, the annual death toll 
from measles stood at about 8 million and there were an estimated 130 million cases. Immunity to 
measles was acquired by natural infection or by passive immunization of neonates by maternal 
antibodies transferred in utero to the fetus. This passive immunity wanes gradually as the growing 
infant dilutes and degrades maternal antibodies. The majority of infants are susceptible to measles by 
the age of 6-9 months in developing countries and 9-12 months in industrialized countries. After 
measles infection, the resulting immunity is believed to be protective for life, and measles vaccination 
has been shown to be protective for at least 20 years (Sutcliffe and Rea, 1996). Since the introduction 
of measles vaccines in the Americas in the sixties, the number of reported measles cases has declined 
rapidly. Both industrial and developing countries have experienced more than 99 percent reduction in 
incidence of reported cases as a result. The creation of the extended progr am of immunization (EPI) in 
1977, and the ensuing increase of vaccination coverage, contributed to a further drop in the number of 
reported measles cases and a tendency towards longer intervals between epidemics. 
 
However, measles remains endemic in many developing countries, with the largest proportion of cases 
reported to occur in children under the age of 5 years. In such areas, the interval between the waning 
of maternal antibodies and the child’s exposure to circulating measles virus is short. Measles highest 
mortality is sustained by children below 1 year of age. Other high-risk groups may include the urban 
poor; school children (who represent cohorts from previous years when coverage was lower and who 
may not have been exposed to measles infection); ethnic minorities (who may have been under-served 
or may have rejected immunization for cultural reasons); hospitalized children (who are at high risk of 
nosocomial transmission); and children in refugee camps (where crowding facilitates the spread of the 
virus).  
 
In both developed and developing countries, the epidemiology of measles has changed since the 
introduction of effective measles vaccines. As vaccine coverage has increased, there has been a 
marked reduction in measles incidence and an increase of the average age at which infection occurs. 
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I.4 The measles virus 
 
I.4.1 Description of the virus 
The measles virus (MV) is a negative -stranded RNA virus member of the genus Morbillivirus  in the 
family Paramyxoviridae. 
 
 
 
Fig 4: The Paramyxoviridae family. 
 
The morbillliviruses are antigenically stable and they differ from other paramyxoviridae by the lack of 
neuraminidase activity and the formation of intranuclear inclusion bodies. Virions are pleiomorphic 
(they do not have a defined shape) and their size ranges from 100 nm to 300 nm. The nucleocapsid 
has a helical structure with a diameter of 21 nm and a central hole of 5 nm (Lund et al, 1984).  
 
Family Paramyxoviridae 
Subfamily Paramyxovirinae  
Subfamily Pneumovirinae 
Genus Paramyxovirus  
Type species: human parainfluenza virus 1  
 
Genus Morbillivirus  
Type species: measles virus  
 
Genus Rubulavirus  
Type species: mumps virus  
 
Genus Pneumovirus 
Type species: human respiratory syncytial virus 
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Fig 5: E.M. Picture of measles virus (source: University of Cape Town Website, 1995). 
 
 
I.4.2 Structure, proteins and cycle of replication 
All MV proteins are encoded in the 15894 nucleotides of a non-segmented single-stranded RNA of 
negative polarity. There are 6 structural proteins: The hemagglutinin protein (H protein, 617 amino-
acids), the fusion protein (F protein, 553aa), the nucleoprotein (N protein, 525aa), the phosphoprotein 
(P protein, 507aa), the matrix protein (M protein, 335aa) and the large protein (L Protein, 2213aa) and 
two functional proteins only present in the target  cell, the C protein (186aa) and the V protein (298aa). 
 
The genome of the measles virus is encoded in a single stranded RNA, surrounded by the N protein, 
the primary protein of the nucleocapsid. The P protein and the large protein are also associated with 
the RNA (Lund et al, 1984) to form the nucleocapsid, which is packed in the lipid phosphobilayer 
envelope as a symmetrical coil. On the inside of this envelope, we find the M protein which is though to 
interact with the nucleocapsid and the two surface proteins H and F. 
 
 18 
 
 
Fig 6: Schematic representation of measles virus. 
 
The MV genome (Alkhatib and Briedis, 1986; Bellini et al, 1986; Bellini et al, 1985; Blumberg et al, 
1988; Richardson et al, 1986) starts with a 55 nucleotide  leader sequence (Billeter et al, 1984) that 
shows a high degree of complementarity to a similar sequence at the 5’ end of the genome, suggesting 
the possibility of the formation of a panhandle sequence (Crowley et al, 1988). It also has a non-coding 
region between the M and F genes. The 6 major structural proteins are encoded by the 6 genes (Fig 7) 
and the two additional non-structural proteins are coded by differential translation form the P gene. 
 
3’end                                                                                                                                  5’end 
 
 
 
 
Fig 7: Genome of the measles virus. 
 
I.4.3 Genetic variability  
MV is considered as an antigenically stable monotypic virus. Antisera from individuals infected 
decades ago retain the ability to neutralize current wild-type strains. Nevertheless, MV has an RNA-
dependent RNA polymerase with an inherent error rate and no proofreading ability allowing some 
degree of variability. 
Hemagglutinin protein 
Fusion Protein 
Lipid Bilayer 
Matrix protein 
Viral RNA (-) 
Nucleoprotein 
Phosphoprotein 
Large protein 
N P\V\C L M H F l 
Noncoding 
region 
Leader 
sequence 
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Few differences have been described among the current vaccine strains regardless of the geographic 
origin of the parent virus, suggesting that MV globally was quite similar when most of the parents’ 
strains were isolated (Rota et al, 1994). Wild-type viruses are more variable and a number of different 
lineages of MV are currently circulating worldwide (Ogura et al, 1991, Mulders et al, 2001). 
Measles isolates from many regions of the world have been characterized in parallel studies by our 
laboratory and by others. In conjunction with classical epidemiologic investigations, these well-
characterized viruses have formed a picture of the distribution of wild-type measles viruses in most 
parts of the world. Eight distinct genotypes have been identified (designated A – H) and the number of 
genetic groups is likely to increase since the full extent of genetic heterogeneity among wild-type 
measles viruses is still unknown. Most genetic groups have worldwide distribution except for two of the 
groups (Clades B and H) which appear to have a more limited circulation (Bellini and Rota, 1998). 
Clade A consists of vaccine and vaccine-related wild -type viruses (Rota et al, 1994), and it is thought 
to have been a major genotype before routine vaccination was introduced in the late 60s. However, 
before the introduction of the B95a cell line, which is 10.000 times more efficient for MV isolation 
(Kobune et al, 1990), most MV were isolated on Vero cells, which may have introduced a selection 
bias. 
In most cases, genetic characterization of wild-type measles viruses has been conducted by 
sequencing the genes coding for the hemagglutinin (H) protein or the nucleoprotein (N). Of the six 
genes on the viral genome, the H and N genes are the most variable. Over their protein coding 
regions, the H and N genes vary by up to 7% at the nucleotide level. The single most variable part of 
the measles genome is the 450 nucleotides that code for the COOH-terminus of the N protein, where 
nucleotide variability between various wild-type viruses can approach 12%. Several laboratories 
including our own have analyzed the sequences of wild-type measles viruses and assigned the viruses 
to various genetic groups (Rota et al, 1996; Taylor et al, 1991b; Mulders et al, 2001). 
 
Despite sequence variability, the genetic groups are still antigenically similar, allowing cross-protection 
from viruses of all groups using current vaccine strains developed from one of those groups. However 
cross-neutralization studies indicate that sera from recently infected individuals neutralize some wild-
type viruses six to eight times better than they neutralize the vaccine strain, this could be explained by 
a selective pressure in favor of viruses genetically distant from the vaccines strains (Bellini et al, 1994). 
This phenomenon may lead in the future to the emergence of antigenic variants of the measles virus. 
 
I.4.4 Biological properties of the structural proteins of MV 
I.4.4.1 The hemagglutinin protein (H protein) 
The H protein is one of the two surface proteins of the MV. It is a type II transmembrane glycoprotein 
that consists of 617 amino acids. The hydrophobic transmembrane domain of the N terminus acts as a 
signal sequence for targeting the protein to the endoplasmic reticulum, as well as a membrane anchor 
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(Hummel and Bellini, 1995). The main function of the H protein is to initiate the infection by binding the 
virus to the receptors on the target cell (Varsanyi et al, 1984), and it cooperates with the F protein to 
mediate the fusion of the virus with the membrane of the target cell (Schmid et al, 1992; Taylor et al, 
1991a; Wild et al, 1991). It is therefore not surprising that the H protein is the main target of neutralizing 
antibodies and a large number of B-cell epitopes have been documented on this protein (Makela et al, 
1989; El Kasmi et al, 1998; Beauverger et al, 1994). 
 
This protein is present on the surface of virus-infected cell and virions as a disulfide-bridged 
homodimer (Alkhatib and Briedis, 1986). The H protein is folded and dimerized in the endoplasmic 
reticulum (Bellini et al, 1983; Malvoisin and Wild, 1993). It has 13 highly conserved cysteines in the 
extracellular domain that form intra- and intermolecular disulfide bonds. These are critical for 
maintaining the three-dimensional structure of the protein, and thus its antigenic characteristics (Hu 
and Norrby, 1994). There are 5 predicted glycosylated positions in this glycoprotein (Alkhatib and 
Briedis, 1986), but the one at position 215 is heterogeneous. The glycosylations play an important role 
in the folding, dimerization and export from the Golgi apparatus as well as for the antigenicity of the 
protein (Griffin, 1996).  
 
Both hemagglutination and hemadsorption are properties of the H protein (Takenhara et al, 1992; 
Varsanyi et al, 1984). Strains of MV that vary in hemagglutinating ability have been described. Many 
recent wild-type MV isolates have low hemagglutination ability (Saito et al, 1992) and many of these 
viruses encode an H protein with an additional glycosylation site at residue 416 (Saito et al, 1995; Saito 
et al, 1994). 
 
I.4.4.2 The fusion protein (F protein) 
The F protein is another surface glycoprotein of the MV. It is a type I membrane protein constituted of 
553 amino acids, anchored in the viral membrane by a C-terminal hydrophobic domain. Its sequence is 
highly conserved. The protein is synthesized as a biologically inactive polyprotein of 60kd. After 
translation, the F protein is glycosylated, which is necessary for further processing, tetramerized and 
transported to the plasma membrane. In the trans-Golgi compartment, the protein is cleaved by a 
protease of the host-cell to generate a 41kd F1 and an 18kd F2 disulfide-linked mature F protein 
(Hardwick and Bussel, 1978). The N-terminus of F1 contains a highly conserved sequence of 
hydrophobic amino acids. This region is postulated to mediate virus fusion with the cell. This process 
can also be blocked by F-specific virus neutralizing antibodies. Fusion occurs preferentially when the H 
protein is present (Schmid et al, 1992; Taylor et al, 1991a; Wild et al, 1991) and F1 seems to be 
interacting with H using a cystein-rich region (337-381). The F protein plays also a role in viral budding 
(Cattaneo and Rose, 1993). 
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While both surface glycoproteins, H and F, induce virus -neutralizing antibodies, the fusion protein 
seems to be considerably less immunogenic. The F protein is easily accessible to humoral immunity 
but also to an MHC-II restricted response as is apparent from large amount of CD4+ epitopes found on 
this protein (Muller et al, 1995; Partidos and Steward, 1990; Partidos et al, 1991; Partidos and 
Steward, 1992; Obeid and Steward, 1994; Steward et al, 1995; Obeid et al, 1995; Atabani, 1997). 
 
I.4.4.3 The nucleoprotein (N protein) 
The mRNA of the nucleoprotein is the first and most efficiently transcribed protein. The N protein is 
also the most abundant of the measles proteins. The N protein is synthesized on free ribosomes and 
folded in the cytoplasm (Gombart et al, 1993). It self-assembles into the nucleocapsid containing the 
RNA (Fooks et al, 1993) but usually surrounds viral genomics and messenger RNA possessing the 
leader sequence (Castaneda et Wong, 1990) to form the nucleocapsid. This structure is the required 
template for both replication and transcription and constitutes the ribonucleid complex with the P and L 
proteins (Ray and Fujinami, 1987). Due to its abundance in infected cells, the N protein is a major 
antigen of the measles virus, although it does not generate neutralizing antibodies and contributes only 
indirectly to virus clearance. Its intra -cytoplasmic function and origin triggers MHC-I type of response 
and a number of CTL-epitopes are known on this protein (Nanan, 1995; Beauverger et al, 1993).  
 
I.4.4.4 The phosphoprotein (P protein) and the C and V proteins 
The P protein is a 72kd phosphorylated protein that binds to the nucleoprotein and the RNA. The P 
protein also takes part in the replication complex (Huber et al, 1991; Robbins and Bussel, 1979; 
Stallcup et al, 1979). The P protein is very sensitive to proteolysis and is found in limited number in the 
packaged vi rus despite its abundance in the infected cell. The P gene codes also for two other 
proteins, the C and V proteins. The C protein is encoded by the same mRNA using a different AUG 
codon and overlapping reading frame (Bellini et al, 1985). The V protein shares the initiator methionine 
and the amino-terminal 231 amino acid residues of the P protein but has a shift in the reading-frame 
due to an extra non-template-directed guanosine residue at position 751, resulting in replacement of 
the last 276aa of the P mRNA with a cysteine-rich sequence of 68 residues (Cattaneo et al, 1989) with 
zinc-binding properties (Liston and Briedis, 1994). The function of C and V protein in uncertain but they 
are required for efficient MV replication indicating that they may play a role in the regulation of 
transcription and/or replication. The immunological role of the P, C and V proteins is minimal. 
 
I.4.4.5 The matrix protein (M protein) 
The matrix protein constitutes the major protein of the envelope. M interacts with the F and H 
transmembrane proteins by several conserved hydrophobic regions. In infected cells, the M protein are 
associated with the nucleocapsid and with the inner layer of the plasma membrane, suggesting that it 
may play a role in the viral budding by stabilizing or organizing the membrane environment (Tyrell and 
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Ehrnst, 1979). The M protein elicits only small amounts of antibody, except in atypical measles (Graves 
et al, 1984; Machamer et al, 1980) and has only a minor immunological role. 
  
I.4.4.6 The large protein (L protein) 
The large protein is a 2213aa protein is highly homologous to the polymerases of other negative 
stranded viruses (Blumberg et al, 1988). It is present in small quantities in the infected cells and is 
associated with the viral nucleocapsid in the cell and in the virion. Little is known about the 
immunological role of L but it is probably minimal. 
 
I.4.5 Main target cells and receptors 
CD46 and the newly discovered CDw150 molecule are the two identified cellular receptor for measles 
virus (Naniche et al, 1993; Tatsuo et al, 2000).  
 
The CD46 (also know as Membrane Cofactor Protein or “MCP”) is a 55-67kd type I transmembrane 
protein that binds to the complement’s proteins C3b and C4b to permit their degradation by Factor I. 
 
Fig 8: Structure of CD46 
This cell receptor is present on hematopoietic and non-hematopoietic nucleated cells. Its cellular 
function is to set a protective barrier threshold against inappropriate complement activation and 
deposition on plasma membranes, especially by the alternative pathway of complement activation, by 
limiting formation and function of the C3 convertases (Liszewski et al, 1991). The expression of CD46 
is downregulated by infection with some MV strains (vaccine strains) but not by others (wild type 
strains). This suggested that CD46 is the main receptor for the vaccine-like strain but not for the wild 
type viruses (Gerlier et al, 1994; Schneider-Schaulies et al, 1995a, b; Buckland and Wild, 1997). 
Crosslinking CD46 downregulates IL-12 production. This may be especially important in the 
immunosuppressive sequelae of measles infections (Liszewski et al, 1996). Different isoforms (by 
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alternate exon splicing plus glycosylation) exists but no distinct functions have been attributed to these 
tissue-specific isoforms (Johnstone et al, 1993). In human, CD46 is found on salivary gland ducts and 
kidney ducts, moderately on lymphocytes and endothelium, weakly on interstitial tissues and muscle 
cells. Its expression is often increased on tumor cells and CD46 is not expressed on human 
erythrocytes (Gerlier et al, 1995). A CD46 homolog has been identified in African monkeys but mice do 
not seem to have a similar protein (Liszewski and Atkinson, 1992; Naniche et al, 1992; Nickells and 
Atkinson, 1990). 
 
CDw150 (also known as Signalling Lymphocytic Activation Molecule or “SLAM”) is a membrane 
glycoprotein expressed on lymphocytes and dendritic cells, and plays an important role in lymphocyte 
activation (Tatsuo et al, 2000; Yanagi, 2001). A binding assay with a soluble form of meas les virus H 
protein demonstrated that B-cell lines, activated with Epstein-Barr virus, or T cells, transformed with 
human T-cell leukemia virus, exhibit this receptor on their cell surfaces. On the other hand, resting 
lymphocytes, monocytes, or immature leukocytes either failed to express or possessed reduced levels 
of this receptor (Hsu et al, 2001). After infection of cells, and after surface contact with MV envelope 
proteins, SLAM is downregulated from the cell surface of activated PBL and cell lines (Erlenhoefer et 
al, 2001). Some authors suggest that measles viruses in patients use SLAM but probably not CD46 as 
a cellular receptor (Ono et al, 2001). Furthermore, most measles, canine distemper, and rinderpest 
virus strains examined could use any of the human, canine, and bovine SLAMs to infect cells. This 
data suggest that the use of SLAM as a cellular receptor may be a property common to most 
morbilliviruses and may explain the lymphotropism and immunosuppressive nature of morbillliviruses 
(Tatsuo et al, 2001).  
 
Other possible candidate receptors have been identified on cells of hematogenous, epithelial, 
fibroblastic and neural origin. These candidate receptors include 20 kd and 30.6 kd proteins on Vero 
cells identified with an anti-idiotipic antiserum (Krah and Choppin, 1988) and a substance P-binding 
protein on neurons (Harrowe et al, 1990). Moesin (a membrane-organizing extension spike protein) on 
human leukocytes and astrocytes cell lines was thought to be one of the candidate receptor (Dunster 
et al, 1994) but appeared to be an experimental artifact. 
 
I.4.6 Cycle of the virus 
As mentioned before, measles is mainly transported by respiratory droplets ejected from the 
respiratory tract from infected individuals. These droplets will penetrate the lungs of  the naïve 
individuals during the respiration cycle. The infection starts with the adsorption of the virus on tracheal 
and bronchial epithelial cells (Sakaguchi et al, 1986; Sherman and Ruckle, 1968) and pulmonary 
macrophages (Kamahora and Nii, 1961; Sergiev et al, 1960) using the H protein. Viral infectivity 
requires maturation of the F glycoprotein probably induced by a conformational change of the H protein 
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after adsorption. This transmembrane protein initiates fusion with the plasma membrane as a means of 
introducing the viral genome into the cytoplasm. The nucleocapsid is thus liberated into the cytoplasm 
of the target cell (Lecouturier et al, 1996). 
 
Fig 9: Cycle of measles virus 
The genomic RNA is tightly wrapped around the N protein to form a helicoidal structure to which the P 
and L proteins are attached. This ribonucleoproteic complex (RNP), and not the naked genome RNA, 
is the template for both transcription and replication. Upon infection, the RNP complex is released into 
the cytoplasm of the hos t cell and transcription of viral genes occur using endogenous NTPs as 
substrates. The product of the L gene, the RNA -dependant RNA-polymerase, plays a key role in 
transcription and replication. Although it is distributed along the RNP complex, the polymerase can 
initiate RNA synthesis at the 3'-end of the MV genome only. Viral mRNAs are capped and 
polyadenylated. Each gene is flanked by untranslated 3' and 5' regions. Between the gene-end 
boundaries are intergenic regions which contain exactly 3 nucleotides. During transcription, the 
polymerase skips these intergenic regions and re-initiates synthesis at the downstream promoter. 
Since the polymerase may fall off the RNA template after transcription termination of any gene, 
transcript initiation at the next ORF occurs less frequently. Accordingly, there is a gradient in the 
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relative abundance of the different mRNAs, which follows the order of the genes from the 3' to the 5' 
end of the viral genome. The re-initiation frequency is estimated to be about 50% but more pronounced 
gradients have been observed in the case of persistent infections of the human brain. Moreover, in 
these patients the P-M gene junction may be specifically ignored by the polymerase, thus resulting in 
the production of bicistronic mRNAs. As only the first ORF is translated, this phenomenon leads to the 
down-regulation of M gene expression. Translation of the N, P, L and M proteins takes place in the 
cytoplasm whereas the H and F surface proteins are synthesized in the endoplasmic reticulum and 
undergo a conformational maturation before being transported to the surface. Surface expression of 
these proteins induces cell fusion with non-infected cells leading to the formation of giant 
multinucleated cells. 
 
I.4.7 MV genome replication 
Following primary transcription and translation of viral genes, the polymerase switches to a processive 
mode and ignores the gene junctions to synthesize a full, complementary strand of genome length. 
This positive-stranded RNA (antigenome) does not serve as a template for transcription and its unique 
role is to provide an intermediate in replication. The intracellular concentration of the N protein is 
thought to be the main element controlling the relative rates of transcription and replication. When N is 
limiting, the polymerase would be preferentially engaged in transcription, thus leading to an increase in 
the intracellular concentration of viral proteins, including N. When N levels are high enough to allow 
encapsidation of the RNA chain, the polymerase would switch to a replication mode. Since 
encapsidation and genome synthesis are concomitant, a helicase-like activity responsible for the 
separation of the neosynthesized RNA strand from the template must exist. The polymerase acts in 
concert with the N and P proteins, as indicated by the observation that both proteins are strictly 
required for in vitro transcription and replication. Conversely, C and V proteins are not essential 
components of the replicative complex. They are supposed to play a role in the regulation of the switch 
between transcription and replication.  
 
After synthesis of viral RNA, the (-) genome is rapidly associated with the nucleoprotein, N.  The N 
protein appears to provide the genomic RNA with an appropriate configuration for transcription and 
replication. The N protein is then associated with the P and L protein to form the nucleocapsid. This 
structure moves to the plasma membrane where it is associated with the M proteins. Electron 
microscope studies reveal the genome associating with the viral matrix proteins at the plasma 
membrane.  This region of the membrane appears thickened, due to the presence of H and F proteins.  
From here, the virus is released from the cell by budding.  Viral replication takes about 24 hours 
(Plotkin and Mortimer, 1992; Lamb et al, 1996) 
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During 2-4 days, MV replicates locally in the respiratory mucosa. After this initial period, there is an 
extension of the infection to the local lymphatic tissues, perhaps carried by pulmonary macrophages 
(Kamahora and Nii, 1961; Sergiev et al, 1960). MV replication in lymphoid tissue results in the 
appearance of lymphoid or reticuloendothelial giant cells first described by Warthin (1931) and 
Finkeldey (1931). These are multinucleated cells resulting of the fusion of MV infected cells. These 
cells are thought to be a major source for spread to other tissues. The amplification of the virus in the 
regional lymph nodes results in the appearance and spread of the virus through the blood to infect a 
variety of organs. The primary cell infected in the blood is the monocyte (Esolen et al, 1993). MV 
infection of macrophage cell increase the expression of LFA1, and the cell entry into the tissue is 
increased (Attibele et al, 1993). The late stages of the infection are accompanied by leucopenia. 
 
The lymphoid organs (thymus, spleen and lymph nodes) and the lymphoid tissues (tonsils, appendix) 
are the main sites of virus replication in the body (Hall et al, 1971; Ono et al, 1970; Sakaguchi et al,  
1986) although MV also spread into the skin, conjunctivae, kidney, lung, gastrointestinal tract, liver, 
respiratory and genital mucosa. In these sites, the virus replicates primarily in endothelial cells, 
epithelial cells, monocytes and macrophages. The maculopapular rash is generated by the infection of 
the dermal endothelial cells (Blake and Trask, 1921; Kimura et al, 1975a; Kimura et al, 1975b) followed 
by the spread of the infection into the overlying epidermis with infection of epithelial cells in the stratum 
granulosum leading to focal keratosis and edema. Epithelial giant cells form and a perivascular 
mononuclear infiltrate accumulates (Denton, 1925; Ewing, 1909). Koplik’s spots are pathologically 
similar, with involvements of submucous glands (Denton, 1925). 
 
I.4.8 Cytopathic effects 
Under a microscope, MV replication in cell culture monolayers of permissive cell lines results in 
cytopathic changes (Enders et al, 1957). The formation of multinucleated giant cells results from fusion 
of infected cells with uninfected cells. Infected cells also may change from a normal polygonal shape to 
a stellate, dendritic or spindle-shaped appearance with increased refractivity to light (Milovanovic et al,  
1957). Both spindle-shaped cells and syncytial cells may contain intracytoplasmic and intranuclear 
inclusion bodies. Cytoplasmic inclusions contain RNA encapsidated with N protein and covered with P 
and M proteins (Bohn et al, 1990; Robbins et al, 1980). 
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Fig 10: Electron micrograph of a hamster brain infected with an SSPE strain of MV. 
The arrows show nucleic inclusion bodies. 
 
I.5 Immunity to measles 
 
I.5.1 Immune response to the Virus 
The immune response to MV is important for clearance of the virus and recovery from infection. Both 
the humoral immunity (Black, 1989) and the cellular immunity (Uytdehaag et al, 1994) are necessary to 
stop measles infection.  
After the early infection of the lungs, the innate immunity will try to control the infection. NK cells will 
lysate the infected cells although they are downregulated during MV infection. The abrogation of the 
NK response may be another element explaining the observed immunosupression during measles 
infection (Griffin et al, 1990b). Macrophages can even phagocyte free MV and destroy it. 
The peripheral blood mononuclear cells (PBMCs) start to proliferate (Besser et al, 1967; Ward et al,  
1990), and local inflammatory effect induced by cytokines increase the presence of leukocytes in the 
tissue, due to vasodilatation and adhesion molecules expression. Polyclonal activation of B cells 
occurs (Griffin et al, 1985) and activation antigens are expressed on T cells (Griffin et al, 1986). The 
concentration of cytokines and soluble cell surfaces proteins also increases (Furukawa et al, 1992; 
Griffin et al, 1989; Griffin et al, 1992).  
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Fig 11: Pattern of cytokines changes in plasma during uncomplicated measles. 
These patterns suggest early CD8+ T-cell activation followed by th2 CD4+ T-cell activation.  
 
Production of TNF-a, IL1 and IL6 by the macrophage induces prodromal fever. Cell infected by MV will 
also produce interferons that will induce anti-viral state (Jacobson and McFarland, 1982; Volckaert-
Vervliet and Billiau, 1977). INF -a and INF-b production seems to be induced by the presence of 
double-stranded RNA in the cell. Such interferons seems to inhibit the viral replication due to the 
activation of endoribonucleases that degrades viral RNA and inhibit translation along with an 
overproduction of MHC-I molecules, TAP proteins and proteasomes components, enhancing the 
capacity of the cell to present viral antigens to CD8+ T cells (Dhib-Jalbut et al, 1993). INF-a  and INF-b  
also further activate NK cells. 
 
After an initial replication phase, MV spread to the local lymph node, probably transported by an 
infected macrophage, or caught by resident cells, where the activation of T and B cell will occur. The 
ability to recover from measles was postulated by Burnet to be an indication of the adequacy of the T-
lymphocyte-mediated immune response (Burnet, 1968). Although early demonstrations of cytotoxicity 
of leukocytes from patients with measles were primarily antibody dependent (Kreth and ter Meulen, 
1977; Kreth et al, 1979; Whittle et al, 1980), there is abundant evidence that CD8+ T cells are activated 
during infection. MV antigens inducing CD8+ cytotoxic T cells have not been completely identified, but 
the F protein is one target for MHC-I restricted T cells (Van Binnendijk et al, 1993) and several authors 
have identified CD8+ epitopes on H and N proteins (Beauverger et al, 1994; Beauverger et al, 1993; 
Nanan et al, 1995). 
 
CD4+ T cells are also activated. Binding of the H protein to CD46 is targeting virion proteins to an 
endosomal compartment for efficient presentation by MHC-II proteins (Gerlier et al, 1994). CD4+ are 
proliferating during the rash (Ward et al, 1990). Classic CD4+ T cell responses, such as MV antigen 
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specific proliferation can be induced by most MV proteins in immune individuals (Pette et al, 1993; 
Rose et al, 1984). Proliferation has been shown to be specific to H, N, P, F and M proteins (Bellini et al, 
1981; Van Binnendijk et al, 1993). 
 
 
Fig 12: Summary of the humoral and cellular response to normal MV infection 
 
Depending upon cytokines present during the initial phase of CD4+ T cell proliferation, activated T cells 
become either inflammatory CD4+ (Th1 cell) or helper cell (Th2 cell), determining whether the immune 
response will be dominated by antibody production or macrophage activation. Th1 CD4+ produces 
INFg which activates macrophages and IL-2 which promotes T cell proliferation. Th2 CD4+ produces 
IL-4, IL-5 and IL10 which are important for B-cell growth and differentiation as well as macrophage 
deactivation.  
During measles infection, the earliest cytokines are INFg, neopterin (produced by activated 
macrophages) and soluble IL-2 receptor (Griffin et al, 1990a; Griffin et al, 1989). This is followed by the 
elevation of IL-2, soluble CD4 and soluble CD8 at the time of the rash (Griffin et al, 1989; Griffin et al,  
1992). As the rash fades, IL4 becomes elevated and this elevation persists for weeks (Griffin et al, 
1992). This suggest early activation of CD8+ and type 1 CD4+ during the rash, followed by type 2 
CD4+ during recovery. 
 
Full activation of T cell takes 4-5 days and generates changes in the surfaces adhesion molecules to 
help them to reach the infection focus.  Activated Helper T cells will link to a B cell for activation and 
development of T-cell dependent antibody response. The antibodies only become detectable when the 
rash appears (Bech, 1959; Graves et al, 1984; Hicks et al, 1977). The isotype of MV specific antibodies 
is initially IgM and is detectable 3 days after onset of the rash, but later switches to IgG1 and IgG4 
(Ehrnst, 1978; Mathiesen et al, 1990; Schluederberg, 1965) that persists for long period of time. 
Therefore, presence of IgM antibodies indicates an early infection where IgG antibodies refer to 
recovery from an infection or a secondary immune response following a new contact with an MV 
antigen. 
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The most abundant antibodies are produced against the N protein (Graves et al, 1984; Norrby and 
Gollmar, 1972). Antibodies towards F and H proteins contribute to virus neutralization by preventing 
adsorption and fusion of the virus to the cell (Malvoisin and Wild, 1990; Giraudon and Wild, 1981;  
Giraudon and Wild, 1985; McFarlin et al, 1980).  
 
Fig 13: Production of antibodies to measles virus proteins in response to natural infection. Adapted 
from Graves et al (Graves et al, 1984). 
 
During fusion of the MV with the plasma membrane, the nucleocapsid is injected into the cytosol from 
where it does not have access to the endosomal pathway, unlike the F and H proteins (Rose et al,  
1984). Therefore, the N protein in the cytoplasm are degraded and derived peptides are bound and 
presented by MHC-I molecules. Recent studies have suggested that N protein MHC-I presentation 
may be TAP independent (Neumeister et al, 2001). 
 
At the end of an immune response, when the antigen is cleared, the B cell population decreases, 
leaving a persistent sub-population of memory cells. Immunological memory is manifest as a 
heightened ability to respond to pathogens that have been encountered previously and successfully 
eliminated. It is a property of memory T and B cells, which can transfer memory to naïve recipients 
(Van Binnendijk et al, 1990). One month after contact with the virus, both memory helper T cell and 
memory B cell can be detected at what will be their higher levels. Immunologic memory includes both 
continued production of antibody (Black and Rosen, 1962) and circulation of MV specific T cells (Lucas 
et al, 1982; Van Binnendijk et al, 1990; Wu et al, 1993). The mechanism(s) by which memory cells 
persist is not fully understood. One theory is that memory cells live for a long time (Mackay, 1993). 
Another is that memory cells are restimulated at some low level.  A number of mechanisms for 
restimulation have been proposed. Jerne (1974) proposed the idiotypic network theory in which cells 
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co-stimulate each other in a way that mimics the presence of the antigen. Another theory is that small 
amounts of the antigen are retained in lymph nodes (Tew and Mandel, 1979; Tew et al, 1980). Another 
is that related environmental antigens provide cross-stimulation (Matzinger, 1994). 
 
I.5.2 Immune suppression 
There is evidence of in vitro and in vivo immune suppression in measles. Production of antibodies and 
cellular immune response to new antigens are impaired (Coovadia et al, 1974; Whitley et al, 1982). In 
vitro, lymphoproliferative responses and lymphokines production are abnormal (Archibald et al, 1974; 
Arneborn and Biberfeld, 1983) suggesting that both monocytes and lymphocytes responses are 
suppressed. Monocytes are infected during measles (Esolen et al, 1993) and infection can lead to 
changes in monocyte function. TNFa production is decreased during infection. In vitro experiments 
with infected macrophages generated similar decrease suggesting that such abnormalities may result 
directly from MV infection of monocyte/macrophages. Circulating T cells are also decreased during the 
acute phase of measles (Alpert et al, 1984; Dagan et al, 1987; Joffe et al, 1983; Whittle et al, 1978) 
and it is postulated that it could be due to inadequate production of IL2 (Griffin et al, 1986; Ward and 
Griffin, 1993). IL4 production seems to be increased during in vitro infection, contributing to immune 
suppression by inhibiting Th1 CD4+ T cells (Griffin and Ward, 1993). In vitro infection of lymphocytes 
with MV vaccine strains induces abnormalities of B- and T-cell function, which may be relevant to 
immune suppression during measles (Lucas et al, 1977; Casali et al, 1984). 
 
I.6 Measles vaccination 
 
1.6.1 The history of measles vaccination 
The first measles vaccines used were viruses inactivated (killed) by physical or chemical means (by 
formalin inactivation). This vaccine was then primarily a virus with a destroyed genomic RNA that was 
able to elicit humoral immunity but no cellular immunity due to its inability to generate viral protein 
production in the target cell. This kind of vaccine was used in the United States from 1963 to 1967 and 
was then abandoned after numerous reports of atypical measles in vaccinees when they were exposed 
to the wild virus . This atypical measles was a severe form of measles with unusual clinical features like 
higher and prolonged fever, severe skin lesions and pneumonitis (Brodsky, 1972; Nader et al, 1968; 
Rauh and Schmidt, 1965; Rod et al, 1970) as well as evidence of hemorrhage. Initial studies of the 
immune response to the killed measles vaccine have shown that the recipients developed antibodies to 
the H protein but little to the F or N proteins (Norrby et al, 1975; Norrby and Gollmar, 1975). However, 
more recent studies suggest that these observations may not be related to the induction of atypical 
measles. These recipients had good lymphoproliferative (Krause et al, 1978) and delayed type 
hypersensitivity responses (Fulginiti and Arthur, 1969; Harris et al, 1969, Lennon et al, 1967). The 
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more recent studies suggest that inappropriate cellular response causes atypical measles (Polack et 
al, 1999).  
 
The inactivated vaccines were therefore replaced by attenuated vaccines. This vaccine is a live virus 
with an attenuated infectivity obtained by passaging the virus on culture cell, thus selecting a “variant” 
adapted to an unnatural target and therefore having lost its initial efficiency in infecting its original 
target cell. Such a virus spreads much slower in the organism, allowing the immune system to 
generate a full response before a wider infection occurs. A drawback of such live vaccines is that they 
represent a risk to immunocompromised patients. 
 
Current measles vaccines based on the Schwartz strain are further attenuated virus preparations 
derived from the Edmonston strain isolated in the 1950's (Enders and Peebles, 1954).  The culture of 
this virus on chicken cells resulted in a significant attenuation of its infectivity towards human cells. 
 
Standard titer vaccines contain about 1000 infectious units per dose; higher potency vaccines do not 
increase sero-responses when administered to children aged 9 months or above and even increased 
mortality of children between 6 and 9 months (Schnorr et al, 2001). Other studies have shown that 
recipients of high titer measles vaccine formulations suffered increased mortality 2-3 years after 
vaccination (EPI, 1992).  
The normal-titer vaccine is highly effective. In developed countries, the vaccine is administered at 
twelve to fifteen months, when maternal antibodies have waned. In such conditions, sero -conversion 
rates reach 95 to 98%. In developing countries, where the vaccine is administered at nine months, 
sero-response rates and clinical efficacy have usually exceeded 85%. Studies have shown that there is 
lower seroconversion rate if the vaccine is given to children at six months. This lower sero -conversion 
rate is partially due to the persistence of maternal antibody in children, but even in infants that have no 
maternal antibodies, the effectiveness of the vaccine is reduced because of the poor response to the 
live vaccine of immature immune systems. 
Current recommendations for routine vaccination are that a single dose of the measles vaccine be 
administered to children at the age of nine months in developing countries. An early dose at six months 
may be useful where there is high risk from measles infection followed by a second dose at 9 months 
(Cutts, 1993). In developing countries, a single routine dose is insufficient for measles control and a 
second dose is applied at various ages by an increasing number of countries. 
 
Measles vaccine is administered subcutaneously immediately after reconstitution. In many countries it 
is combined with the mumps and rubella vaccine and can be administered simultaneously with other 
vaccines. The vaccine must be kept cool and protected from ultraviolet light after reconstitution. 
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Inhalation of aerosol or dry powder have also been shown to give satisfactory levels of protection 
(Licalsi et al, 2001; Dilraj et al, 2000) and bear some interesting perspectives.  
The basis of measles control is to achieve high vaccine coverage with a single routine dose of vaccine 
given in the first year of life. However, because of factors related to the high infectivity of the disease 
and its epidemiology, this strategy alone is unlikely to provide sufficiently high levels of control except 
in isolated environments where transmissibility is low or where very high coverage has been achieved 
consistently for a number of years. 
Despite reaching levels of approximately 82% vaccine coverage throughout the world, outbreaks 
continue to occur, particularly in pockets of low coverage. Therefore routine vaccination progresses 
have been invigorated by a second dose at 6 or 12 year of age. In addition, national or regional 
campaigns, with the vaccination of a wide age group, irrespectively of their vaccination status, have 
made important progress towards measles control.  
 
I.6.2 Limitations of the current vaccine strategy 
Although current live -attenuated measles vaccines have dramatically reduced morbidity and mortality, 
a very high proportion of the population must be covered to eradicate the disease. Reaching 
sufficiently high levels of vaccination with a single-dose routine vaccination seems very difficult or 
impossible. Therefore, nation-wide catch-up campaigns have been set-up in particular in developing 
countries, to vaccinate all children between a wide age brackets (e.g. 9 month to 14 years) 
independently of their immune status. Such vaccination campaigns would allow immunizing children 
that either were missed by routine programs or experienced primary or secondary vaccine failure. 
Individuals with a weak response to the first vaccination may also benefit from a boost of their 
immunity. But despite all these efforts, outbreaks continue to occur in countries with high vaccine 
coverage and two-step vaccination campaigns (Gustafson et al, 1987). Current re-emergence of the 
virus (e.g. in South America) raised questions about the possibility to eradicate measles and about the 
main hurdles towards elimination of measles. 
 
In an unimmunized population, the virus infects susceptibles who develop measles. After clearing the 
virus, individuals are immune against the disease. In vaccinees, there is increasing evidence that 
measles is able to survive and circulate in seropositive individuals (Pedersen et al, 1989). After re-
exposure to measles, seroconverted individuals may even develop mild disease (Edmonston 1990). In 
addition, individuals that are fully protected against disease may become transiently infected and 
develop an asymptomatic secondary immune response (SIR) (Pedersen et al, 1989; Muller et al, 
1996a; Huiss et al, 1997). This group of person would be the most likely to support viral transmission in 
the absence of disease. Although the virus has been isolated from the urine of re-exposed individuals 
which did not develop symptoms (Vardas and Kreis, 1999), sub-clinical virus transmission has not 
been directly observed. 
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Another point of concern with respect to the current vaccination strategy is the susceptibility gap in 
infants. Young children sustain a higher rate of serious complications from measles and increased 
mortality but persisting maternal antibodies that interfere with seroconversion complicate early 
vaccination. In developing countries, children have a higher risk of being exposed shortly after 
maternal antibodies have waned because of higher measles prevalence and more intensive contacts 
with susceptibles. In addition, waning of maternal antibodies seems to be quicker in low-income 
developing countries than previously estimated (Muller, 2001) with high rates of seron egativity already 
at 4 month of age (Hartter et al, 2000). In Nigeria, 21% of measles patients develop disease before 
being vaccinated at 9 month (Hartter et al, 2000). The majority of measles-related death (>50%) occurs 
with the children between 6 and 12 month (Aaby et al, 1990). 
 
Another possible cause of lower vaccine efficacy may be differences in antigenicity of the measles 
virus. Although the measles virus is serologically monotypic, it is genetically diverse and different 
clades and genotypes can be distinguished. In contrast; all vaccine strain viruses are derived from 
genetically similar viruses of the clade A. Thus within a population of vaccinees, the immune response 
tends to become increasingly uniform, generating considerable immune pressure on wild-type viruses 
and allowing the possibility of the emergence of resistant strains. A study in progress in our laboratory 
has shown that the neutralization capacity of hemagglutinin specific monoclonal antibodies (mAbs) was 
different in their relative hemagglutination and neutralization activity (Klingele, in preparation). In this 
study, 24 MV representing 6 genotypes from 5 different clades were evaluated. The clade A viruses 
were neutralized by all mabs whereas some of the wild-type viruses were neutralized by only 60% of a 
panel of non-redundant H-specific mabs. Moreover, neutralizing mab titers were substantially higher for 
vaccine strains than those against wild-type strains. These results suggested that there are significant 
differences in antigenicity between some wild-type viruses and vaccine strain viruses that appeared to 
make them more resistant to vaccine induced antibodies. In a similar study, up to 75% of the sera of 
vaccinees did not neutralize some of the currently circulating viruses in vitro (Klingele et al, 2000). 
However, such vaccinees may still be protected by cellular mechanisms (Griffin, 1995), although the 
viruses may be able to avoid cellular mechanisms similarly to humoral immunity. These data suggest 
that differences in antigenicity between wild type and vaccine strains may further reduce protection of 
vaccinated people and infants (protected only by maternal antibodies).  
 
The sum of the effects of primary and secondary vaccine failure and such factors as lower antibody 
levels due to vaccination, reduced boosting of immunity by circulating viruses, differences of 
antigenicity between vaccine strains and a possible asymptomatic virus transmission, rises questions 
about the need of improved vaccination strategies, using new kind of vaccines that could circumvent 
some of the above drawbacks of the current vaccines. In addition, after 25 years, 50% of the 
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individuals vaccinated with life-attenuated measles vaccines are though to have lost protective levels of 
antibodies (Mossong et al, 2000). Whether some of these vaccinees may still be protected by a 
residual T cell immunity is presently unclear. Such populations would require simple vaccines to boost 
their immunity. 
 
I.6.3 Novel Vaccine candidates and strategies 
Current life attenuated measles (MV) vaccines have effectively reduced the morbidity and mortality of 
measles world-wide and some progress has been made towards a better heat-stability of life-
attenuated measles vaccines, however the attenuated vaccines has a number of drawbacks (Table 1) 
that could be circumvented by novel vaccines strategies fully exploiting the opportunities provided by 
molecular biology. Research to develop new vaccines has focused mainly on subunit vaccines based 
on recombinant Measles H protein combined or not with the fusion protein. A number of different 
experimental vaccines have been explored by different authors (Table 2). These experimental vaccines 
may be a favorable long-term solution to the emerging problems of the current measles control 
campaign. Such vaccine may be more stable at ambient temperature, may be more resistant to 
maternal antibodies and may be more appropriate for revaccinated vaccinees that have lost protection 
as a result of waning immunity (Obeid and Steward, 1994).  
 
The current research priorities of the WHO with respect to measles include the characterization of the 
immunobiology of the measles virus infection and immunization. This goal can be reached by studies 
of the protective immunity responses including the study of humoral and cell-mediated immunity in 
animals and man, the identification of the B and T cell epitopes of protective antigens and to 
investigate the immune response and characteristics of the infection during natural MV infection and 
immunization.  
 
The WHO has given guidelines for the design of new vaccines. Such new vaccines should provide a 
high sero-conversion rate and a long term protection, along with low vaccine-related side-effects and 
complications. Such new vaccines should be resistant to maternal antibodies, have a long shelf-life 
and be stable at ambient temperature, be easily administered and that could eventually combined with 
vaccines of other diseases. 
 
Other current research concentrates on developing technologies that eliminates the need to 
reconstitute measles vaccines before use, or on existing or improved vaccines that explore alternative 
routes of immunization. For instance, revaccination with an oral vaccine would possibly be one strategy 
since it does not require the involvement of trained health workers and avoid the risks of infection 
associated with needles injections. The potential of a parenteral/oral prime-booster schedule has been 
demonstrated in several studies (Schmucker, 1999). 
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Moreover, the measles eradication requires simple and quick diagnostic tests of measles infection that 
can be used in a primary healthcare setting and that could distinguish measles from other diseases. 
The possibility to discriminate between natural and vaccination-induced immunity would also be a great 
asset to the possibility to eradicate the measles disease. 
 
In this study, the author will first describe characteristics and changes of immunity in a highly 
vaccinated population and then describe the design of an immunization strategy based on chimeric 
recombinant proteins of the measles virus in the context of a changing epidemiology.  
 
Table 1: Advantages and drawbacks of life attenuated vaccines. 
Advantages Drawbacks 
· single dose 
· life-long protection 
· high seroconversion rate(>95%) 
· low complication rate (1:20000)  
 
· heat-sensitive 
· lack of resistance to maternal antibodies  
· concern for immunodeficient vaccinees 
· no discrimination between vaccine and 
wild-type induced immunity 
· low titers of transplacentally transmitted 
antibodies  
· possibility to revert to Wild-type virulence 
· All vaccine derived from clade A 
attenuated vaccines  
· role and frequency of SIR susceptibles ? 
 
Table 2: Recent studies on experimental measles vaccines  
· Recombinant vaccinia virus (NYVAC) (Kovarik et al, 2001) 
· Recombinant avian pox viruses – fowlpow virus, canary pox (ALVAC) (Wyde et al, 2000) 
· Recombinant vesicular stomatitis virus (Schlereth et al, 2000a) 
· Recombinant adenovirus (Fooks et al, 1998) 
· Recombinant Bacille Calmette-Guerin (Fenelly et al, 1995) 
· Recombinant Streptococcus gordonii (Maggi et al, 2000) 
· MV glycoproteins in immunostimulating complexes (ISCOMS) (Pedersen et al, 1992) 
· DNA vaccines (Polack et al, 2000) 
· Micro-encapsulated live MV (Nechaeva, 1999) 
· Epitope -based vaccines (Hsu et al, 1996) 
· Recombinant measles virus (Moeller et al, 2001) 
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I.6.4 The secondary immune response (SIR) 
Measles infection normally results in life-long protective immunity (Panum, 1940). After the introduction 
of vaccination, measles morbidity and mortality dramatically decreased (Mitchell and Balfour, 1985),  
but despite high vaccination coverage measles outbreaks occur (Frank et al, 1985; Gustafson et al,  
1987) because the virus continues to circulate in seronegative individuals. In populations with 
vaccination rates exceeding 99%, outbreaks were observed in individuals with primary or secondary 
vaccine failure (Mitchell and Balfour 1985; Gustafson et al, 1987). However, there is also evidence that 
measles virus (MV) can circulate in seropositive populations (Pedersen et al, 1989; Gustafson et al,  
1987; Ozanne and d’Halewyn, 1992; Pedersen et al, 1992). The characteristics of this transmission are 
so far only poorly understood. It is reasonable to assume that people susceptible to develop a 
secondary immune response (SIR) after reexposure to measles are the most likely seropositive 
candidates to support viral transmission. There is no direct evidence that such a transmission could 
lead to clinical measles in seronegatives, although isolated cases without apparent contacts may be 
suggestive of such a mechanism. With an increasing fraction of vaccinated people, anti-MV titers in the 
general population tend to decrease (Christenson and Böttiger, 1994) and the epidemiological 
relevance of SIR-susceptibles may increase. It is therefore important to understand the role of SIR-
susceptibles for the epidemiology of measles in a world of global vaccination. We have characterized 
SIR in parents exposed to children with measles during an outbreak in 1996 (Muller et al. 1996a). On 
the basis of the characteristics of SIR-susceptibles, we will estimate the frequency of SIR-susceptibles 
among individuals with natural and vaccine-induced immunity to define a high-risk population in which 
asymptomatic viral transmission could potentially be investigated.  
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II. Material and Methods. 
 
II.1 Principles of the experiments 
 
II.1.1 Cohort study on measles immunity 
The secondary immune response (SIR) was investigated in the parents of children with confirmed 
measles. 
 
Definition of the SIR.  An asymptomatic secondary immune response (SIR) to MV is defined as a 
clinically unapparent increase of specific IgG and/or neutralization (NT) and/or hemagglutination (HI) 
titers, with or without increase in IgM of an individual with a serologically confirmed fi rst MV exposure 
and a documented re-exposure to MV.  
 
Parents. Sera of the parents of 84 measles patients were drawn by standard venupuncture during the 
outbreak. In general, the blood of the parents was drawn when the blood of the children was drawn (14 
to 59 days after rash. Average 32 days). They were exposed to one or two children with IgM -confirmed 
measles. None of the children were vaccinated. As all other parents, they reported having had measles 
before entering school. Although this was not independently confirmed by a physician, they were born 
at a time (1949-1970) were immunity was acquired by early natural infection. One to seven pre-
exposure serum of each of 45 parents (37 mothers, 7 fathers and 1 grandmother, average age of 
37.2years, range 26.3-50.5 and one 67 years old) of children with measles are available from the LNS 
serum bank. Additional blood samples were later drawn from the same parents (in January 1997, 
March 1999 and January 2001) to monitor the evolution of their immune status. 
 
Further studies were performed on the following cohorts: 
 
Late convalescent donors.  Sera were obtained from 324 consecutive out -patients above 25 years of 
age of the Laboratoire National de Santé which underwent venupuncture for unrelated reasons in 
December 1995 and January 1996. Characteristics of the volunteers were as follows: 113 males (25-
79 years old, mean 48) and 211 females (25-91 years old, mean 38.4). It can be assumed that the vast 
majority of the persons in this age bracket had measles during their childhood because they were born 
at a time (1905-1970) were immunity was mostly acquired by early natural infection. Routine 
vaccination against measles was introduced in Luxembourg only in 1975.   
 
Vaccinated children. In august and September 1996, sera were also collected from 503 children of 
the Grand Duchy of Luxembourg from a co-ed public and an all-girls private high school (the Lycée R. 
Schuman, LS, and the Fieldgen, FI) in Luxembourg-City and a co-ed public high school form a small 
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town (Wiltz, WI). Only children of the first high school year were included and participation was 63, 76 
and 86% respectively. Their median age was 12.7 (date of birth between 12/03/81 and 30/10/85). 
Immunization status was recorded from vaccination documents. 63.2 % (80.3, 80.5, and 59.7%, for the 
three schools respectively) of children had record (vaccination card) of at least one measles 
vaccination, 9.7 % (19.7, 10.3 and 3.6%, respectively) of the children were vaccinated twice and 27 % 
(20, 19.5, 40.3 respectively) had no vaccination records and were not included in the study. 
 
Early convalescents.  With the support of the Direction de la Santé of the Ministry of Health, 
Luxembourg, a hot -line (00352-490648) for measles surveillance was installed in the Dept. of 
Immunology of the Laboratoire National de Santé (LNS). Between March and July 1996, an outbreak 
of measles occurred in the cantons of Wiltz and Clervaux in the Grand-Duchy of Luxembourg affecting 
at least 84 patients, mostly children. Single or paired sera were obtained. Only sera drawn 14-59 days 
after rash were included in this study. 
 
II.1.2 Principles, clonages strategy and expression systems 
We have developed chimeric antigens based on selected T and B cell epitopes. To explore their 
potential for a new vaccine strategy, two different sets of chimeric proteins were developed.  
 
1. One set of constructs was based on minimal epitopes. This strategy uses 15aa long T cell 
epitope and one 8aa long mimotope mimicking a conformational B cell epitope of the Measles 
virus fusion protein. The 3 epitopes will be genetically combined to form a set of 
permutationnal constructs. This should allow to study candidates vaccines for closing the 
susceptibility gap in young infants. 
2. A second set of constructs uses larger viral protein fragments, to produce a candidate vaccine 
to boost the residual immunity of individuals with waning immunity. 
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Although our two strategies will use different elements, the main frame will be as follows: 
 
Fig 14: General strategy of design of the chimeric antigens 
 
II.1.2.1 Principle of the clonage strategy 
To assemble our constructs into pUC18, we have used a multiple cloning site cassette cloned into 
pUC18 (seq 400-538) called pUC Start. This cassette contains restriction sites for the 
isoschizomeric enzymes SalI and XhoI. 
The cassettes containing our epitopes were ordered as oligonucleotides (Eurogentec, Liège) with 
an XbaI and SalI site on its 5’ end and an XhoI site on its 3’end. These sequences were then 
cloned into pUCstart using the XbaI-XhoI sites allowing only one orientation of ligation (5’->3’).  
 
The oligonucleotides sequences are extracted using SalI-XhoI digestion. The free ends of the SalI 
and XhoI sites are compatible (can be religated) but cannot be digested anymore using SalI or 
XhoI. This system allows serial cloning as described in the Fig15.  
 
 
 
Subunit Vaccine 
strategy 
Immunization with recombinant proteins 
Ligate sequences in pUC vector 
Transfer assembled chimeric sequence into Expression Vector 
Induce expression of chimeric proteins 
Select epitopes 
Purification and analysis of the products 
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Fig 15: Schematic description of the ligation strategy 
 
In this strategy, a vector containing an instert called A and another vector cont aining an insert B 
are digested using the enzymes SalI and EcoRI. The vector A and the insert B are purified and 
ligated together. The resulting sequence is the contiguous sequence of inserts A and B. The 
strategy can be reused using SalI and EcoRI or XbaI and XhoI without having the risk of 
separating A and B since the ligation of the 5’ end of B and the 3’end of A is not a restriction site 
for SalI or XhoI. 
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Cloning using such system results in the ligation of the two sequences separated by 6 nucleotides 
(5’ CTC GAC 3’) coding for Leucine and Aspartic acid. When the constructs are cloned and 
sequenced, they are transferred into their expression system. The constructs of the “mimotopes 
constructs” are transferred into pSFV1 using BamH1 digestion and the constructs of the “mv 
antigenic region strategy” are transferred into pET using NcoI-BamHI digestion. 
 
II.1.2.2 Description of vectors 
II.1.2.2.1 pUC vector : The vector used for building our constructs 
The pUC vector is derived of the first cloning vectors pBR322 constructed in 1977 by Bolivar and 
Rodriguez (Bolivar et al, 1977). The vector pBR322 was in fact a tripartite replicon consisting of 
segments from the Col -factor pMB1 (contributing oriV), and from the two R-factors R6-5 
(conferring TcR) and R1 (conferring ApR from transposon Tn3). This construct had two resistance 
markers which could be used alternatively for transformant selection and insertional inactivation.  
In 1982 the next generation of cloning vectors emerged constructed by J. Messing and named the 
pUC series (Messing et al, 1982). They were derived from pBR322 by replacing the TcR-gene 
with the gene for the alpha-peptide of the ß-galactosidase (lacZ') including a multicloning site 
(MCS) starting at nucleotide 15 (aminoacid 4) of the lacZ' gene.  
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Fig 16: Map of the original pUC18 vector. 
 
In our case, the multiple cloning site of the original pUC18 was replaced by a Start cassette 
compatible with our whole range of cloning strategies. The fragment HindIII-EcoRI (seq 400-451) 
of the pET16 was digested out and our cassette (Fig 17) was cloned at its position.  
 
The Start Cassette 
 
HindIII                             BglI 
|     BamHI              NcoI       SfiI    XbaI         SalI 
|     |                  |          |       |            | 
AAGCTTGGATCCGAGCTCCTGCAGACCATGGCCATTTTGGCCGGTCTAGAGCTAGCGGTCGACACGCGTTGA 
400 -+---------+---------+---------+---------+---------+---------+---------+ 470 
TTCGAACCTAGGCTCGAGGACGTCTGGTACCGGTAAAACCGGCCAGATCTCGATCGCCAGCTGTGCGCAACT 
 
                              BglI 
            XhoI              SfiI               BglII BamHI EcoRI 
            |                 |                  |     |     | 
GAAGCGGCCGCCCTCGAGCTTAAGGCCGCTGGGGCCGATAATTAATTGAAGATCTGGATCCGAATTC 
471 ---------+---------+---------+---------+---------+---------+------- 538  
CTTCGCCGGCGGGAGCTCGAATTCCGGCGACCCCGGCTATTAATTAACTTCTAGACCTAGGCTTAAG 
 
Fig 17: Map of the START cassette Multiple Cloning Site. 
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II.1.2.2.2 pSFV : The eukaryotic expression system 
Several expression systems have been used to study and overexpress cloned eukaryotic proteins. 
The pSFV gene expression system is a novel expression system based on the Semilki Forest 
Virus (SFV) replicon that can produce recombinant proteins into eukaryotic cells (Liljeström and 
Garoff, 1991). In this system, the DNA of interest is cloned directly into the pSFV1 vector that 
serves as a template for in vitro  synthesis of recombinant RNA. The RNA can then be transferred 
into cultured animal cells, or even packaged into conditionally infective, recombinant SFV 
(Berglund et al, 1993). Due to the broad host range of the SFV system, almost any eukaryotic cell 
type (unlike bacculovirus systems) can be infected with recombinant viral particules. The SFV 
RNA molecule has a positive polarity and thus functions directly as mRNA. This system has 
already been used successfully for expressing several proteins in mammal cells (Liljeström and 
Garoff, 1991). 
 
 
Fig 18: Recombinant gene expression in vitro using pSFV1. 
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Fig 19: Map of the pSFV1 vector. 
 
                                                       BamHI 
                                            EcoRI      |   XmaI                                
            28S Promoter                    |          |   | 
pSFV1 ACCTCTACGGCGGTCCTAGATTGGTGCGTTAATACACAGAATTCTGATTGGATCCCGGGT  
      ---------+---------+---------+---------+---------+---------+ 
 
                                        XmaII 
    STOP Cassette                       | 
      AATAATTGAATTACATCCCTACGCAAACGTTTTACGGCCGCCGGTGGCGCCCGCG  
      ---------+---------+---------+---------+---------+---------+ 
 
Fig 20: Polylinker region of pSFV1 
 
Our constructs are transferred into pSFV1 using the BamHI site at position 7000.  
 
II.1.2.2.3 pET system, the bacterial expression system  
For an easier and more efficient expression of recombinant proteins and polyepitopes that do not 
require mammalian glycosylation, a new set of vectors has been designed. These vectors will 
express our recombinant proteins into prokaryotic systems, allowing potentially high output and 
possible long-term conservation of the transformed bacteria. 
Our new vectors include a signal sequence for periplasmic expression (pel -B) to ensure the 
formation of disulfide bridges, necessary for the right conformation of some epitopes used as 
subunits (our MVH fragments have 3 cysteines at positions 382, 387, 395). They also feature a 
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His-tag region for easy purification and detection of the recombinant proteins from bacterial 
supernatants.  
 
The starting point of this system construction is the pET16 vector from Novagen (plasmid featuring 
a T7 promoter and a lac operator for regulation of its expression), a plasmid for cytoplasmic 
production in E Coli, originally designed by Studier et al (Studier and Moffatt, 1986; Rosenberg et 
al, 1987; Studier et al, 1990).  
 
 
Fig 21: Map of the pET16b vector. 
 
The pET system is used for the cloning and expression of recombinant proteins in E. Coli. The target 
genes are cloned in pET plasmids under the control of the strong promoter of bacteriophage T7. The 
expression is induced by providing a source of T7 RNA polymerase in the host cell. The T7 RNA 
polymerase is so selective and active than almost all of the cell resources are converted to target gene 
expression. The desired product can represent a significative proportion of the total cell protein after a 
few hours of induction (Studier and Moffatt, 1986, Tabor and Richardson, 1985). Another important 
benefit of this system is its ability to maintain target genes transcriptionnaly silent in the uninduced 
state. Target genes are initially cloned using hosts that do not contain the T7 RNA polymerase gene, 
thus eliminating plasmid instability due to the production of proteins potentially toxic to the host cell. 
Once established in a non-expression host, plasmids are then transferred into expression hosts 
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containing a chromosomal copy of the T7 RNA polymerase gene under LacUV5 control, and 
expression is induced by the addition of IPTG.  
 
Selected host strain : 
The used host cell is the BL21DE3 {genotype: F- ompT hsdS b (rb
- mb
-) gal dcm (DE3)}. A lDE3 
lysogen on strain BL21 is the most widely used host for target gene expression. As an E. Coli B strain, 
BL21 lacks the lon proteases and ompT outer membrane protease that can degrade proteins during 
purification (Grodberg and Dunn, 1988). Thus, at least some target proteins should be more stable in 
BL21 that in host strains containing these proteases.  
BL21DE3 containing pET recombinants can be kept at -80°C in glycerol 10% stocks. Higher 
concentration of glycerol can lead to plasmid instability. Expression of the target DNA is induced by 
the addition of IPTG to a growing culture.  
 
Principle and method of induction 
Induction cells must have a chromosomal T7 RNA polymerase gene under LacUV5 repression. The 
expression is induced by addition of IPTG (isopropyl-D-thiogalactopyranoside) that binds to lacUV5 
and prevents repression of the polymerase.  
 
Fig 22: Principle of the expression control of pET vector in BL21DE3 cells 
 
To allow transport of the target proteins to the periplasmic space where dissulfide bonds formation may 
take place in E-Coli (Derman et al, 1993), the pelB leader cassette will be cloned in front of our 
recombinant genes. Translocation in E. Coli is incompletely understood (Wickner et al, 1991) but it is 
known that translocation also depends on the mature domain of the target protein, which is recognized 
LacUV5 T7 RNA polymerase 
T7 promoter T7 Terminator Pel B 
Construct 
Multiple cloning site His-Tag 
Induction 
with IPTG 
lDE3 DNA 
pET Start vector 
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by SecB, the major chaperone of export. The pelB will be transferred from another vector of the pET 
family: the pET27 vector, and be ligated in front of pET16 multiple cloning site.   
 
Our vectors have been designed to remain compatible with the pSFV1 eukaryotic expression vector to 
allow the comparisons of proteins expressed in prokaryotic and eukaryotic cells and with other 
strategies using BamH1, Xba1–Xho1, Sal1-EcoR1 Bgl1 or Sfi1 for cloning.  
 
    BglII 
    |                                            Lac Operator 
    AGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA 
519 ---------+---------+---------+---------+---------+---------+---------+ 450  
 
                                       NdeI  
                                       |                     PEL B 
    GGAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAAATACCTGCTGCCGACCGCTGCTGCTGG 
449 ---------+---------+---------+---------+---------+---------+---------+ 380 
 
                                    NcoI                  BamHI 
                                    |    Insertion Site   |  
    TCTGCTGCTCCTCGCTGCCCAGCCGGCGATGGCCATGgatatcggaattaattcgGATCCGGCTGCTAAC 
379 ---------+---------+---------+---------+---------+---------+---------+ 310 
 
                                        Bpu1102 
                                        |                    T7 Terminator 
    AAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCT 
309 ---------+---------+---------+---------+---------+---------+---------+ 240 
 
 
 
    CTAAACGGGTCTTGAGGGGTTTTTTG 
    ---------+---------+------ 214 
 
Fig 23: The cassette of our designed pET vector. 
Note: The sequence is numbered by the pBR322 convention, so the T7 expression region is reversed 
on the circular map. 
 
Our constructs are finally transferred in pET using the NcoI-BamHI site. Prior to the transfer, the XbaI 
site in pET16 has been eliminated by cloning a mutated oligonucleotide in XbaI-NdeI. 
T7 
RBS 
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Fig 24: The pet vector MCS with its construct ready for expression. 
 
II.1.2.3 Principle of the purification method 
The unknown quantity of our recombinant protein obtained by induction and the need to remove all 
active bacterial components from our test samples required an extensive purification. We have used 
the His-Tag region cloned at the end of our proteins to purify them on an HPLC Nickel column. This 
step would also allow to purify only the complete proteins, since the C terminal His-Tag would be 
missing on incomplete or cleaved proteins. 
Our chromatography column has nickel atoms (Ni2+) stationed inside it. Nickel (and other 2+ metals) is 
a "transition metal" and therefore is able to bind electron-rich molecules like histidine. Proteins without 
poly-histidine tail will flow through the column but our his-tag protein will be bound by the Ni2+. A first 
washing of the column is done with imidazole to release the weak binders (for examples, the bacterial 
proteins with few histidines). The release of the His-tag proteins is done using higher imidazole 
concentrations.  
Sfi I 
Bgl I 
Xba I Bam HI XbaI Sal I Xho I 
Sfi I 
Bgl I 
T7 prom 
T7 term 
Bgl II NcoI 
Pel B Construct 
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II.2 Protocols 
 
II.2.1 Immunology techniques 
II.2.1.1 Serum Collection 
II.2.1.1.1 Measles Hotline and LNS serum bank 
With the support of the Direction de la Santé of the Ministry of Health, Luxembourg a hot-line (00352-
490648) for measles surveillance was installed in the Dept. of Immunology of the Laboratoire National 
de Santé (LNS). Between March and July 1996, an outbreak of measles has occured in the cantons of 
Wiltz and Clervaux in the Grand-Duchy of Luxembourg affecting at least 84 patients, mostly children. 
Single or paired sera were drawn from the measles patients and their parents by standard 
venupuncture after informed consent. Sera were aliquoted and frozen/thawed not more than twice 
before the assays. An additional 110 pre-exposure sera from parents of children with measles were 
used after informed consent from the LNS serum bank.   
 
II.2.1.1.2 Blood clotting and serum conservation 
The analysis of human and mice blood has required extensive blood sampling. The separation of the 
serum and blood clot had to be carried out carefully to avoid perturbation of the experiments. 
 
The blood was sampled in clean, empty non-heparinized tubes. The blood was heated to 37°C for 
30min to allow the blood clot to aggregate. The tube was then centrifugated at 3000RPM for 20min and 
the supernatant was carefully removed, avoiding to pipet the blood cells. The aliquots of serum were 
usually transferred into multiples 1.5ml tubes and frozen at -20°C. 
 
II.2.1.2 Serum Analysis 
II.2.1.2.1 ELISA  
The principle of ELISA (Enzyme Linked Immunosorbant Assay) is to detect an immobilized antigen 
using antibodies conjugated with an enzyme (usually horseradish peroxydase or alkaline phosphatase) 
which transforms a substrate into a soluble chromogenic product. After washing away the unbound 
antibodies, the substrate of the enzymes is added to the antibody/antigen complex and coloration 
appears. We have used ELISA for the detection of recombinant proteins at key steps of production and 
purification, or to test the capacity of induced sera to recognize recombinant proteins or complete 
measles viruses. 
 
The 96 well Maxisorp plates (Nunc) were coated overnight at 4°C with dilutions of protein (max load 
300ng/well in coating buffer). The plates were washed 5 times by immersion in washing buffer and the 
wells were blocked with 200ul of blocking buffer (containing BSA to saturate non -specific binding sites 
to prevent non-specific background) for 90 min at room temperature. The plates were washed and 
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filled with 50µl of antibodies in dilution buffer (1:1000 dilution for monoclonal antibodies and 1:100 for 
polyclonal serum). The plates were incubated 90 min with the first step antibodies, washed and filled 
with 50µl of a 1:1000 dilution of an alkaline phosphatase-labelled Fc specific antibody (goat anti-
Human or goat anti-mouse antibody, Southern Biology Associates). After washing, wells are filled with 
100µl of substrate solution. 
After 30-60 minutes, the plates can be read in an ELISA-reader at 405nm.  
 
Buffers used for ELISA: 
Coating Buffer (pH 9.6): 
Na2CO3(H2O) 0.1M (Merck) 
NaHCO3 0.1M (Merck) 
 
Washing Buffer (pH 8.0):  
Tween20 0.1% v/v (Sigma) 
Tris-Base 1mM (Sigma) 
NaCl 154mM (Merck) 
 
Blocking Buffer (pH 7.4): 
Bovine serum albumin 1% w/v 
(Sigma) 
Tris-Actetate 15mM (Sigma) 
NaCl 136 mM (Merck) 
KCl 2mM (Merck) 
 
Dilution Buffer (pH 7.4): 
Bovine serum albumin 1% w/v 
(Sigma) 
Tween20 0.1% v/v (Sigma) 
Tris-Acetate 15mM (Sigma) 
NaCl 136 mM (Merck) 
KCl 2mM (Merck) 
Substrate Buffer (pH 10.2): 
2-Amino-2-Methyl-1-propanol 
hydrochloride 1mM (Sigma) 
MgCl2.6H2O 0.1mM (Sigma) 
 
Substrate solution:  
1 tablet of SIGMA104 (p -
Nitrophenyl Phosphate 
disodium salt) in 10ml of 
Substrate Buffer. 
 
 
II.2.1.2.2 Commercial ELISA (Enzygnost)  
MV specific IgG and IgM were measured with a commercial ELISA kit based on continuously MV-
infected permanent simian kidney cells (Enzygnost, for MV -IgG or IgM purchased from Dade Behring, 
Marburg, Germany) following the manufacturer’s instructions (serum dilution 1:23 1 for IgG and 1:42 for 
IgM). For IgM determination, IgG was complexed with sheep anti-human IgG Fc fragment, which 
enhances the sensitivity and adsorbs rheumatoid factor. Net IgG or IgM (or DA) corresponded to the 
difference in mO.D.450 between infected and uninfected control wells. According to the manufacturer, 
DA <100 mO.D. or >200 mO.D. are negative and positive respectively. Sera with intermediate values 
are recommended for retesting, and if not defined are considered “equivocal”. Background levels were 
80-110 (mean 87) mO.D. for IgG and 70-135 (mean 83) mO.D. for IgM. 
 
II.2.1.2.3 Hemagglutination inhibition (HI) assay 
Hemagglutination Inhibition is a diagnostic technique that operates on a principle similar to that of the 
Coomb's test, except that virus agglutinates monkey erythrocytes. The Hemagglutination Inhibition 
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allows antibodies to bind to the measles virus before the virus can bind to red blood cells. This type of 
testing is used in the detection of antibodies to influenza, hepatitis, measles, and rubella. Potency of 
antibody titers can be obtained using Hemagglutination Inhibition by determining the minimum dilution 
of serum required to completely inhibit agglutination of red blood cells in the presence of virus. 
 
Triplicates of 2-fold serial dilutions of sera (25 µl/well), were incubated in precooled V-shaped 96 well 
plates with 25 µl of a standard dose of purified Measles Virus (Edmonston strain, obtained from Dr. 
Berbers, RIVM, Bilthoven, NL) and 25 µl containing 106 African Green Monkey erythrocytes 
(Cercopithecus aethiops,) (Norrby, 1962). All dilutions were done in PBS (pH 7.4) containing 0.2% 
BSA. HI titer was defined as the highest dilution which completely prevented hemagglutination after 3 h 
at 37°c. The highest serum concentration tested was 1:22.   
 
II.2.1.2.4 Neutralization (NT) assay 
This assay is complementary to the HI test and allows the detection and titration of functionally 
important antibodies under the same principles than the Hemagglutination inhibition assay. In this 
case, the titrated antibodies neutralize the virus and prevent it from infecting a monolayer of Vero cells. 
The antibody titer in the NT test is the highest dilution of serum that still prevents cell infection, 
monitored by the presence of cytopathic effects (Cell death or presence of giant multinucleated cells).  
 
Two-fold serial dilutions of heat -inactivated serum in DMEM (Dubbleco’s Modified Eagle Medium, Life 
technologies) were preincubated in triplicates for 3h at 4°C with 100 TCID50/well of Measles Virus. After 
adding 6x103 Vero cells per well the micro titer plates were incubated under tissue culture conditions. 
On day 5, virus infection was monitored using a binocular magnifier and each well was checked for the 
presence of MV-induced cytopathic effects. Serum concentrations refer to the serum dilution in the 
presence of MV, before Vero cells were added. NT titer is defined as the highest dilution which 
prevented virus infection in at least 2 out of 3 wells. Sometimes intermediate values were estimated 
both for NT and HI titers after replication of the experiment. The highest serum concentration tested 
was 1:32. 
 
The Vero cells used in the NT assay were obtained from the ATCC and maintained in culture in the lab 
in DMEM (Gibco) containing 1% Ultroser G (Gibco) and 1% Pennicillin Strepomycin Glutamine (Gibco). 
Before use, the cells were harvested using 5ml of Trypsin/EDTA (Gibco) and washed in PBS (Gibco). 
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II.2.1.3 Immunological methods 
II.2.1.3.1 Mice T cell proliferation Assay 
 
The principle of a T cell proliferation assay is to induce the proliferation of specific T cell line by using 
peptides presented by antigen presenting cell. The induced proliferation is measured either by Tritiated 
thymidine incorporation, or by estimating the amount of IL2 produced using tetrazolium salt. 
 
The T cell hybridomas used in Mice T cell assays are immortalized T cells by fusion with a TCR 
negative thymoma. Stimulation by antigen can only be measured by cytokine (IL2) secretion. T cell 
hybridomas are weak responders and need high quantity of peptide (over 10 ng) for stimulation. 
 
This assay allows us to test the efficiency of expression of our T cell epitopes (and thus the expression 
of the whole construct) in vitro. In addition, adding antibodies binding to the B cell epitopes can be 
used to test whether they would enhance the antigen uptake, by measuring the increase of stimulation 
of epitope-specific T cell line induced by our proteins. 
 
We have performed a T cell assay using the M12.4.1 cell line as antigen presenting cell, which is a B 
cell lymphoblastoma (Fournier et al, 1996). The T cell lines used are two mouse T cell lines, the TNP79 
(stimulated by epitope 330 -345 of the MV nucleoprotein) and the TNP408 (stimulated by the epitope 
380-395of the MV nucleoprotein). 
 
Due to low sensitivity (compared to human T cell line) of the used lymphocytes, we have enhanced the 
antigen uptake of our APC, by incubating our constructs with a set of antibodies at a final concentration 
of 100ng per ml and per antibody. 
 
The antibodies used were:  
BH47 (specific of the NE region of the H protein: aa236-255) 
BH195 (specific of the HNE region of the H protein: aa379-410) 
BNP146 (directed to the 376-395 region of the Nucleoprotein) 
BNP176 (directed to the 136-144 region of the Nucleoprotein)  
 
All the cell lines used in this assay have become semi-adherent. To harvest the cells, the culture 
medium was collected and 10ml of PBS/EDTA were added to the TC flask. The flask was incubated for 
5 minutes at 37°C. In the meantime, the collected cell medium was centrifuged for 5 minutes at 
1200rpm and the supernatant was carefully discarded. The cells were resuspended in PBS/EDTA then 
added to the cell pellet and recentrifugated 5minutes at 1200rpm. The obtained pellet was 
resuspended in T cell medium (TCM). 
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TCM Culture medium: 
RPMI 1640 (Gibco) 
10% Fetal calf serum (Gibco) 
100ug/ml penicillin (Gibco) 
100ug/ml streptomycin (Gibco) 
2mM glutamine (Gibco) 
Sodium Pyruvate (1mM final) (Additional sugar) (Gibco) 
Non essential amino-acids (1:100 dilution) (Gibco) 
2B-mercaptoethanol (5µM) (reduction agent) (Sigma) 
Hypoxanthine-Thymidine (1:50 dilution) (Gibco) 
 
In each well of a 96well tissue culture quality microtiter plate was added 50µl of a serial (1:3) dilution of 
our 4 antigens diluted in TCM, 50µl of Antibodies (or a corresponding volume of TCM for the wells 
without antibodies) and 100µl of a suspension containing 100.000 T cell and 30.000 antigen presenting 
cell per well. 
 
Specific peptides served as positive controls: the Nucleoprotein derived peptides 2111C and NP379 
peptide (sequence from aa 379 to 394 of the N protein) were synthesized by solid phase FMOC 
synthesis. 
 
After filling the wells, the plate was sent back to the incubator for 24hours, to allow the antigen to be 
processed by the APC and to give some time to the APC to stimulate the T cells. 
After the incubation, the plate was removed from the incubator and frozen at –20°C to kill the T cells. 
The supernatant of every well was then transferred to another 96 well plate which contains 10000 IL2-
dependent T cells (CTLL). The IL2 that was produced during the priming of the T cell line induces the 
proliferation of the CTLL cells. 
 
After 24 hours, WST1 (Takara biomedicals) was added. WST1 is a tetrazolium salt that is cleaved by 
mitochondrial dehydrogenase in viable cells to produce fromazan, which has a red color. This red dye 
is proportional to the number of viable cells in the well and allows the quantification of the IL2 produced 
by the specifc T cell. Twenty-four hours after adding the WST1, the plates are read at 450nm (optical 
density subtracted from a reference wavelength at 650nm).  
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II.2.1.3.2 Human T cell experiment 
Amplification in the immune response usually involves proliferation of a particular subpopulation of 
lymphoid cells that are usually in a resting state.  Lymphoid cell responses to antigens are primarily 
measured by proliferation assays (Kozbor et al, 1989).  
 
Measurement of proliferative responses of cultured lymphocytes is a fundamental technique for the 
assessment of their biological response to the stimuli of our constructs. 
This experiment differs from the Mice T cell assay by the measurement of the proliferation induced by 
the stimulatory agent by the incorporation of tritiated thymidine (3H-Thymidine) into the DNA of dividing 
cells, a process which is closely related to cell proliferation.  
 
The antigen presenting cell used in this assay is an Epstein-Barr transformed human B lymphocyte, 
EBV6396 with the MHC-II haplotypes DR1 and DR1103.  
 
The specific T-cells will be stimulated by contact with the antigen-pulsed APC and will proliferate in 
response to the specific antigen, incorporating 3H-thymidine in their DNA.  The cells will be harvested 
and the proliferation will be measured by scintillation in a b-counter.  
 
In this test, we will use the following T-cell lines: 
FR6.6 (Specific of the fragment 254-268 of the F protein) 
254T2 (Specific of the fragment 254 -268 of the F protein) 
NP1.5 (specific of the fragment 185 -199 of the Nucleoprotein) 
TT830 (Specific of the tetanus toxoïd used as a negative control) 
 
The 4 T-cell lines and the APC cell line were kindly provided by Dr Stephan Demotz from the Institut de 
biochimie, Epalinges, Switzerland.  
 
Starting with a concentration of 1mg/ml solution in PBS, serial 4fold dilutions of our purified constructs 
lysate have been prepared. The APCs were washed 3 times in RPMI 1640 culture medium (Gibco) and 
centrifuged 5minutes at 200G. Before use, the APCs should be blocked to prevent non-specific signal 
generated by the proliferation of the B Lymphocytes. Therefore, the APC are incubated 30min at 37°C 
with 100mg/ml of Mitomycine C in 10ml of RPMI1640, which will block the cell cycle by cross-linking 
DNA. After incubation, the APC are washed 3times using RPMI containing 1% Fetal calf serum (FCS). 
The T-cell lines were washed once in T-Cell Medium (TCM) to remove the IL-2. 
 
After that process, 50µl of T cell were added to the wells, giving 30000 cells per well for FR6.6, 254T2 
and TT830 cell lines and 20000 cells per well for the NP1.5 cell line. Finally, 50µl (25000cells) of APC 
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were added to every wells. The plates were put back in the incubator at 37°C for 48h. At this time, the 
3H-thymidine is added to the wells. The dose added to every well correspond to 0.5 µCi (micro -curie) 
per well. The plates are put back into the incubator for 16hours.  
 
After the incubation, the wells are washed through absorbent paper (Titertek filter paper, ICN) to get rid 
of the 3H-tymidine that was not fixed by the cells and to coat the cells on the filter paper. This operation 
is performed using a Skatron 11025 cell harvester (ICN). The filter papers are dried at room 
temperature during 5-6hours to let the water evaporate (to prevent quenching and to limit the 
radioactive waste). 
 
The filter papers are then cut and placed into scintigraphic tubes that are filled with 1ml of scintillation 
cocktail (Optiphase 'hisafe' 2, Wallac). The tubes (Minis 2000, Zinsser Analytic) are loaded in a b-
counter (Rackbeta 1209, LKB) for a counting time of 1minute. 
 
Peptides representing the specific epitopes were used as positives controls: One peptide derived from 
the F protein (P1760, sequence 256-270), from the tetanus toxoid (P2049) and from the nucleoprotein 
(P1253, sequence 185-199). Control wells containing the APC or the T-cells alone were also planned, 
to assess the “background” effect of the cellular components alone (spontaneous cell division, non-
induced 3H-Thymidine uptake,…). 
 
II.2.1.3.3 Human T cell experiment with pulsing 
After seeing the results of the previous T cell assay, we wondered if some of the questionable results 
obtained could be caused by the blocking of the cell cycle by the Mitomycine C (to prevent proliferation 
of the APC). Although short peptides can be directly linked to free MHC molecules on the cell surface, 
longer peptides requires intra-cellular processing that may require full cell activity. In this T cell 
experiment, we reproduce a part of the previous T cell assay and we compare it with a similar setting 
where the APC is pulsed 8hours with the constructs before being blocked by the mitomycine C. 
 
For this experiment, we use the NP1.5 T cell line (specific of the fragment 185-199 of the 
Nucleoprotein) in conjunction with the EBV6396 APC (DR1, DR1103).   
 
We have the same quantities of constructs than in the previous T cell experiment, namely a serial 4fold 
dilutions of our purified constructs lysate (ABMVH1, AB NP1-7, MVH1 and CBMVH3), starting with 
50ul of a 1mg/ml solution of constructs in PBS. Peptides representing the specific epitopes were used 
as positives controls (P1760 is the sequence 256-270 from the F protein and P2049 as a negative 
control of proliferation.  Two plates were filled as exact duplicates. 
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One of the plates was kept at 4°c and the other was filled with 50.000 APC per well and incubated 
8hours at 37°C. This time will give to the APC enough time to process and express our constructs to its 
cell surface. 
After the incubation, the plates are washed three times with RPMI1640 (Gibco) and blocked with 
100mg/ml of Mitomycine C for 30min at 37°C. Five ml of RPMI medium containing 2.500.000 APC 
were also incubated with 100mg/ml of Mitomycine C, to be added to the non-pulsed plate. 
The APC are the washed 3 times in RPMI/TCM medium (4:1) (The FCS in the TCM medium helps 
inactivating the Mitomycine C) and centrifuged at 1200RPM (200g) for 5 minutes. The APC can then 
be distributed in the non-pulsed plate (25.000 APC per plate). 
 
The two plates are then filled with the T Cells (30.000 Tcell per well) and placed into the incubator for 
48hours. Reading of results is done as in II.2.1.3.2. 
 
II.2.1.3.4 FACS analysis and Staining 
An excellent way to detect if our obtained serum contained anti-MV antibodies was to test them in flow-
cytometry against MV-infected WMPT cells. The anti-MV antibodies would then bind to the MV-
proteins expressed on the surface of the WMPT cell (as H and F proteins) or intracellular proteins (as 
the N protein) after cell permeabilization. Detection of bound antibodies will be made possible by the 
use of FITC-labelled secondary-step antibodies.  
 
The WPMT cells must be harvested using PBS-EDTA (the use of trypsine damages the surface 
proteins) and washed 3 times in FACS medium at 1200RPM at 4°C. 20µl of serum diluted 1:10 are 
then added to 80µl of cells (200.000 cells) and incubated 15 min on ice. After the incubation, the cells 
must be washed 3 times as before to remove all unbound antibodies, being very carefull not to suck 
the pellet up during the removal of the supernatant. The cells are then resuspended in 100ul of FACS 
medium containing GaM/IgG FITC-labelled secondary-step antibodies diluted 1:200, and incubated 
15minutes on ice. After a last washing step to remove the unbound antibodies, the cell pellet is 
resuspended in 200µl of FACS medium containing 1µg/ml to allow dead cells discrimination. The 
analysis has been done on a Coulter Epics Elite ESP. 
 
Facs Medium: 
PBS 1X (Gibco) 
Bovine serum albumine 1% (Sigma) 
Sodium Azide 0.1% (Sigma) 
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II.2.2 Molecular biology techniques 
II.2.2.1 Enzymatic manipulation of nucleic acids 
II.2.2.1.1 Minipreparation of DNA  
This protocol is designed to allow the isolation of small quantities of DNA from bacterial cells, usually to 
screen bacterial colonies from a Petri dish. Our method is derived from the alkaline lysis protocol 
(Birnboim and Doly, 1979; Birnboim, 1983). In this technique, the bacteria are lysed with a solution 
containing Sodium-dodecyl sulfate (SDS) that will denature bacterial proteins, and NaOH that will 
denature chromosomal and plasmid DNA. The mixture is then neutralized with pot assium acetate that 
causes the covalently closed plasmid DNA to re-anneal rapidly. The chromosomal DNA and bacterial 
proteins will precipitate with the SDS and are removed by centrifugation. The plasmid DNA contained 
in the supernatant is concentrated by ethanol precipitation.  
 
Singles colonies are transferred to 1ml of LB medium using sterile toothpicks. The tubes are incubated 
4h to overnight at 37°c then centrifuged at 13000rpm for 5minutes. The supernatant is discarded and 
the pellet is resuspended (vortexed) with 100ul of ice-cold solution1 containing RNAse (120mg/L), and 
incubated for 5 minutes. 200ul of solution 2 are added and gently homogenized (to prevent genomic 
bacterial DNA to be separated from the membrane). After 5minutes of incubation at room temperature, 
150ul of solution3 are added and mixed. After 5 minutes on ice, the mixture is centrifuged at 13000rpm 
for 15minutes. The DNA is in the supernatant and must be precipitated with 1volume of 
Phenol/Chlorophorm/Isoamly-alcohol (Sigma) and centri fuged 5 minutes at 13000rpm. The aqueous 
phase is precipitated using 2 volumes of Ethanol 100% and put at –80°c for 30minutes. The tubes are 
centrifuged for 30minutes at 13000rpm and the pellet is washed with –20°c Ethanol 70%, dried and 
finally resuspended in 50ul of ddH2O or TE buffer. 
 
Solution 1: 
For 100ml: 
5ml Glucose 1M (ICN) 
2.5ml Tris-HCl 1M pH8.0 (Sigma) 
2ml EDTA 0.5M pH8.0 (Sigma) 
 
Solution 2 (freshly prepared): 
200ul NaOH 10M (Sigma) 
1ml SDS 10% (Merck) 
 
Solution 3: 
60ml KOAc (Merck) 
11.5ml Glacial acetic acid (Hanff frères) 
28.5ml ddH2O 
 
 
 
 
 60 
II.2.2.1.2 Maxipreparation of DNA 
The maxipreparation of DNA uses the same principle as the minipreparation, but adapts it to larger 
volumes of bacterial culture (up to 500ml) and uses anion exchange resin to purify plasmid DNA from 
the bacterial lysate. The negatively charged phosphates on the backbone of the DNA interact with the 
positive charges on the surface of the resin equilibrated in a low-salt buffer. Under moderate salt 
conditions, plasmid DNA remains bound to the resin while RNA, proteins, carbohydrates and other 
impurities are washed off. Finally, the plasmid DNA is eluted under high salt conditions. The eluate is 
ethanol-precipitated and the pelleted DNA resuspended inTE buffer.  
 
The alkaline lysis protocol follows the guidelines and uses the solution of the CONCERT high purity 
plasmid maxiprep system (Gibco). The purification uses the resin provided in the same kit with the 
following procedure. The column is equilibrated with the provided equilibration buffer and the DNA 
lysate is filtered on a nylon filter and poured in the column and the solution will drain by gravity. The 
resin is the washed twice with 50ml of provided washing buffer. The DNA is eluted using 12ml of 
elution buffer and collected in 1.5ml Eppendorf tube by fraction of 800ul. 570ul of Isopropanol are then 
added to the fraction. The tubes are cooled at –80°C for 30minutes and centrifuged at 13000rpm for 
30minutes at 4°c. The obtained pellet is washed with 70% Ethanol, dried and resuspended in 100ul of 
ddH2O or TE buffer. 
 
II.2.2.1.3 Annealing of oligonucleotides 
As our cloning fragments were purchased as short oligonucleotides, the two strands of DNA  
needed to be assembled to make double-stranded DNA.  
 
Both complementary oligonucleotides should be resuspended at the same molar concentration, using 
Annealing Buffer. Annealing should perform well over a wide range of oligo concentrations. 
Equal volumes of both complementary oligos (at equimolar concentration) are mixed in a 1.5ml 
microfuge tube. The tube is placed in a standard heatblock at 90 - 95ºC and then allowed to cool to 
room temperature (or at least below 30ºC) on the workbench. For sequences with significant hairpin 
potential, a more gradual cooling/annealing step is beneficial; this is easily done by placing the oligos 
in a water bath or temp block with a slow temperature decrease. The obtained fragments should be 
stored on ice or at 4ºC until ready to use. 
 
Anealling Buffer (pH 7.5 – 8.0): 
Tris 10 mM (Sigma) 
NaCl 50mM (Merck) 
EDTA 1mM (Sigma) 
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II.2.2.1.4 Enzymatic digestion 
The major tools for manipulating DNA and inserting defined inserts into expression vectors are 
restriction enzymes. These enzymes recognize short DNA sequences and catalyze specific reactions 
that cleave DNA molecules at specific sites within or adjacent to the recognition sequence. The 
enzymatic cleavage is achieved by incubating the DNA sample with the enzyme(s) in appropriate ionic 
conditions at specific, enzyme-depending, temperatures (most frequently 37°C).  
 
In general, we have used the commercially available buffers provided with the enzyme (Invitrogen). 
One unit of enzyme (1U) is the amount of restriction enzyme required to cleave 1ug of lDNA in one 
hour in the optimal conditions. 
The reaction protocol requires DNA in H2O or TE buffer. 
 
A typical DNA restriction reaction mix contains: 
0.1µg to 4µg of DNA 
2µl of 10x reaction buffer 
ddH2O up to 20ul 
1U to 5U/µg DNA of Restriction enzyme 
The total volume of the reaction may be increased to fit the quantity of DNA that needs to be digested, 
but the proportions of the reagents must be conserved. 
 
Two or more enzymes can be added in the same reaction mix if their respective conditions (buffer and 
temperature) are compatible and that given the max percentage of glycerol in the reaction -mix should 
not exceed 5% of total volume. If the two buffers are different, the best buffer is the one with the lowest 
NaCl concentration, provided that no unspecific cleavage occurs under these conditions. If the active 
temperature of the enzyme was different, the digestion was done with the first enzyme, then the 
temperature was changed and the second enzyme added.  
 
The mix is then incubated at the recommended temperature (mostly 37°c, 25°C for i.e. SpeI) for 30-
60minutes. Increasing the incubation time over 2hours does not improve the efficiency of the assay. 
The reaction can be stopped by adding 10% of Stop gel loading buffer (SGLB), or by precipitating the 
DNA using ethanol 95%. After washing in cold 70% ethanol, the DNA restriction fragments are ready 
for further enzymatic manipulations or electrophoretic separation in preparative agarose gels. 
 
Stop gel loading buffer (SGLB): 
For 50ml: 
25ml of glycerol (ICN biomedicals) 
10ml EDTA 0.5M pH7.5 (Sigma) 
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0.5g SDS (Merck) 
0.05g bromophenol blue (Serva) 
 
TE buffer (10 mM Tris-HCl pH 7.8; 1 mM EDTA) : 
For 600 ml solution:  
0.727 g Tris-HCl (Sigma) 
1.2 ml of 0.5M EDTA (Sigma) 
ddH20 is added up to 600ml and the solution is autoclaved.  
pH must be adjusted to 7.8 using 1 M HCl. 
  
II.2.2.1.5 Dephosphorylation of DNA using CIP  
Calf intestine phosphatase (CIP) catalyses the hydrolysis of 5’-phosphate residues from DNA. This 
phosphate residue is necessary for the ligation between two ends of cleaved DNA. 
 
In our case, we have used CIP to prevent the intramolecular ligation (self-ligation) of Bam-H1 cleaved 
pSFV1 vector and to improve the efficiency of the ligation with an (non-dephosphorylated) insert. 
 
The protocol of the manufacturer (Takara) recommends for 50ul of reaction: 
1 to 20pmoles of DNA termini 
0.1U of CIP (Alkaline phosphatase from calf intestine, Takara) 
in a buffer composed of: 
20mM Tris-HCl, pH8.0 (Sigma) 
1mM MgCl2 (Sigma) 
1mM ZnCl2  (Sigma) 
 
As a reference, for a vector of 5700base-pairs, 2ug of vectors is equal to 1.35pmole of DNA termini. 
The reaction takes place at 37°c for 1 hour and is stopped by either 10min at 70°c, or a double 
extraction with phenol/chloroform. 
 
II.2.2.1.6 Ligations 
To covalently link two 5’ phosphorylated dsDNA fragments, for example vector and insert, in a cloning 
experiment, we have used T4 DNA Ligase. The vectors and insert used for the ligation must have been 
carefully purified (using gel separation) to prevent external DNA fragments to be involved in the 
ligation. 
 
The Ratio between the vector and the insert is critical to obtain high-efficiency ligation. To increase the 
cloning efficiency, we usually did the experiment in triplicates using different ratios (usually 1:1, 1:5 and 
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5:1 in molarity) allowing to find the best vector/insert ratio. The recommended total amount of DNA 
(vector + insert) per ligation is comprised between 0.1µg and 0.5µg. 10µl of plasmid ligation buffer 
(Clontech) is added to the DNA solution. 1.2ul on a 10mM ATP solution is the added to the reaction 
mix, followed by 1ul of T4DNA ligase (Clontech). 
 
The reaction was then incubated in a waterbath at 16° for 30minutes. The efficiency may sometimes 
be increased by elongating the ligation time up to 12hours (overnight). 
 
At the end of the ligation time, glycogen is added to increase the precipitation yield at low DNA 
concentrations prior to stop the reaction. The mixture is then precipitated with 2 volumes of 100% 
Ethanol at –80°c for 1hour or more and centrifuged in a microfuge at 13000rpm for 30minutes.  The 
obtained pellet is then resuspended in ddH2O and used for electroporation.  
 
For ligations using single restriction site (i.e. ligation of a BamH1 -BamH1 insert in a pSFV1 vector), the 
dephosphorylation of the vector is strongly recommended to reduce the amount of intramolecular 
ligations. 
 
II.2.2.1.7 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) is an in vitro method for a site-directed enzymatic amplification 
of specific DNA sequences. The specificity of the PCR amplification is based on two oligonucleotide 
primers that flank the DNA segment to be amplified and hybridize to opposite strands. 
In our case, we have used PCR to extract the desired epitopes from cDNA of measles proteins and it 
was also used routinely to test the results of plasmid ligations. 
 
The specificity of the amplification reaction can be improved by fine tuning of the annealing 
temperature and magnesium concentration. A standard reaction mix for a 25ul reaction includes : 
 
2.5 µl of 10x Buffer (Gibco) 
1.5 µl of MgCl2 (Sigma) 
1 µl dNTP (Gibco) 
DNA template  
5-10 pmole of forward primer  
5-10 pmole of reverse primer 
0.3 ul of Taq polymerase (Gibco) 
Sterile H2o (Rnase/Dnase free) up to 25µl 
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The cycling conditions described hereafter are generic and could vary following the annealing 
temperature of the primers and the length of the amplified fragments. 
 
Thermal cycler program. 
The programs start when the lid of the cycler has reached 105°c  
Step Temp Time Action 
1 94°c for 2 minutes Denaturation (separation of DNA strands) 
2 94°c for 50 sec   
3 55°c for 15 sec  Annealing of the primers with the DNA  
Temperature must be the optimal t° for the primers used 
4 72°c for 15 sec  Elongation time.  
The time may be increased for fragments bigger than 1000bp 
5 ----- ------------- The programs restart at step 2 for 29 times  
6 72°c for 6 minutes Polymerase run -off 
7 4°c Until stop The cycler cool down to 4°c and stops  
 
II.2.2.1.8 Acrylamide Gel used for DNA separation 
Horizontal agarose gels prepared in TAE buffer, are generally used to analyse the size of DNA 
fragments. The concentration of agarose determinates the resolution of the electrophoresis separation 
(ranging form 0,8% to 1,5% agarose in TAE). Gels of 8x8 cm (called “Mini gels”) have been used. The 
DNA samples are loaded into the wells with 1:10 (V/V) of loading buffer. 
A current of 100V, 80mA is applied to the gels for 30minutes and the DNA can be visualized on an 
U.V. light due to the ethidium bromide added into the gel. A well of the gel must always be reserved for 
a reference ladder (In our case,  the 1kB+ ladder from Gibco). 
 
TAE buffer (Tris-Acetate EDTA) : 
Tris acetate : 40mM (Sigma) 
EDTA : 2mM (Sigma) 
Acrylamide gel (1%): 
50 ml of TAE buffer 
1% (W/V) of Acrylamide (Bio-Rad) 
0,5 µg/ml of Ethidium Bromide (Gibco) 
SGLB (Stop Gel Loading buffer) (for 50ml): 
25ml glycerol (ICN biomedicals) 
10 ml EDTA 0,5M pH 7.5 (Sigma) 
0.5 g SDS (Merck) 
0.05 g Bromophenol blue (Serva) 
ddH2O ad 50ml 
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II.2.2.1.9 Phenol/chloroform extraction 
Phenol/chloroform extractions are used for the separation of DNA and proteins. The DNA is soluble in 
the aqueous phase while most of the proteins remain in the organic phase, allowing a quick and safe 
separation. 
 
An equal volume of buffer-saturated phenol/chloroform/isoamyl alcohol (25:24:1) is added to the DNA 
solution. The solution is the mixed. Most DNA solutions can be vortexed for 10 sec except for high 
molecular weight DNA which should be gently rocked. The solution is spun in a microfuge for 3 min 
and the aqueous layer is carefully transferred to a new tube, being careful  to avoid the interface. This 
washing step can be repeated until an interface is no longer visible in the aqueous phase. To remove 
traces of phenol, an equal volume of chloroform is added to the aqueous layer and centrifugated for 3 
min. The aqueous phase is transferred to a new tube and precipitated using Ethanol 100%.   
 
II.2.2.1.10 DNA purification using silica matrix 
The gel extraction protocol hereafter is designed to purify small quantities of DNA from agarose gels. 
This method is suitable for non-supercoiled DNA only. The protocol uses silica resin (Gibco) to capture 
and purify the DNA fragment. The gel fragment is dissolved in sodium perchlorate and the DNA is 
adsorbed on the silica support as described by Vogelstein and Gillespie (1976). 
 
The desired fragment is excised from the acrylamide gel. The size of the gel fragment should be as 
small as possible, following closely the limits of the desired band. The gel fragment is mixed 1:3 (w/v) 
with a solution containing Sodium Perchlorate and Sodium acetate (Gel solubilization buffer, Gibco) 
and heated at 50°C for 10minutes with gentle agitation until the gel is dissolved. Add 1ul of silica resin 
(Gibco) for every 10mg of gel and incubate another 20minutes at 50°C with agitation. The mixture is 
then centrifuged at 12000g for 1 min and the supernatant is carefully removed and the resin pellet is 
washed first with a high salt solution (3 gel volumes of gel solubilization buffer) and then with a low salt 
wash containing ethanol (Matrix wash buffer, Gibco). After centrifugation (12000g for 1min) the resin is 
air-dried (to remove the ethanol from the wash buffer) and 20ul of TE buffer (pH 8.0) are added and 
incubated 5 min at 50°C. After another centrifugation, the aqueous phase containing the DNA can be 
separated from the resin. 
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II.2.2.1.11 DNA Sequencing  
At critical moment of our experiments, and after assembly of long stretches of DNA, we have confirmed 
the correct assembly of our constructs and the absence of mutations and frameshifts by automatic 
sequencing.  
The following protocol is based of the user manual for cycle sequencing from the Perkin-Elmer 
corporation and is used in conjunction with an ABI PRISM 377 automatic sequencer running 36 wells 
gels. 
 
The PCR reaction requires the following reagents: 
Terminator ready reaction Mix (Perkin-Elmer): 8µl 
Template: around 0.2µg/µl in a volume between 1.5µl and 2.5µl. 
Specific primer: 5pmole 
dH2O: ad 20µl. 
 
A reference sample, used as a positive control for the reaction, is added in every sequencing 
experiment. It is a pGEM vector used with a M13 (-21) primer. 
 
The thermocycler program is the following:  
The programs start when the lid of the cycler has reached 105°c  
Step Temp Time Action 
   Rapid thermal ramp to 96°C 
1 96°c for 1 minute Denaturation 
2 96°c for 10 sec  Denaturation 
   Rapid thermal ramp to 50°C 
3 50°c for 5 sec Annealing 
   Rapid thermal ramp to 60°C 
4 60°c for 4 minutes Elongation 
5 ------- --------------- The programs restart at step 2 for 25 cycles 
   Rapid thermal ramp to 4°c 
6 4°C Until stop  
 
Upon completion of the sequencing reaction, the DNA is precipitated using conditions where 
unincorporated nucleotides do not co-precipitate. Unincorporated nucleotides need to be separated 
from the sequencing product, to prevent them to interfere with the sequence determination near the 
primer region.  
In general, this can be achieved by Ethanol precipitation of the reaction. The reaction can be 
precipitated using 50µl of ethanol 95% and 2ul of 3M sodium Acetate, pH5.2. 
 67 
The tube is the placed into a –80°c freezer for 30minutes and then centrifuged at 13000rpm for 
20minutes. The supernatant was discarded as completely as possible. The pellet was then rinsed with 
70% ethanol and centrifuged 20 minutes. The washing process has to be done twice. Alternatively, 
Centrisep spin columns (Princeton separations) can be used to purify the sequenced products. 
 
Obtained pellets are resuspended using 3.5µl of a loading buffer composed of deionized formamide 
and 25mM EDTA (pH8.0) containing 50mg/ml blue dextran in a ratio 5:1 formamdide to EDTA/Blue 
dextran. 
Before loading to the gel, the samples must be thoroughly vortexed to resuspend the pellet and 
denatured at 90°c for 2 minutes. The samples can be loaded immediately. Cooling of the samples on 
ice is NOT recommended.  
 
Sequencing gels have been prepared according to the manufacturer’s instructions. 
The gels have to be prepared between two and six hours before loading. Preparation of the 
polyacrylamide gel is the most important variable that determines the number of bases that can be 
read when sequencing DNA. Polyacrylamide gels are formed by the copolymerization of acrylamide 
and bis-acrylamide (19:1 mix). The process begins when TEMED (N,N,N’,N’ 
Tetramethyethylenediamine) reacts with APS (ammonium persulfate) to yield a TEMED radical cation, 
a sulfate radical and a sulfate ion. The sulfate radical adds an unpaired electron to the acrylamide 
monomer, converting it to a free radical which then reacts with more monomer, causing polymer chain 
elongation. The polymer chains are randomly cross-linked with bis-acrylamide to form the gel matrix. 
 
10X TBE stock solution, pH 8.3 
Tris-base 108g (Sigma) 
Borate 55g (Sigma) 
Na2EDTA 2H2O 8.3g (Sigma) 
 
40% Acrylamide bis-acrylamide (19:1) stock solution 
Acrylamide 38g (Sigma) 
Bis-acrylamide 2g (Sigma) 
H20 ad 100ml 
Acrylamide solution has to be de-ionized by stirring 10minutes with 10g of 
mixed-bed, ion-exchange resin and filtered on a 0.2µm filter. 
The solution is very sensible to light and heat and must be conserved 
accordingly. 
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Gel solution: 
Urea 18g (Sigma) 
40% Acrylamide stock 5.5ml 
dH2O 25ml 
Mixed bed ion exchange resin 0.5g (Bio-Rad) 
 
The solution is stirred until all the urea crystals have dissolved then filtered on a 0.2µm cellulose nitrate 
filter and degassed for 2minutes. 
5ml of 10xTBE solution is then added and volume is completed to 100ml with dH2O. 
Upon injection, 250µl of freshly prepared 10% APS (Bio-Rad) and 35µl of TEMED (ICN) are added to 
the gel solution and mixed. The solution should be casted immediately after adding the polymerizing 
reagents. Loading can be done 2hours after casting, when the gel is fully polymerized.  
 
II.2.2.1.12 In vitro transcription of pSFV1 constructs 
In vitro transcription of our pSFV1-cloned constructs has been performed to obtain RNA of our 
recombinant proteins. The obtained RNA will be used later for transfection of Eukaryotic cells. 
 
First of all, the concentration of our DNA constructs should be precisely estimated by measuring their 
absorbance at 260nm. As a second step, all the vectors are digested using SpeI to linearize the 
constructs and prevent polymerization. 
 
The rNTP, enzymes and Cap are provided by Promega. In a tube, add 100µl of rTTP 50mM, 100µl of 
rCTP 50mM, 100µl of rATP 50mM and 50µl of rGTP 50mM. The lyophilisated 5’cap is resuspended 
with 24,2ul of ddH2O. 
 
SP6 buffer 10x stock: 
MgOAc 1M: 30µl (Sigma) 
Spermidine HCl 100mM: 100µl (Sigma) 
Hepes HCl 1M: 200µl (Sigma) 
H2O: 170µl 
Reaction mix: 
DNA (5 µg) 
SP6 10x: 5µl  
DTT 100mM : 2.5µl (Invitrogen) 
Cap (50mM) : 1µl 
rNTP mix : 2µl 
ddH2O : 35µl 
RNAsine (N2511) 40u/µl : 1.5µl 
SP6 20u/µl : 1.5µl 
 
The reaction takes place at 37°C for 1 hour.  
The obtained RNA has to be frozen at -80°C if not used immediately. 
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II.2.2.1.13 Transfection using electroporation for Eukaryotic cells  
This technique will allow the transfection of RNA in BHK-21 cells to induce the synthesis of our proteins 
by eukaryotic cells. Due to the relative fragility of eukaryotic cells, it is extremely important to work 
quickly and on ice. 
 
Sub-confluent BHK-21 cells are resuspended using Trypsine-EDTA. After a washing step in PBS 
without Ca++/Mg++, the pellet containing about 107 cells is resuspended in 10ml of PBS without 
Ca++/Mg++. Before electroporation, 800µl of BHK cells (about 8 105 Cells) is transferred to a pre-chilled 
cuvette containing 25µl of RNA solution.  
 
The cuvette is then loaded in Gene Pulser II electroporation device (Bio-Rad) where two pulses of 
850V, 25µF are applied. The duration of each of these pulses should be in a bracket of 0.36-0.40 
milliseconds. The cells are then transferred into 75cm3 tissue culture flaks containing 20ml of medium. 
The flasks are incubated 18h to 24h at 37°C then the cells are harvested using Trypsine-EDTA. The 
obtained pellet is sonicated 10 seconds to disrupt the cell walls and release the proteins. The 
supernatant is collected after a centrifugation at 500g for 10min.  
 
II.2.2.2 Culture and induction of bacteria 
II.2.2.2.1 Culture medium and agar plates 
The bacterial cultures use Luria -Bertani growing medium and 50mg/L of ampicilin. All bacterial cultures 
are always incubated at 37°C with 150rpm agitation. 
 
LB Broth (Luria-Bertani):  
10 g Bacto-tryptone (Difco) 
5 g Bacto-yeast extract (Difco) 
5 g NaCl (Merck) 
1 L water  
Autoclaving is strongly recommended 
 
For selection of resistant colonies, bacterial cultures are plated on Petri dishes containing agar. To 
prepare the agar plates, 7.5g of bacto agar (Difco) were added to 500ml of LB medium and autoclaved. 
The medium was then put into a 50°C waterbath until its temperature was stabilized and ampicilin (at a 
final concentration of 50mg/L) was added. The LB agar was then poured in sterile Petri dishes. The 
filled plated were let in a lamina flow until the LB was solidified. 
II.2.2.2.2 Production of electro competent cells  
Electroporation is a fast and efficient way to transform bacteria using plasmid DNA. In this process, E-
Coli (DH5a) are prepared and washed to become electro-competent. 
 70 
A fresh overnight culture was used to inoculate LB medium with a commercial stock of DH5a (the use 
of an “old” generation of electro competent DH5a decreases the efficiency of transformation). The 
inoculated culture is incubated at 37°c for about 5 hours until it has reached an optical density at 
600nm of about 0.5 – 0.6. The culture is the centrifuged (5000rpm for 15min) at 4° and the supernatant 
is discarded. The bacterial pellet is resuspended in ice-cold sterile water and resuspended thoroughly. 
The centrifugation and washing steps are repeated twice. If the cells had to been frozen for a later use, 
the cells were resuspended in an equal volume of 10% Glycerol before freezing at –80°c. 
 
II.2.2.2.3 Transformation using Electroporation for bacterial cells 
Electroporation is a method of transformation that allows the introduction of foreign DNA into host cells 
(prokaryotic or eukaryotic) via the application of high-voltage electric pulses. The electric field induces 
pore formation in the cell wall and increases the permeability of the host cells to macromolecules, 
which allows for the uptake of DNA. Electroporation is a common method for the introduction of foreign 
DNA, such as plasmids, into Escherichia coli. (Lurquin, 1997) and can produce between 108 and 1010 
transformed bacteria per µg of plasmid DNA.  
The electroporation device used is a Gene Pulser II equipped with a Pulse controller plus and a 
capacitance extender plus (Bio-Rad). The conditions of the pulse were: 2500 Volts, 200 Ohms and 25 
µFarad. 
 
Ligated vector DNA at a concentration of 5pg to 10ng was added to 20ul of ice-cold competent cell. 
Sterile water was added up to 50ul and the mix was transferred into an electroporation cuvette. 
The filled cuvette was inserted in the electroporation device and the pulse was applied. 
An efficient transformation should show a pulse time of about 5 milliseconds. Lower values may results 
in poor efficiency due to high conductivity of the medium. 
 
The cuvette was then filled with 1ml of freshly prepared SOC medium and put into a 37°c water bath 
for 30minutes, allowing the bacteria to recover in a medium containing high concentration of glucose. 
Two hundred milliliters of transformed bacteria are plated on an agar Petri dish containing selection 
antibiotics and incubated overnight at 37°C to amplify the individual clones. 
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SOB medium: 
For 1liter: 
20g Bacto-tryptone (Difco) 
5g Bacto-yeast extract (Difco) 
0.5g NaCl Merck) 
900ml dH2O 
10ml KCl 250mM (Sigma) 
Adjust to pH7.0 and autoclave 
 
SOC medium: 
For 50ml: 
48.75ml SOB sterile medium  
250ul MgCl2 2M (Sigma) 
1ml Glucose 1M (ICN) 
 
II.2.2.2.4 Glycerol Stock of transformed bacteria 
As mentioned before, the use of bacteria for expressing our proteins offers us a great flexibility that 
allows for example to freeze a stock of our proteins for long term conservation. Bacterial clones in 
intermediate steps of constructs assembly and the final recombinant expression vectors were 
conserved as glycerol stocks at -80°C. These stocks made it easy to restart a new culture that will 
have the same properties as the original strain. 
 
Conservation of our bacteria is simply done by mixing 850ul of bacterial culture (with an Optical 
Density at 600nm between 0.5 and 0.6) with 150ul of sterile glycerol. The vial is then vortexed and 
immediately frozen at –80°c or in a liquid nitrogen tank (for long term storage). 
Cultures frozen in such a way have been shown to keep the vector intact for more that two years. 
 
II.2.2.2.5 Induction of recombinant proteins using IPTG  
For expression of recombinant proteins and polyepitopes, a set of vectors featuring a T7 promoter and 
a lac operator was used. These vectors are derived from Novagen’s pET vectors, a plasmid for 
cytoplasmic production in E Coli, originally designed by Studier et al (Studier and Moffatt, 1986; 
Rosenberg et al, 1987; Studier et al, 1990).  The expression is induced by providing a source of T7 
RNA polymerase in the host cell. Plasmids are transfected into expression hosts (BL21DE3 cells) 
containing a chromosomal copy of the T7 RNA polymerase gene under LacUV5 control, and 
expression is induced by the addition of IPTG.  
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Before induction, a single colony from BL21DE3 transformed with our pET vectors is picked and used 
for inoculating 50ml of LB containing 100mg/L of Ampicilin. Alternatively, 10-20µl of a glycerol stock 
can be used for inoculating the LB. 
 
The Erlenmeyer flask is incubater at 37°C with shaking until the OD at 600nm reaches 0.4-0.6. IPTG 
0.5mM is added to the flask and induction continues for 3-4 hours. The cells can then be harvested by 
centrifugating at 5000g for 5min at 4°C. The cell can then be lysed to recover the periplasmic fraction 
containing the recombinant proteins. 
 
This protocol was generic and showed a poor efficiency with some of our proteins. Its was therefore 
improved by several modifications concerning the time of induction or the concentration of IPTG. This 
part is further developed in the results section. 
 
II.2.3 Protein purification and characterization 
II.2.3.1 Extraction of soluble protein from bacterial cells 
The vector’s manufacturer was recommending a lysis using Tris-HCl and EDTA followed by a second 
step in 5mM MgSO4. As preliminary tests have shown that a proportion of the protein was still 
contained in the cytosolic fraction of the cell, we decided to use a different lysis technique to recover a 
maximum quantity of our proteins. Moreover, the EDTA contained in this protocol would have 
perturbated the planned purification using HPLC Nickel columns (stripping agent). A lysis protocol 
using physical disruption and no EDTA was chosen instead. 
 
At the end of the induction, the culture is centrufugated at 5000g for 5min. The supernatant is 
discarded and the pellet is frozen at -80°C for 30min then reheated at 37°C for 5minutes. The thawed 
pellet is then ultrasonicated for 10minutes in presence of 5ml of PBS. This process is repeated 3 times. 
At the end of the third cycle, the pellet is resuspended in a solution containing 6M guanidine HCl pH 
7.8, 20mM NaPO4 and 500mM NaCl and centrifugated at 3000g for 15min. The supernatant obtained 
contain up to 2ug/ul of total protein. 
 
To concentrate the obtained supernatant, the samples can be passed on Microcon 10kd spin-columns 
and washed with PBS. 
 
II.2.3.2 Purification of histidine -tagged recombinant proteins by metal chelate chromatography 
Soluble recombinant proteins from bacterial lysates were HPLC purified under native conditions on 
imobilised metal affinity chromatography columns (IMAC). Recombinant proteins presenting a hexa-
histidine tag are retained on a chromatographic matrix presenting bivalent metal ions at pH 7.4. The 
metal ions most often used are nickel (Ni2+) copper (Cu2+) and zinc (Zn 2+). 
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The strong interaction of penta- or hexa-histidine motifs with bivalent metal ions allows to retain 
proteins with a histidine tag on an IMAC matrix while non his-tagged proteins are removed from the 
column by a washing step. Elution is generally obtained by increasing the imidazole concentration in 
the mobile phase. Alternatively a decrease in pH can be applied to elute the bound proteins. Imidazole 
competes with the histidine motifs for the binding sites (chelated bivalent metal ions) on the matrix, 
leading thus to the desorption of bound proteins. At low imidazole concentrations histidine containing 
proteins are eluted, whereas histidine-tagged recombinant proteins display a stronger interaction with 
the matrix and require generally higher imidazole concentrations for elution to occur, allowing thus for 
the preparation of a relatively pure recombinant protein in one purification step. If the optimal imidazole 
concentrations for washing and elution are determined the separation can be realized as a two step 
procedure. 
Optimal his-tag mediated binding may be reduced for specific proteins. The folding properties of a 
given recombinant protein may reduce the accessibility of the purification tag for the matrix bound ions 
and thus reduce the yield of the purification. In these cases purifications under denaturing conditions, 
using buffers containing urea or guanidinium hydrochloride, may render the IMAC purification possible 
but require a subsequent refolding step to restaure the initial protein conformation.  
We compared native and denaturing conditions for the purification of several of the recombinant 
proteins used in this study. Since the yields were comparable we prefered the the non-denaturating 
buffer system.  
 
Chromatographic separations were done with a HPLC system, the AKTA explorer 10S station (AP 
Biotech) coupled with a fraction collector, the FRAC950 (AP Biotech). This equipment consists of a two 
pump gradient former for a precise control of elution conditions and a variable wavelength UV detector 
for the monitoring of the protein content by absorbance measurement at 280nm and 230nm. Eluate 
fractions of 200ul were collected in ELISA plates for convenient detection of relevant protein fractions 
after chrom atographic separation.  
The chromatographic columns were 1ml HiTrap chelating columns (AP Biotech, Nr: 17 -0408-01) with a 
maximal binding capacity of 12 mg his-tagged protein / ml matrix. The matrix (Chelating Sepharose 
High Performance) consists of highly cross-linked agarose beads to which iminodiacetic acid has been 
coupled by stable ether bounds via a seven-atom spacer arm.  
The charging of the chelating matrix with Ni++ was achieved by injecting 0,5ml of a 0,1M NiSO4 
solution. Non chelated nickel ions were removed from the column during a washing step with 5 column 
volumes of water before the column was equilibrated at a flow of 1,0 ml/min. in the starting buffer, 
100% buffer A (20mM phosphate buffer, pH 7,4, 500mM NaCl). To avoid cross-contaminations we 
reserved one column per protein sample, following the instructions of the manufacturer for matrix 
regeneration. 
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A representative chromatogram (Fig 25) shows  the different steps of the purification of recombinant 
proteins with a hexa-histidine tag.  
 
The soluble fraction of the bacterial lysate was diluted in buffer A prior to injection on the column. The 
protein sample was loaded on the column by repeated injections of 1ml aliquots, using a 1 ml sample 
injection loop. Non retained proteins were collected in a “flow-through”fraction (fraction Fr3). Upon 
completion of the sample injection the column was washed with 10 column volumes of buffer A. The 
wash was collected in fraction Fr4.  
Elution of matrix bound proteins was achieved using a gradient of buffer B (20mM phospate buffer, pH 
7,4 ,500mM NaCl, 500mM imidazole) in buffer A. This gradient (green curve, %B shown on right y 
axis) increases the percentage of buffer B from 0 to 30%B in 3 column volumes, from 30 to 97%B to in 
4 column volumes, from 97 to 98% in 9 column volumes. A final increase to 100%B cleans the column 
and stops fractionation prior to re-equilibration in starting buffer. After onset of gradient the baseline 
absorbance at 280nm increases due to the increased concentration of imidazole in the mobile phase. 
The eluate between 2% and 100% B buffer was collected in 200ul fractions in 96 well plates. Proteins 
were dectected by UV monitoring at 280 nm (blue curve, left Y axis).  After overnight incubation the 
fractions were transferred in a fresh 96 well plate and the 96 well plate used for fraction collection 
served to test the eluate fractions for reactivity with specific moAbs in ELISA.  
The results of the ELISA assay (red dotted line) are overlayed as an activity histogram on the 
chromatogram. 
Peak A, which is eluted at low imidazole concentration, contains bacterial proteins which are weakly 
bound the Ni++ column, the his-tagged recombinant protein is eluted in peak B.  
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Fig 25: Chromatographic purification of his-tagged recombinant protein 
Wash Sample Injection Elution Equi- 
libration 
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Fractions containing antibody reactive his-tagged proteins were subsequently pooled. The pooled 
proteins were desalted and concentrated using centrifugal filter devices (microcon or centricon, 
Millipore) with appropriate size exclusion membranes (10 kD or 30kD) to retain the proteins of interest. 
The retained proteins were thus transferred in PBS 1x buffer, quantified and used for further tests and 
immunizations. 
 
The elution of histidine-tagged proteins by applying a linear imidazole gradient (brown dotted line) 
under native conditions (20mM Phosphate, pH7.6, 500mM NaCl) has been monitored at 280nm (blue 
line). Eluate fractions (200?l) have been tested in ELISA with an anti-his moAb and  the signals 
(OD405nm) of the fractions are represented as an overlayed histogram (Fig 25 and Fig 26).  
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Fig 26: IMAC purification of his-tagged poly-mimotopes from soluble bacterial protein fraction 
The red line shows the protein elution curve 
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IMAC Buffers : 
 MW     
Na2HPO4 – 2 
H2O 
177.99 1.42 g 
(*1.13g) 
7.1 g 
(*5.66g) 
 * if Na2HPO4 
anhydrous 
NaH2PO4-
H2O 
137.99 1.11 g 5.55 g 
 
  
NaCl 58.44 23.38 g 116.9 g   
H2O  90ml 450ml   
  100ml 500ml   
pH is then adjusted to 7 
 
II.2.3.3 Protein quantification using Bradford reaction (biorad, cat  n°500-0116)  
The determination of protein concentration is extremely important in the course of our experiments for 
the reliability and reproducibility to SDS page, ELISA and other tests, such as immunization with 
recombinant protein. The test we are using is derived from the Bradford reaction, but with a quicker 
and more stable coloration. 
 
A standard curve is prepared using 5 dilutions of a reference protein (Bovine serum albumin) of known 
concentration. The absorbance at 750nm of these dilutions is linear from 0 until 1.5 ug/ul. 
10 ul of every reference and test samples are pipetted into a well of a flat-bottom 96 wells plates. 20ul 
of the reagent A of the kit are then added to the samples and mixed. After shaking thoroughly, 180ul of 
the reagent B are added to the plates and mixed with the pipette. After 15 minutes, the results can be 
read at 750nm in an ELISA reader. The values will remain stable for at least 1hour. 
The values obtained by this method can be easily analyzed by plotting the reference values into an 
excel graph, and using the “trend line” function to obtain the formula of the line. This function can then 
be used to calculate precisely the concentration of the unknown samples. 
 
II.2.3.4 Protein separation using electrophoresis (SDS-PAGE) 
To assess the efficiency of our expression system, we analysed bacterial lysate of expression clones 
using denaturating protein gels, SDS-PAGE (SDS PolyAcrylamide Gel Elecrophoresis). 
 
One-dimensional electrophoresis using discontinuous gels is a high resolut ion method used to 
separate mixtures of proteins to investigate subunit composition.  
Our protocol is based on the standard Laemmli method (Laemmli, 1970), used for discontinuous gel 
electrophoresis under denaturing conditions (using 0.1%SDS). Dithiotreitol (DTT) can be added in the 
samples before loading to reduce the disulfide bonds to minimize protein aggregation.  
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Casting of the gels:  
The gel is composed of two parts: A separating gel, where the actual size separation will take place, is 
casted first. The acrylamid concentration can vary between 6% and 15%, defining the gel porosity and 
thus the separation range. The stacking gel is casted on top of the separating gel. This stacking gel will 
concentrate the sample before entering the separating gel. 
 
The gel material is home made and consists of two 9cm x 9cm glass squares assembled on 1mm thick 
spacers and held together using metal clamps. Agarose is poured on the side and bottom of the gel 
casing to prevent leakages. 
 
Separation gel composition: 
For 10ml of separating gel mix 
Density 6% 8% 10% 12% 15% 
Optimal range 150-60kD 70-45kD 55-30kD 35-15kD 25-5kD 
H20 5.3ml 4.6ml 4.0ml 3.3ml 2.3ml 
30% acrylamide mix 2.0ml 2.7ml 3.3ml 4.0ml 5.0ml 
1.5M Tris (pH 8.8) 2.5ml 2.5ml 2.5ml 2.5ml 2.5ml 
10% SDS 0.1ml 0.1ml 0.1ml 0.1ml 0.1ml 
10% APS 0.1ml 0.1ml 0.1ml 0.1ml 0.1ml 
TEMED 0.008ml 0.006ml 0.004ml 0.004ml 0.004ml 
 
Remark: The TEMED is a polymerization catalysor that works only at basic pH. The pH of the solutions 
is critical to ensure correct polymerization. 
After casting, the gel is covered with a layer of isopropanol to prevent oxidation. The gel is let to 
polymerize for 30minutes. When the gel is polymerized, the isopropanol is removed and the stacking 
gel is casted. 
 
For 4ml of stacking gel 
H20 2.7ml 
30% acrylamide mix 0.67ml 
1.5M Tris (pH 8.8) 0.5ml 
10% SDS 0.04ml 
10% APS 0.04ml 
TEMED 0.004ml 
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Right after casting, the comb is inserted into the stacking gel. The gel is the allowed to polymerize 30-
60 minutes and the transferred to the electrophoresis tank (X-Cell 2, Novex). The tank is immediately 
filled with the electrophoresis buffer to prevent the gel from drying. 
 
Electrophoresis buffer (final concentration): 
25mM Tris (Sigma) 
250mM glycine (pH8.3) (Sigma) 
0.1% SDS (Merck) 
 
Prior to sample loading, the wells are rinsed with a syringe and a long needle to remove the non-
polymerized acrylamide. 
Before loading, the samples are mixed with 1 volume of loading buffer containing SDS: 
50mM Tris-HCl (pH 6.8) (Sigma) 
2% SDS (Merck) 
0.1% bromophenol blue (Serva) 
10% glycerol (ICN biomedicals) 
 
100mM (final concentration) of dithiotreitol (DTT) can eventually be added in the mix. 
The samples are then boiled for about 3minutes to unfold the proteins. 
After loading of the sample, the electrophoresis is connected to a power supply (E835, Consort) at 
100V, 80mA until the bromophenol blue reaches the bottom of the gel. 
 
The gel can then be used for coloration using Coomassie brilliant blue or for western blot analysis. 
 
Products used: 
Tris (Sigma) 
Glycine (Sigma) 
SDS: Sodium Dodecyl sulfate (Sigma) 
Tris-HCl (Sigma) 
Bromophenol blue (Serva) 
Glycerol (ICN biomedicals) 
APS: Ammonium persulfate (Sigma) 
30% Acrylamide mix: Consists of a mix of 29% of acrylamide (Sigma) and 1% of 
N,N’-methylenebisacrylamide (Sigma) in ratio weight/volume in deionized water.  
TEMED: N, N, N’,N’-tetramethylethylenediamine (Bio-Rad) 
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II.2.3.5 Reversible protein detection kit (Sigma, cat ref R-PROB) 
This kit is an analog to the Ponceau S reaction for reversible staining of proteins on membranes and 
presents the great advantage of a reduced background on PVDF membranes after destaining. The 
protocol has been slightly modified. After the blotting process, the membrane is washed 5 minutes and 
incubated with the protein detection kit solution for about 15 minutes. The membrane is then washed 
with ddH20 until the desired contrast is achieved. The membrane can then be scanned or 
photographed. Finally, the coloration is removed using EDTA 50mM prior to immunostaining.  
 
II.2.3.6 Coomassie brilliant blue coloration 
Coomassie staining is one of the simplest non-radioactive methods to visualize proteins in gels. To 
color a gel using Coomassie brilliant blue, 125 mL of methanol is combined with 25 mL of glacial acetic 
acid and 100 mL of dI water to make 250 mL of destaining solution. 0.1g of Coomassie Brilliant Blue R-
250 is dissolved in 50 mL of the destain solution to make 50 mL of Coomassie staining solution. The 
gel can then be immerged in the Coomassie staining solution on a rocking platform shaker for 1 hour to 
overnight. Increasing the time can improve the detection of possible faint protein bands. After 
coloration, the Coomassie stain is discarded and the gel is washed in destain solution until the 
background in the gel is clear. The destaining usually takes 1 hour or longer and the solution can be 
replaced with fresh solutions several times as necessary.  
II.2.3.7 Western Blotting 
Western blotting (or immunoblotting) will allow us to identify proteins separated by SDS-page using 
monoclonal antibodies. This experiment consist to transfer elelectrophorically the proteins from the gel 
to a PVDF membrane (Bio-Rad) using a semi-dry transfer apparatus. The membrane-bound proteins 
are then probed with a selection of antibodies. 
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In the semi-dry blotting, the gel is placed in contact with the PVDF membrane and compressed 
between buffer-saturated Whatmann paper in contact with the electrodes, with the following 
organization: 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 27: Structure of a Western blot “sandwich” 
 
The electrodes are the connected to the generator and a current of 8V, 100mA is applied to the 
assembly for 1hour. 
 
Cathode buffer: Anode Buffer I: Anode Buffer II: 
25mM Tris-Base 
40mM 6-aminohexanoic acid 
20% methanol 
30mM Tris-Base 
20% Methanol 
 
300mM Tris-Base 
20% Methanol 
 
 
At the end of the transfer, the membrane is colored with Ponceau S or Reversible protein detection kit 
(Sigma). 
 
The membrane can then be prepared for immunostaining using mono- or polyclonal antibodies. First, 
all remaining binding sites have to be blocked with PBS, 0.1% Tween20 and 5% powdermilk (Gloria, 
Nestlé) for 1hour with a gentle agitation. At the end of the blocking, the membrane has to be carefully 
washed using PBS 0.1%Tween20 (3 times 2minutes). The membrane is then incubated 1 hour with the  
diluted antibody and subsequently washed as indicated in the previous step. The antibody-antigen 
complex is then incubated with a Goat Anti-mouse IgG labeled with alkaline phosphatase (Southern 
biotechnology associates) during 1 hour, with a gentle agitation. After the washing step, the substrate 
(5-Bromo-4-Chloro-3-Indolyl phosphate/Nitro blue tetrazolium tablets, Sigma) is added to the 
3 layers of absorbant paper in Anode II Buffer 
3 layers of absorbant paper in Anode I Buffer 
PVDF membrane 
Acrylamide Gel 
3 layers of absorbant paper in Cathode Buffer 
Anode (+) 
Cathode (-) 
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membrane to monitor the activity. The reaction is usually quick and can be stopped after 5 to 15 
minutes depending on the signal intensity and background staining. 
 
II.2.3.8 Proteinase inhibitor  
To prevent our cell lysate containing our proteins to be degradated by proteases, we have added to our 
lysates a preservation mix made of several proteinase inhibitor: 
Leupeptin: 10µg/ml (Sigma) 
PMSF (Phenylmethylsulfonyl  fluoride): 10mM (Roche) 
Apoprotein: 10µg/ml (Sigma) 
Iodoacetamide: 108mg/ml (ICN) 
 
II.2.4 Animal experiments 
II.2.4.1 Animal anesthetics 
During the course of our animal experiments, Mice anesthesia was sometimes needed for critical 
manipulations requiring easy access to the mouse’s body during, for example, blood collection or ear-
tagging. The described injectable anesthetic mixture paralyses the mouse and leaves it for 10 to 15 
min in stable position for facilitated handling. 
 
For 4ml of anesthetic mixture, mix: 
0,5ml of Imalgene 1000 
0,5ml of Rompun 1:10 in PBS 
1ml of Atropinum sulfuricum 1:10 in PBS 
2ml of PBS 
 
The mixture should be prepared freshly before injection. A volume of 100 ul/10mg of body weight is 
injected into the peritoneal cavity using 1ml syringes. The mice fall asleep 2-5 minutes after injection. 
 
The anesthetic mixture reagents can only be ordered by veterinary prescription: 
Imalgene 1000 (ketamine 100ng/ml) (Merial) 
Rompun 2% (Xalyzine 20mg/ml) (Bayer) 
Atropinum sulfuricum 1% (WDT) 
 
II.2.4.2 Immunization and boostings 
The most critical and final step of our experiment is the animal experiment. During this long process, 
our constructs will be injected in the mice that will generate an immune response towards our 
constructs.  
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Production of good antisera depends in large part upon the quality, purity and amount of available 
antigen as well as on the specificity and sensitivity of the assay. Immunization of inbred mice allows 
the study of precisely defined antibody specificity along with high reproducibility of the results due to 
the high similarity between individuals. The adjuvant used is the Freund’s adjuvant (Freund et al, 
1937). 
 
Every construct will be injected to a group of five Balb-c mice (H2d). A week prior to immunization, 
every mouse is bleed to collect a sample of “naïve” reference serum. The day of immunization, one 
volume of a solution of 0,5ug/ul of each construct is mixed with one volume of complete Freund’s 
adjuvant. 
The solution is mixed in a glass tube using a glass syringe until a stable emulsion is obtained. 
Two hundred µl of emulsion are then injected in the peritoneal cavity of each mouse. 
Boosting injections are done in the same way, but using incomplete Freund’s adjuvant instead. 
 
After the primary immunization, naïve B cell of the mice are stimulated to differentiate into antibody -
secreting plasma cells. For most soluble protein antigens, specific antibodies begin to appear 5 to 7 
days after the animal is injected. The antibody concentration continues to rise and peaks around day 
12 after which it decreases. In addition to differentiating into antibody-forming cells, the stimulated B 
cells proliferate to form a large population of memory B cells, which quickly become activated after the 
booster injection is administered. Thus, the lag period before the appearance of the specific antibody is 
much shorter after a booster injection than that observed for the initial immunization. In addition, a 
significant higher titer of specific antibodies is achieved and maintained for a longer period of time. The 
peak of antibody production occurs 7 to 14days after boosting. Finally, the average affinity and degree 
of specificity of the antibody population for the antigen increase with repeated immunizations (Klinman 
et al, 1976 ) 
 
After the first injection, the next boost will be scheduled 4 weeks later, followed by a blood sampling the 
next week. A second and third boost followed every 15 days. 
 
In our case, it meant the following schedule: 
Day 1 Day 7 Day 35 Day 42 Day 50 Day 60 Day 66 Day77 
Pre-Bleeding Immunization Boost1 Bleeding1 Boost2 Bleeding2 Boost3 Bleeding3 
       
To allow immunization with a homogeneous batch of proteins, every immunization and boosts were 
done with the same protein pool, obtained by the pooling of the bests samples (batches) of proteins 
produced and purified. 
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II.2.4.3 Blood sampling in the retro-orbital plexus 
To monitor the humoral immune reaction generated by the injection of our recombinant proteins, 
regular blood sampling (bleeding) was necessary.  
The easiest way to get a sufficient (100 to 200ul) amount of serum is the blood sampling in the retro-
orbital plexus. 
Prior to sampling, the mice are anesteziated (following the protocol described in unit II.2.4.1). Then the 
experimentator gently pull the skin of the mouse’s skull from the opposite side of the head and the eye 
will pop out. A glass capillary can then be inserted between the eye bulb and the retro-orbital plexus. 
Gently pushing the tip of the glass capillary on the array of veins behind the eye generates a quick and 
abundant bleeding that can easily be stopped by pushing the eye back into place. However, this 
manipulation requires calm and dexterity not to wound the mouse. 
 
For the last blood sampling, a higher quantity of blood can be collected by cardiac punction using a 
syringe, after killing the mice by cervical dislocation. 
 
After collection, the blood is incubated 30min at 37°C and centrifuged 30 min at 3000rpm. The serum 
is then aliquoted and frozen at -20°C.  
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III. Results 
 
In the first part of the Results Section, we will present the results obtained of study of the outbreak that 
occured 1996. In the second part of the Results Section, the development, construction and expression 
of chimeric proteins as the basis of a novel vaccination approach will be described. 
 
III.1 Secondary immune response in adults with low levels of antibodies 
 
III.1.1 Description of the phenomenon  
Secondary immune responses (SIR) against measles have been observed in fully immunized 
populations (Gustafson et al, 1987). With vaccination rates on the increase, it becomes increasingly 
urgent to understand the role of individuals without symptoms, such as those with inapparent SIR, in 
measles virus transmission (Pedersen et al., 1989). 
The secondary immune response of parents from the children with measles was investigated during a 
measles outbreak that happened in Luxembourg between March and July 1996. All children had 
clinical measles according to the Centers for Disease Control case definition (CDC, 1990) and 
developed specific IgG. 46 children were tested positive for IgM (Fig 28) and showed a significant 
increase of specific IgG titers when paired sera were available (Fig 29). 
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Fig 28: Evolution of the patients IgM titer after MV infection 
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Fig 29: Evolution of the patients IgG titers after MV infection 
 
We have investigated whether immune parents would respond to the re-exposure to a measles -
infected person. 45 parents (37 mothers, 7 fathers, 1 grand-mother), for which 1 to 7 pre-exposure 
sera were available, were considered having been exposed while taking care of their children with 
measles. Some parents were exposed to up to 4 children with measles. The average age of the 
parents was 37.2 years (range 26.3-50.5 and one with 67.5 years). All parents reported that they were 
not vaccinated and that they have had measles before entering school. Pre-exposure sera, obtained 
during routine venupuncture for unrelated reasons between August 1990 and March 1996, were 
available from the serum bank of the Laboratoire National de Santé. The interval from the last pre-
exposure sera to the exposure was 2-66 months. The post-exposure interval was between 2-12 weeks. 
None of the parents reported any measles-related symptoms during the time of the study.  
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Fig 30: Specific IgG (grey bars), NT ( ) and HI ( ) titers of all available pre-exposure sera of the 
parents, in chronological order. In each graph, the last point to the right (May to August 1996) is serum 
drawn immediately after the outbreak  
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Fig 31: Specific IgG (grey bars), NT ( ) and HI ( ) titers of parents with high variation of titers. In 
each graph, the last point to the right (May to August 1996) is serum drawn immediately after the 
outbreak. 
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Fig 30 and Fig 31 show that, prior to exposure, sera of all the parents were clearly MV-IgG positive 
(DA>400 mO.D.), according to the manufacturer’s specifications of the ELISA (cut-off for positivity: 
“corrected” DA>200 mO.D.; cf. Materials and Methods). In the sera of Fig 30, no significant 
changes in titers (<2-fold dilution) were observed during the 66 months before exposure. Also after 
measles exposure, most of the parents showed no significant changes in antibody titers as tested 
by either one of the 3 assays, however (Fig 31) four parents HS1327, HS1337, HS1338 and 
HS1343 (refered to as C, B, A, D respectively) with lower IgG titers showed a significant and 
concomitant increase of NT (>4-fold increase, p<0.005 by paired t-test of pre- and post-exposure 
sera) and HI titers (>8-fold; p<0.006). If the serum titer of the parents did not change during during 
measles re-exposure, the values obtained with the pre-exposure sera should be similar to the 
values of the post-exposure sera. None of the other parents showed a significant increase in post-
exposure titers above a 2-fold dilution (p>0.1). Although IgG levels of some of the other parents 
shown in Fig 30 and 31 had antibody titers only slightly higher (as parents 1363, 1334 and 1328) 
these did not develop SIR by any of the parameters measured here. 
 
Fig 32: Comparison of last pre-exposure and post-exposure IgG-titers of parents (n=45) of measles 
children. 
 
In Fig 32, specific IgG reactivity of the last pre- and post-exposure IgG levels of all parents are 
shown. All but 4 parents exhibit no significant difference between pre- and post-exposure IgG 
levels. Above a pre-exposure level of 780 mO.D., post-exposure antibody levels were <150 mO.D. 
higher than pre-exposure titers (pre- vs. post-exposure MV-IgG above 780 mO.D. pre-exposure 
absorbance: p>0.5, by paired t-test), except for one parent with considerable fluctuations in pre-
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exposure IgG levels (parent H or HS1370 : DA=300 mO.D.) not seen in his NT or HI titers, or in any 
other parent. Below 780 mO.D., measles antibodies of 4 out of 5 parents were boosted by 750-
1400 mO.D. (pre- vs. post-exposure MV-IgG below 780 mO.D. pre-exposure absorbance: p<0.02, 
by paired t-test). Pre-exposure titers of parents with and without boosted antibodies were also 
significantly different (p< 10-4). 
 
This shows that some parents developed SIR when re-exposed to measles. This observation was 
also confirmed by similar data obtained in HI and NT tests. 
 
 
Fig 33: Comparison of last pre-exposure and post-exposure HI-titers  
of parents (n=45) of measles children 
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Fig 34: Comparison of last pre-exposure and post-exposure  NT-titers  
of parents (n=45) of measles children 
 
Fig 33 and Fig 34 show the pre-exposure HI and NT plotted against the corresponding post-
exposure titer. The individuals (designated by A, B, C, and D in Fig 32, 33 and 34 (or 1338, 1337, 
1327,1343 in Fig 31) were also lowest for their pre-exposure NT and HI titers. Above defined pre-
exposure titers (1:25.5 dilutions for NT; 1:26.5 for HI), no significant booster effect was observed (pre- 
vs. post-exposure titers: p>0.1 by paired t-test). Pre-exposure NT and HI titers of SIR-parents were 
significantly lower than pre-exposure titers of parents without SIR (NT: p<10-12; HI: p<10-3 by non-
paired t-test). The comparison of pre-exposure NT and HI titers of parents with and without SIR 
also shows that, while individual G was below the IgG threshold (780 mO.D.), she was well above 
the HI and NT threshold. Conversely, parents E and F are below the threshold for NT and HI 
respectively, but not for IgG. Parents E, F, and G did not undergo SIR, suggesting that one 
parameter may not be sufficient to predict SIR.  
  
IgM levels of the parents were also tested using IgM Enzygnost kits (Fig 35) and were negative 
(<200mO.D.) in all the parents, including the SIR parents. During primary measles responses, IgM 
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levels of DA>200 mO.D. are considered positive, while DA<100 are negative according to the 
manufacturer’s instructions. Such values are not necesseraly valid for SIR. 
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Fig 35: IgM levels of the 4 SIR parents 
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Fig 36: IgG subclasses of the 4 SIR parents 
 
Fig 36 shows that among the IgG subclasses, mainly IgG1 was boosted during the SIR. Two 
parents which were IgG4 negative, became positive for this subclass after exposure (HS1337 and 
HS1338), but this subclass showed elevated background values (500 mO.D.). IgG2 and IgG3 were 
essentially negative, before and after exposure.  
 
The results suggest that the SIR seems to be an “all or none response” since parents with IgG, NT 
or HI levels just above the defined threshold do not develop SIR. This threshold become further 
evident when the pre-exposure values of the 3 tests are plotted in a single graph (Fig 37). 
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Fig 37: Combined HI, NT and IgG pre-exposure values 
 
Fig 37 shows the pre-exposure levels of IgG, NT and HI with the corresponding thresholds were 
observed in the previous figures. The brackets between the highest values of individuals with SIR 
and the lowest values of non-SIR individuals delimit a “gray zone” in which the SIR-susceptibility is 
not defined. Using these serological characteristics, it may be possible to identify individuals 
susceptible to SIR when exposed to a measles patient using the combined thresholds (Table 3). 
Fig 37 also shows that all parents were positive by in vitro neutralization (>1:32) and by 
hemagglutination inhibition (>1:22), i.e. at least for the lowest dilutions tested. 
 
 Minimal Threshold Maximal Threshold 
Enzygnost (IgG) 780 mO.D.405nm 870 mO.D.405nm 
NT  1:25.5 1:26.5 
HI 1:26.5 1:27 
Table 3: Combined threshold describing SIR-susceptibility.  
Minimal and maximal values define a grey zone where SIR susceptibility is undetermined 
 
In Fig 37, the thresholds are shown as lines which define an area in which the SIR-susceptibles 
can be found. In this specific group, the proportion of SIR-susceptibles reaches 9% (4/45). All the 
SIR parents were women. 
 
By transposing this frame of threshold to other groups or populations, it may be possible to 
estimate the proportion of SIR-susceptibles in these populations. In the next section, we will 
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estimates the proportion of SIR-susceptibles persons in a group of  children that recently got 
measles (Early Convalescent), in a group of adults that got measles during their childhood (Late 
convalescents) and in groups of school children vaccinated once or twice against measles. 
 
III.1.2 Estimation of susceptibility to SIR 
III.1.2.1 Description of the cohorts 
In the following, we apply the above serological characteristics to different populations in order to 
estimate the proportion of SIR-susceptibles in these populations. The proportion of SIR-susceptible 
persons were estimated in a group of children that recently recovered from measles (Early 
convalescent), in a group of adults that had measles during their childhood (Late convalescents) 
and in a group of school children who were vaccinated either once or twice against measles. 
 
Fig 38 shows the relative distribution of HI and NT titers and specific IgG for late convalescent 
donors and high school children stratified according to their vaccination status. Sera from early 
convalescent measles patients, drawn at a time when the antibody response was fully developed in 
most patients (i.e. 14-59 days), are shown for comparison.  
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Fig 38: Comparison of the different cohorts 
 
 HI NT IgG 
Cohorts Median St Dev Median St Dev Median St Dev 
Late convalescent 7.5 1.39 8.0 1.26 1501 599 
Early convalescents 11.5 1.09 8.75 0.98 1424 464 
Vaccinated once 7.0 1.12 6.0 1.21 587 463 
Vaccinated Twice 7.0 1.16 6.0 1.24 591 449 
Table 4: Median and standard deviation of the cohorts from Fig 38 
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   Cohorts  
Assays Cohorts early convalesc. late convalesc. vaccinated (1x) 
 early convalesc. ----- ----- ----- 
HI late convalesc. <10-60 ----- ----- 
 vaccinated 1X) <10-100 <10-6 ----- 
 vaccinated (2x) <10-38 n.s. n.s. 
 early convalesc. ----- ----- ----- 
NT late convalesc. <10-4 ----- ----- 
 vaccinated 1X) <10-42 <10-57 ----- 
 vaccinated (2x) <10-24 <10-21 n.s. 
 early convalesc. ----- ----- ----- 
MV-IgG late convalesc. n.s. ----- ----- 
 vaccinated 1X) <10-22 <10-59 ----- 
 vaccinated (2x) <10-14 <10-17 n.s. 
 
Table 5: Levels of significance (P by unpaired Student T-Test) of HI, NT and IgG between Early 
and Late convalescent donors and vaccinated school children.  
n.s. not-significant 
 
Early convalescents have significantly higher MV titers (by HI, NT and specific IgG) than late 
convalescents or vaccinees (see Table 4 and 5). This observation indicates that the immunity 
obtained after measles infection is waning. The difference is much more important in HI than in NT 
and IgG. Late convalescent persons had significantly higher NT and HI titers than individuals 
vaccinated once indicating that natural measles infection provide better and longer protection that 
the immunity provided by vaccination. After a second vaccination, HI titers but not NT titers became 
similar to those of late convalescents. No statistical difference was found between children 
vaccinated once or twice although some individuals with the lower HI titers seem to have converted 
to higher HI titers. This indicates that a second vaccination do not icrease the immunity level but 
gives a second chance to the individuals that did not respond to the first vaccination. Within the 
cohorts of once- or twice-vaccinated, no serological differences between boys and girls or between 
different schools were detectable by Student t-test. Also, no significant difference in titers was 
detected between the different measles vaccines used (Rimparix- and Pluserix) (data not shown). 
 
III.1.2.2 Susceptibility to SIR 
Fig 39 to 42 show the HI and NT titers combined with levels of specific IgG of convalescent and 
vaccinated donors in relation to the described thresholds of Table 3. Different estimates of the 
frequency of SIR-susceptibles are obtained whether sera within the undefined “gray zone” were 
included or not. The more conservative (i.e. lower) estimate is obtained when individuals with 
values within the undefined region are considered SIR resistant.  
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Fig 39: Titers of early convalescents. 
 
As expected, none of the early convalescents fulfills the criteria of SIR susceptibility (SIRS). Their 
recent, full scale Measles infection generated high levels of circulating antibodies that will protect 
them against disease as well as reinfections 
 
Fig 40: Titers of late convalescents 
Among the late convalescents only 3.2-3.9 % (1 male, 8 females) seems to be SIR-susceptibles 
which is lower than the 9% of SIR-susceptibles found in the parents of measles children (not 
significant). 
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Fig 41: Titers of children vaccinated once 
 
In Fig 41, it can be seen that among the vaccinated school children the frequency of SIR 
susceptible vary from 22.2% to 33.2%. This is 7-8 times higher that for the late convalescent group, 
suggestion that vaccination may generate a higher proportion of SIR-susceptibles. 
 
Fig 42: Titers of children vaccinated twice 
In the group of children vaccinated twice, the proportion of SIRS is 32.2%, a value equals to the 
group vaccinated once suggesting that a second vaccination do not seems to reduce the proportion 
of SIR-susceptibles.  
 
H
I-t
ite
r (
lo
g 2
) 
NT-titer (log2) 
2 
4 
6 
8 
10 
12 
14 
2 4 6 8 10 12 14 
SIRS : 22.2 - 33.2 % 
n=319 
IgG < threshold 
 IgG > threshold 
H
I-t
ite
r (
lo
g 2
) 
NT-titer (log2) 
n=49 
IgG < threshold 
2 
4 
6 
8 
10 
12 
14 
2 4 6 8 10 12 14 
SIRS : 32.2 % 
 IgG > threshold 
 99 
In all of the above figures, the estimated frequencies of secondary immune response would be 
higher if only two parameters were considered although a reasonable approximation would be 
obtained in a cohort of late convalescents, but not in vaccinees, by combining NT titers and 
Enzygnost data. Another point is that the SIR-susceptible late convalescents tended to be younger 
in comparison to the average age of this cohort (33.6 versus 43.5 years; P=0.07). All late 
convalescents were born before 1973 (five before 1965) and 63.5% were women.  
 
Among the vaccinated children, no difference in sex distribution or the vaccines used was found 
between SIR-susceptibles and resistant subpopulations (male/female for SIR-susceptibles and 
non-SIR susceptibles: 0.21 and 0.29).  In the SIR-susceptible and resistant groups of vaccinees a 
similar percentage (8.6 and 7.8%) was vaccinated before the age of 15 months. With a single 
exception all SIR-susceptibles were vaccinated before the third birthday, whereas in the resistant 
(non-SIR) group, 17.2% were vaccinated after this date. The latter may have had contact with wild-
type MV before being vaccinated which would explain their higher titers. Alternatively, vaccination 
at a later age may induce higher titers. 
 
III.1.3 Duration of the booster effect induced by the secondary immune response  
 
Fig 43: Duration of booster effect 
 
Fig 43 shows the evolution of the titer of the four SIR parents. The graph shows that after the boost 
generated by the measles contact, their immunity is rapidly decreasing. The booster effect seems 
then to be relatively transient. Parents HS1343, HS1327 and HS1337 have lost around 30% of 
their boost 6 month after the outbreak although it takes a bit longer for parent HS1338 to reach this 
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level. The 4 parents have lost on average 42% of their boosted immunity 42 months after the 
outbreak. Table 6 shows the relative decrease of the immunity of the 4 parents. 
 
 
Parent : 
Outbreak  
Mars 1996 
January 1997 March 1999 January 2001 
HS1327 100% 71% 48% 34% 
HS1337 100% 69% 58% 35% 
HS1338 100% 88% 66% 63% 
HS1343 100% 70% 50% 35% 
Average 100% 75% 55% 42% 
Table 6: Decrease of the titer of the 4 parents 
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III.2 The vaccine strategies 
 
The previous section has shown that the neutralizing humoral response is much weaker in 
vaccinees than in late convalescents. It is furthermore known that vaccine-induced immunity wanes 
much faster than immunity due to natural infection. In some studies, a considerable proportion of 
vaccinated children have lost their immunity within less than a decade (Ratnam et al, 1996; 
Ramsay et al, 1994; Guris et al, 1996; Aaby et al, 1999). In other studies, it is estimated that 50% 
of the vaccinees have lost their immunity within 25 years after vaccination and that 80% of 
vaccinees will eventually become unprotected (Mossong et al, 1999). The previous Section shows 
also that, in contrast to late convalescents, a considerable proportion of vaccinees may not be 
protected against infection although they are protected against disease. Thus the current vaccine 
may protect less efficiently than previously thought and considerable efforts are made to develop 
improved vaccination strategies. Here we propose to develop antigens that are based on selected 
T and B cell epitopes of the most immunodominant proteins as a complement to the live attenuated 
vaccine.  
 
Another group of susceptibles for whom there is currently no vaccine available are young infants 
before the age of 9-15 month. These children are partially protected by maternal antibodies. Thus 
the vaccine should be resistant to preexisting anti-(whole) measles virus antibodies. Furthermore, 
to avoid priming of T cells for atypical measles, such a vaccine should not contain measles -specific 
sequences that could serve as T cell epitopes. 
 
Vaccines for the above applications require a vastly different design. The following sections 
describe the development and the construction of these antigens. 
 
III.2.1 Design and development of the antigen : Polyepitopes based on mimotopes 
III.2.1.1  Selection of epitopes and building of the constructs 
This strategy was meant to explore the potential of a conformational epitope of the measles virus 
fusion protein that was mimicked by a peptide mimotope. The litterature has shown that the fusion 
protein is the target of efficient neutralizing antibodies (Malvoisin and Wild, 1990) and that the 
specific mimotope selected for this study generates in vivo protective antibodies in a laboratory 
animal model (Stewart et al., 1995). Here, we generated chimeric proteins containing the mimotope 
sequence and selected T cell epitopes. The conformation of the mimotope is critical for the 
induction of neutralizing antibodies. The number and position of the sequences flanking the 
mimotope are likely to be critical for the proper cross-reactive neutralizing immunogenicity. Since 
the influence of the flanking sequences cannot be predicted, we have chosen a permutational 
approach to build series of chimeric polyepitopes in which the mimotope is embedded in different 
microenvironments. 
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The selected epitopes included: 
 
The T cell epitope F256-270 (LLGILESRGIKARIT) is an epitope in the mouse described by Muller 
et al (1995). This peptide was selected from 108 pentadecapeptides of the measles fusion protein 
and is part of a cluster of strong H2d restricted T cell epitopes.  
 
A MV-F derived mimotope (NIIRTKKQ), described by Steward et al (1995) as a B cell epitope. 
This mimotope has the sequence of a peptide selected from a solid-phase random combinatorial 
octamer peptide library (synthesized on a polystyrene-polyethylene resin using the Fmoc 
chemistry) using a monoclonal antibody against the MV-F protein, F7-21. This peptide shows some 
structural similarity with F protein of MV and CDV. Steward et al (1995) showed that this peptide 
induced a good antibody response and was significantly protective against a neuroadapted MV or 
CDV after immunization together with a T cell epitope. Althrough this mimotope was referred to in 
the publications of Steward et al (1995) as M2, in our constructs we designated it as M for 
simplicity. 
 
The TT 830-844 “universal” has been described as a promiscuous human T cell epitope 
(QYIKANSKFIGITEL), (Kumar et al, 1992).  A so-called promiscuous T cell epitope is able to be 
presented by a wide range of MHC-II haplotypes and ensures T cell activation in the majority of the 
human population. It is derived from the tetanus toxoid (TT). High antibody titers were obtained 
when immunization is done in the presence of this “universal” T cell epitopes (Kumar et al, 1992; 
Hathaway et al, 1995; El Kasmi et al, 1999).  
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The following constructs were assembled by genetic fusion of the above epitope sequences (F 
refers to the TCE F256-F270, T to the tt830-844 fragment of the tetanus toxoïd and M to the 
mimotope): 
 
Sequence    Molecular weight 
2xT-8xM-2xF   16730 
2xF-8xM-2xF   16560 
2xF-8xM-2xT   16730 
4xM    4500 
8xM    9000 
2xF-8xM-2xF-8xM-2xF-8xM-2xT 42290 
2xT-8xM-2xF-2xF-8xM-2xT 33460 
2xT-8xM-2xF-2xF-8xM-2xF 33290 
2xF-8xM-2xT-2xF-8xM-2xT 33460 
2xF-8xM-2xT-2xF-8xM-2xF 33290 
2xF-8xM-2xF-2xT-8xM-2xF 33290 
2xF-8xM-2xF-2xF-8xM-2xT 33290 
2xF-8xM-2xF-2xF-8xM-2xF 33120 
4xT-8xM-4xF   24460 
4xF-8xM-4xT   24460 
4xF-8xM-4xF   24120 
8xT    15800 
8xT-4xT-4xF   31260 
8xF    15120 
8xF-4xF-4xT   30580 
16xM    18000 
 
Table 7: List of constructs using minimal epitopes 
 
III.2.1.2 Expression and testing of the constructs  
Oligonucleotides coding for the above epitopes were synthesized as single-stranded DNA (by 
Eurogentec, Liège, Belgium) and then annealed into double-stranded DNA.  The synthetic DNA 
fragments encoding the epitopes were flanked by restriction sites, designed to allow oriented 
cloning, a Sal I site at the 5’end and a XhoI site at the 3’end. Such fragments served as base-units 
for the preparation of polyepitopic constructs. 
 
After assembly of the epitopes following the procedures described in the Materials and Methods, 
the constructs in Table 7 were removed from pUC 18 and inserted into the pSFV1 expression 
vector using the Bam H1 restriction enzyme. The constructs were then transcribed into RNA in 
vitro. This was followed by transfection of the RNA-constructs into BHK -21 cells. The expression of 
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recombinant protein in transfected cells was analyzed by flow cytometry (FACS). Cell lysates were 
obtained and tested in ELISA using polyclonal sera generated with peptides, corresponding to the 
M, F256 and TT830 sequences, or the F7-21 monoclonal antibody (courtesy of Prof. Osterhaus, 
Netherlands) which was used to select the mimotope M2 (Steward et al, 1995). None of these 
detection methods revealed the presence of recombinant protein in the transfected cells. 
 
Although the constructs could not be detected by the above antibodies, transfected cell lysates 
were tested by T cell proliferation assays to detect the presence of the TCE of the recombinant 
protein.T cell lines specific for the TCE F256-270 and the TT830-844 were generated and were 
used to compare the potential of the constructs to stimulate T cells.  
 
Fig 44: Stimulation of F256 specific T cell line by polyepitopes 
 
Fig 44 shows that the cell lysates induced a significant IL2 production of the F256 specific cell line. 
The “2F-8M-2F” constructs induced the strongest proliferation. This could be due to its 4 copies of 
the F256 epitope. The analoguous but longuer “2F-8M-2F-2F-8M-2F” construct gives a somewhat 
weaker T cell stimulation perhaps as a result of lower expression.  The “2F-8M-2T-2F-8M-2T” 
construct gives a better T cell stimulation than 2F-8M-2F-2F-8M-2F although the latter incorporates 
twice as much F256 epitopes. Properties of the constructs during the synthesis (RNA structure and 
stability, protein half-life) or position and flanking sequences of the epitopes may explain that result. 
The “8M” constructs, as well as the negative peptide, did not induce any proliferation, confirming 
the specificity of the stimulation index. 
 
The T cell assay confirms that the constructs were processed and probably presented by MHC 
class II restriction elements. It also confirms that the constructs were produced in the cells, but 
surprisingly the mimotope was not recognized by the monoclonal antibody F7-21. 
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Since the recombinant constructs were not detected by mab F7-21 neither in ELISA nor by flow 
cytometry, synthetic peptides corresponding to the TCE and BCE constructs alone or in 
combination were injected into mice to generate specific sera. All M units in the recombinant 
constructs were flanked by the two amino acids leucine and aspartic acid, which are left over of the 
SalI–XhoI restriction sites required for the assembly of the polyepitope constructs. To investigate a 
possible influence of the spacer amino acids on the epitope conformation, two M-dimers differing 
only by the spacing amino acids between the mimotopes were synthesized as peptides.  
 
Thus, the two peptide dimers were: 
Mimotope – Leu – Asp - Mimotope   (spacer as in the recombinant protein) 
Mimotope - Gly – Gly – Gly – Mimotope  (neutral spacer).  
 
These peptides were used for immunizing mice. The sera obtained with the synthetic peptide 
containing the glycine spacer (gly-gly-gly) reacted strongly with the corresponding synthetic 
peptide, but failed to recognize the polyepitopes in flow cytometry and in ELISA (data not shown). 
The sera obtained after immunization of the peptide with the Leu-Asp spacer did not react either 
with the polyepitope, the corresponding peptide in flow cytometry and ELISA and was negative on 
MV. None of the sera obtained reacted with MV, indicating that neither of the peptides elicited MV 
cross-reactive antibodies. 
 
Fig 45: Reactivity of mAb F7-21 with mimotope peptide dimers 
 
The ELISA test with the two synthetic peptides as antigens and the monoclonal antibody F7-21 (Fig 
45) showed that this epitope-specific antibody is able to recognize the Mimotope-Gly-Gly-Gly-
Mimotope whereas it did not detect the Mimotope-Leu-Asp-Mimotope peptide. This surprising 
result obtained with the monoclonal antibody and the polyclonal serum suggested that the LD 
spacer obliterated the antibody binding. The induction of a change in the peptide conformation and 
charge distribution, is likely to explain this effect. 
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III.2.2 Design and development of the antigen: Polyepitopes derived from antigenic regions 
In this strategy, we used longer stretches of the 3 most immunogenic proteins of the measles virus, 
the hemagglutinin protein (MVH), the fusion protein (MVF) and the nucleoprotein (MVN). Different 
regions of the three most immunogenic measles virus proteins of the Edmonston strain (EMBL id: 
MV03669) have been selected for their content in B and T cell epitopes previously described in the 
literature (MVH, Table 8; MVF, Table 9 and MVN, Table 10). 
 
On one hand, longer fragments of MVH proteins may improve the three-dimensional structure of 
the B cell epitopes which would have a greater chance to be conserved and stabilized by its natural 
flanking sequences. On the other hand, the conservation of the flanking regions of the T cell 
epitopes would potentially improve the generation of natural T cell epitopes during antigen 
processing. These long stretches of proteins may of course also contain important epitopes that 
have not been described.   
 
The two surface proteins, but mainly the H protein, are the main targets of neutralizing and 
protective antibodies and provide the B cell epitopes for the constructs. The N and F fragments 
contain clusters of known T cell epitopes that are restricted by human and mouse MHC haplotypes. 
The inclusion in the chimeric constructs of TCEs which are potentially processed and presented by 
diverse human and murine MHC of class I and II should allow the testing of these constructs in vivo 
and in vitro in a mouse model and in vitro on human T cell lines. The CD8+ TCE on different N 
fragments should support the induction of a cytotoxic response in addition to the CD4+ restricted 
response. In fact, some studies (An and Whitton, 1997) have shown that CTL responses may, by 
themselves, give full protection.    
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Fig 46: Position of the selected epitopes on the three MV proteins. 
 
III.2.2.1 Description of the epitopes included in our strategy 
III.2.2.1.1 H protein antigenic regions 
Most of the protective activity of anti-MV antibodies is directed against the haemagglutinin protein 
(Giraudon and Wild, 1985; Sato et al, 1985), therefore it is not surprising that most of the 
neutralizing B cell epitopes have been described on this protein. 
 
The MVH fragments MVH-1, MVH-2 and MVH-3 (Table 8) have been designed in order to contain 
several neutralizing BCE, which have been described in our laboratory using synthetic peptides, the 
NE (neutralizing epitope) and HNE (hemagglutinin noose epitope) (Fournier et al, 1997; El Kasmi et 
al., 1998), and as well as by other authors (Makela et al, 1989). The HNE and NE epitopes have 
been selected since they have been shown to induce protective antibodies in the presence of virus-
neutralizing maternal antibodies (El Kasmi et al, 2001). 
 
The selection of these antigenic regions of the H protein should allow the induction of virus 
crossreactive antibodies. In addition, the choice of sequences of different length (see Table 8) may 
also provide information on the sequence environment required for the display of these BCE in their 
natural conformation. In fact for some applications of this antigen, it may be interesting to include 
long sequences containing many T cell epitopes, but where the conformation of such epitopes 
would have little resemblance with natural protein and therefore resist neutralization by residual 
pre-existing antibodies. The DNA fragments encoding these protein regions were generated by 
PCR from the cloned cDNA or they were available as synthetic oligonucleotides.  
-C N- 
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N- -C 
Protein F 
MVF B MVF A 
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Name Sequence Composition Reference 
MVH-1 
  
125-410aa 125-135 : Neutralizing BCE  
185-195 : Neutralizing BCE 
236-255 : BCE  (NE) 
343-351 : Epitope CD8+, Ld  
379-410 : BCE (HNE) 
Makela et al, 1989 
Makela et al, 1989 
El Kasmi et al, 1998 
Beauverger et al, 1994 
El Kasmi et al, 1998 
MVH-2  
 
184-410aa 185-195 : B cell epitope, neutralizing 
236-255 : BCE  (NE) 
343-351 : Epitope CD8+, Ld  
379-410 : BCE (HNE) 
Makela et al, 1989 
El Kasmi et al, 1998 
Beauverger et al, 1994 
El Kasmi et al, 1998 
MVH-3  
 
236-410aa 236-255 : BCE  (NE) 
343-351 : Epitope CD8+, Ld  
379-410 : BCE (HNE) 
El Kasmi et al, 1998 
Beauverger et al, 1994 
El Kasmi et al, 1998 
 
Table 8: Known epitopes in the MVH protein fragments 
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III.2.2.1.2 F protein antigenic regions 
Three antigenic regions of the F protein have been selected to be included in chimeric proteins. 
The choice of these subunits is based on their abundance in TCEs. The subunits have been 
obtained using PCR on a Bluescript vector containing the cDNA of the F protein.  
 
Name Sequence  Composition Reference 
MVF-A 197-341aa 199-228 : TCE, human promiscous 
214-228 : TCE, DR1 restricted 
240-252 : BCE and TCE H2s,k,a restricted 
256-270 : TCE H2d restricted (CD4+) 
258-277 : TCE H2d restricted (CD4+) 
259-305 : TCE H2d restricted (CD4+) 
259-273 : TCE H2d restricted (CD4+) 
288-302 : TCE (H2s,a,d,k,q restricted)  
291-306 : TCE mouse and human 
317-329 : TCE, DR1 restricted 
Muller et al, 1996b 
Muller et al, 1995 
Partidos and Steward, 1992 
Muller et al, 1995 
Stewart et al, 1995 
Muller et al, 1995 
Muller et al, 1995 
Obeid et al, 1995 
Partidos et al, 1990 
Partidos et al, 1991 
MVF-B 381-451aa 391-405 : Neutralizing BCE.  
399-423 : TCE DR2,DR7,DR3 restricted 
404-414 : Neutralizing BCE 
408-418 : Non neutralizing BCE 
424-438 : TCE, H2d restricted (CD4+) 
Atabani et al, 1997 
Muller et al, 1996 
Partidos et al, 1991 
Obeid and Steward, 1994 
Muller et al, 1995 
MVF-C 251-341aa 256-270 : TCE H2d restricted (CD4+) 
258-277 : TCE, H2d restricted 
259-305 : TCE, H2d restricted 
259-273 : TCE, H2d restricted 
288-302 : TCE (H2s,a,d,k,q)  
291-306 : TCE mouse and human 
317-329 : TCE, DR1 restricted 
Muller et al, 1995 
Stewart et al, 1995 
Muller et al, 1995 
Muller et al, 1995 
Obeid et al, 1995 
Partidos et al, 1990 
Partidos et al, 1991 
Table 9: Epitopes present of the MVF protein-derived fragments 
 
III.2.2.1.3 N protein antigenic regions 
After MV infection, the earliest and most abundant antibodies are directed against the 
nucleoprotein (Graves et al, 1984; Norrby et al, 1981), but they do not play a direct role in virus 
neutralization (Liebert and Finke, 1995), however they may enhance the processing of the N 
protein or even virus particles by faciliting antibody-receptor mediated uptake (Fournier et al, 1996). 
The N protein plays also an important role in the cell-mediated immune response (Bankamp et al, 
1991; Rose et al, 1984).   
 
The DNA fragments encoding seven antigenic regions, NP1 to NP7, were prepared using synthetic 
oligonucleotides. Given the length of each NP region, we decided to split the sequence into two 
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subfragments which were more easily synthetized. The fragment NP1 was split in NP1a and NP1b, 
for example. The oligonucleotides were designed in such a way that complementary single-
stranded regions at the 3’ end of the a fragments and at the 5’end of the b fragment allowed for the 
assembly of the double stranded a and b DNA without modification of the amino-acid sequence. 
The latter would have been the case if restriction sites were used for the assembly of a and b. 
 
Name Sequence Composition Reference 
MVN-1 185-220aa 185-199 : TCE, DR5 restricted. 
210-218 : CTL, HLA-A2 restricted. 
 
Nanan et al, 1995 
MVN-2 221-256aa 221-240 : TCE, DR restricted. 
226-234 : CTL, HLA-A2 restricted. 
237-256 : CTL, DR restricted. 
Hickman et al, 1997 
Nanan et al, 1995 
Hickman et al, 1997 
MVN-3 281-290aa 281-290 : CTL, Ld, CDV cross-reactive. Beauverger et al, 1993 
MVN-4 329-366aa 329-345 : TCE, H2d and Iad restricted 
340-348 : CTL, HLA-A2 restricted 
Fournier et al, 1996 
Nanan et al, 1995 
MVN-5 
 
 
367-420aa 367-386 : TCE, DR restricted 
377-399 : TCE, H2d  
400-420 : TCE, DR restricted 
Hickman et al, 1997 
Fournier et al, 1997 
Hickman et al, 1997 
MVN-6 445-475aa 445-465 : TCE, H2b 
457-476 : BCE 
 
Giraudon et al, 1988 
MVN-7 476-507aa 483-502 : TCE, DR restricted Hickman et al, 1997 
Table 10: Epitopes present of the MVN protein-derived fragments. 
 
III.2.2.2 Design and assembly of the constructs 
Two different sets of constructs (Table 11) were assembled, which contained either A+B or the 
C+B segment of the MV-F protein. These constructs would allow to study the immune response to 
H protein antigenic fragments in a recombinant construct containing the same T cell determinants. 
The N protein is a source of MHC-I epitopes, providing an activation source for CD8+ lymphocytes. 
 
Fusion protein  
(T cell epitopes) 
Nucleoprotein  
(T cell epitopes) 
Hemagglutinin protein 
(B cell epitopes) 
Used name 
MVF (A+B) MVN (1+2+3+4+5+6+7) MVH-1 
MVH-2 
MVH-3 
No MVH fragment 
AB MVH1 
AB MVH2 
AB MVH3 
AB NP1-7 
MVF (C+B) MVN (1+2+3+4+5+6+7) MVH-1 
MVH-2 
MVH-3 
CB MVH1 
CB MVH2 
CB MVH3 
Table 11: Different types of constructs designed 
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This new set of constructs was built into a pUC18 vector using a modified multiple cloning cassette 
(START Cassette) containing the restriction sites for transfer into a bacterial expression vector.  
 
The oligonucleotides were first annealed and each subunit was cloned into a separate pUC start 
vector, generating the subunits vector pUC MVH1, pUC MVH2, pUC MVH3 for the subunits derived 
from the H protein, pUC MVF-A, pUC MVF-B, pUC MVF-C for the F protein and pUC MVN-1, pUC 
MVN-2, etc, for the subunits of the N protein. These vectors were used to transform DH5a bacteria. 
The transformed bacteria were plated on agar plates containing ampicillin. DNA was extracted from 
the resulting colonies and digested using restriction enzymes to obtain size-discriminating DNA 
fragments. The length of the digested fragments obtained after digestion was checked on an 
acrylamide gel. The best clones of every subunit were selected and further tested by sequencing. 
We proceeded to the next step only after ensuring the perfect conservation of the cloned 
sequences and the multiple cloning sites. The subunits of each protein were then cloned into the 
above pUC START vector. The result of each successive cloning were confirmed by enzymatic 
digestion and sequencing. The sequences of the original measles genes were finally assembled 
into the 6 structures described in the Table 11. The final constructs were confirmed again by 
sequencing. 
 
During the above series of repeatitive cloning steps (which were the longest and most critical series 
of experiments in the present thesis), intermediate steps were kept as references and could be 
used as controls during later experiments or in future projects because of their compatibility with 
other cloning strategies. 
 
The set of constructs were then transferred to the modified pET vector used for expression. A final 
sequencing ensured that the transfer phase was done without altering the sequence.  The colonies 
carrying the constructs were then amplified and stored as glycerol stocks. 
 
III.2.2.3 Optimization of the induction of MVH1 constructs 
The T7 system was used to express the constructs described above. In this experiment, we have 
tested induced cultures of MVH1 subunit, as well as AB NP1-7 and AB MVH1 constructs. Non-
induced AB NP1-7 cultures and induced empty vector (pET16pelB) were included as negative 
controls. After induction, the bacterial pellet has been lysed using the osmotic shock protocol 
described in the pET manual (pET system manual, 7th edition, Novagen, USA). The proteins 
contained in the periplasmic fraction have been coated in a 96-well plate and tested in an ELISA 
test using anti-H Mab BH195 (dilution 1:1000) which would be expected to react with the epitope 
contained in this fragment. The Fig 47 shows low but significant signals (<0.2 OD) for MVH1 and 
AB MVH1 constructs. This indicated a weak expression of the relatively short MVH1 construct and 
a very weak or negative expression of the other constructs. The detection level of of AB NP1-7, 
containing no MVH fragments, was equal to the non-induced cells with pET AB NP1-7 vector or 
cells with an empty pET vector, indicating low but specific detection of the Mab. 
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Fig 47: Detection of constructs using anti-MVH Mab BH195 
 
Such a low expression can be explained by a low efficiency of induction. In the induction protocol 
described in the Material and Methods, several factors could potentially be improved, including:  
 
· Duration of induction: A longer duration would allow more time for the BL21DE3 cells to 
produce the heterologous proteins. The time indicated in the protocol may be suboptimal 
for the size of the proteins investigated here. 
 
· Concentration of IPTG (isopropyl-D-thiogalactopyranoside): Higher concentrations of IPTG 
could possibly recruit more polymerase. On the other hand, larger constructs may also 
require more time for translation and higher concentrations of polymerase may have no 
effect or even a negative effect. Different concentration of IPTG during induction will be 
tested.  
 
· Repetitive pulses: Data about the rate of metabolization of the IPTG are difficult to obtain 
and there is no information on whether it may be more efficient to deliver a higher dose of 
IPTG to start the induction or to provide lower but repetitive doses of IPTG during the 
whole induction process. Different patterns of IPTG delivery will be investigated. 
 
· Reassessment of purification methods: the heterologous proteins might have been 
produced in reasonable amounts but the purification efficiency may have been low, so 
different means of purification procedures including size exclusion (Amicon 10kd filters) 
and affinity purification using monoclonal antibodies and/or his-tag purification will be 
explored. A poly-histidine coding sequence was cloned at the C-terminal end of every 
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construct to avoid the co-purification of incompletely synthesized or degraded proteins. 
Since the poly-histidine tail is produced last, incomplete proteins would not bind to the 
nickel-loaded resin during purification.  
 
III.2.2.3.1 Duration of induction 
To optimize the effect of the duration of induction, a bacterial culture of BL21DE3 cells transformed 
with a pET vector containing the AB NP1-7 MVH1 gene was initiated. When the culture reached 
0.4 OD at 600nm, it was splited into 4 sub-cultures of equal volumes. To each sub-culture 1mM 
final concentration of freshly prepared IPTG was added and returned to 37°C under agitation. One 
culture was removed after 2 hours of induction, a second bottle after 8 hours, a third after 12 hours 
and the last one after 20 hours of induction. The cultures were centrifugated and lysed following the 
standard protocol. 
 
Fig 48: Detection of ABNP1-7 MVH1 using anti-his Mab following different times of induction 
 
Fig 48 shows that maximal levels of proteins were already obtained within 4 hours of induction. 
After 20 hours and more, the efficiency seemed to decrease. This may be due to protein 
degradation by bacteria that suffered from increasing toxicity of the accumulating protein and/or 
exhaustion of the culture medium. The optimal time of induction seems to be in the 4-12 hours 
bracket. 
 
III.2.2.3.2 Concentration of IPTG 
When the cells were incubated with increasing concentrations of IPTG, it became apparent that 
IPTG had an effect on cell growth, measured by optical density at 600nm. The recruitment of cell 
ressources towards protein production at the expense of cell growth and division could be an 
explanation for this observation. While this could be beneficial, it may also affect the overall 
efficiency of protein production negatively as a result of lower cell numbers. A compromise 
between single cell efficiency and overall efficacy of all cells is required. 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0 5 10 15 20 25 
mg per well 
O
D
 a
t 4
05
n
m
 
4 hours 
8 hours 
12 hours 
20 hours 
 114 
 
Fig 49: Effect of IPTG concentration on cell growth 
 
III.2.2.3.3 Effect of repetitive pulses of IPTG 
In this experiment, IPTG was provided to two bacterial cultures derived from a single overnight 
culture. The first culture was supplemented with 2mM of IPTG at time 0 and was harvested 4 hours 
later. The second culture was treated with the same total amount of IPTG but given in two 
separated doses at 0 and 2 hours. 
 
Fig 50 shows that under the two-dose schedule, the expression of the culture induced with two 
pulses of IPTG was improved by about 20%. Based on these results, 1mM IPTG was added every 
2 hours to the culture of the following experiments and 4 to 8 hours of induction was considered 
optimal. 
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Fig 50: Effect of repetitive pulses of IPTG detected using anti-MVH antibody BH195 
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III.2.2.4 T cell stimulation assay 
III.2.2.4.1 T cell stimulation assay using T cell hybridomas 
The T cell assay was used both to detect the chimeric protein and to show that the protein can 
stimulate antigen-specific T cells. Furthermore antibodies specific for B cell epitopes of the 
constructs were used to test whether they would enhance antigen uptake. This T cell proliferation 
assay uses mouse T cell hybridomas which produce IL2 upon stimulation. After incubation of 
antigen and APCs with the T cell hybridomas, the supernatant was transferred to plates containing 
IL2-dependent T cells (CTLL). The IL2 that was produced during priming of the T cell line induces 
the proliferation of the CTLL cells which is measured by WST1 absorbance. WST1 is cleaved by 
mitochondrial dehydrogenase in viable cells and produces a red color that can be quantified by 
reading 96-well plates at 450nm.  
 
The T cell assay was performed using cell line M12.4.1 as antigen presenting cell [B cell 
lymphoblastoma in (Kim et al, 1979)]. Two mouse T cell hybridoma lines, TNP79 (stimulated by 
epitope NP330-345) and TNP408 (stimulated by the epitope NP380-395) were used since these 
two epitopes are present in the constructs. Due to the relatively low sensitivity of T cell hybridomas 
in comparison with human T cell lines, antigen uptake was enhanced by incubating the constructs 
with a set of antibodies at a final concentration of 100ng per ml and per antibody. 
 
The antibodies used were: 
· BH47 (specific of the NE region of the H protein: aa236-255) 
· BH195 (specific of the HNE region of the H protein: aa 379-410) 
· BNP146 (directed to the 376-395 region of the nucleoprotein) 
· BNP176 (directed to the 136-144 region of the nucleoprotein) 
 
 
Fig 51: Stimulation of TNP79 hybridomas induced by our constructs  
with and without incubation with antibodies 
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Fig 51 shows that the constructs ABNP1-7 induced a significant IL2 production at the highest 
concentration (50µg of total protein). ABNP1-7 stimulated the T cells in a dose-dependent manner 
and the addition of antibodies did not enhance antigen presentation. As expected, MVH1 
constructs did not stimulate the T cells, with and without antibodies, as no stimulating epitopes are 
present in this construct. Conversely, ABMVH1 (containing the same NP fragments than ABNP1-7) 
did not stimulate T cells and the addition of antibodies only produced non-specific dose-
independent stimulation. CBMVH3 could not be tested in this assay because it induced cell death 
as observed under the microscope. 
 
Fig 52: Stimulation of TNP408 hybridomas induced by our constructs  
with and without incubation with antibodies 
 
The constructs also contain the epitope N380-395 of the T cell hybridoma TNP408. Fig 52 shows 
that again ABNP1-7 stimulates at the highest concentration and that the addition of monoclonal 
antibodies enhanced antigen presentation, but the antibody also increased unspecific stimulation. 
The response to MVH1 and ABMVH1 was negative irrespectively of the presence or absence of 
monoclonal antibodies. As with the TNP79, we observed cell death induced by CBMVH3.  
 
III.2.2.4.2 T cell proliferation assay using human T cell line 
In this experiment, specific human T cell lines were used to test the ability of the chimeric 
constructs to induce T cell proliferation. In general, human T cells tend to be more sensitive than 
murine T cell hybridomas.  
 
Four different T cell lines were tested: two cell lines were specific for the epitopes 254-268 of the F 
protein (cell line FR6.6 and  254T2) but these two F-specific cell lines were not stimulated by either 
the constructs containing the epitope or the positive control (data not shown). They were therefore 
excluded from the study. Cell line NP1.5 is specific of epitope 185-199 of the nucleoprotein. In 
addition, TT830 T cell line, specific of the tetanus toxoid, was used as a negative control.  
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Fig 53: Stimulation of T cell line NP1.5 induced by our constructs 
 
Fig 53 shows that ABNP1-7 induced a proliferation of the NP1.5 cell line, with a maximum 
stimulation at 12 µg per well. Higher concentration of the constructs seemed to be toxic to the cells, 
as observed in previous experiments for the CBMVH3 (data not shown). MVH1 (that does not 
contain the specific T cell epitope) has a pattern similar to the negative peptide and is thus 
considered negative. The ABMVH1 constructs is completely negative over the whole range of 
concentration, perhaps because of its low concentration in the antigen mix.  
 
The TT830 T cell line was used to monitor non-specific proliferation. As expected, this cell line 
reacted with its specific peptide but was negative for all the investigated constructs (Fig 54), none 
of which contained the tetanus toxoid T cell epitope. 
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Fig 54: Stimulation of T cell line TT830 induced by our constructs 
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III.2.2.4.3 T cell proliferation assay using human T cell lines and antibody priming 
In the previous experiments, mytomycin C was used to prevent the proliferation of the APC during 
the experiment. The previous experiments raised the question whether mytomycin C could interfere 
with the processing of the longer constructs, by inhibiting the synthesis of proteosomes or MCH 
molecules (Tomasz et al, 1987; Rahmsdorf et al, 1986). Therefore, the experiment of Fig 53 was 
repeated with NP1.5 human T cell line, adding mytomycin C only 5 hours after antigen pulsing. 
 
Fig 55 shows that this experiment essentially confirms the results of the previous ones. 
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Fig 55: Stimulation of T cell line NP1.5 induced by our constructs, using primed APC 
 
III.2.2.5 Immunogenics studies 
To investigate if mouse serum obtained after immunization with different constructs contained 
cross-reactive antibodies, sera were tested by flow-cytometry against MV-infected WMPT cells. In 
this assay, anti-MV antibodies would bind to the MV-glycoproteins budding from the cell surface.  
 
Fig 56: Controls of the WMPT experiments. 
 
In Fig 56, the MV-specific mabs BH26 and BH101 show a very strong expression of hemagglutinin 
protein associated with budding MV (in fact, the signals are virtually off-scale). In contrast, 
uninfected cells are negative with the same mab. A serum from an MV-positive individual binds to 
the MV surface protein and the serum of a naïve individual did not generate a positive signal. 
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Fig 57: Histograms of the WMPT cells reacted with sera from mice immunized with the MVH1, 
ABNP1-7, CBMVH3 and ABMVH1 proteins. The gray histogram shows the un-infected WMPT cells 
and the black bold line shows the results obtained with the MV-infected WMPT 
 
Fig 57 shows only very weak or negative reactivity. This would suggest that none of our constructs 
elicited antibodies cross-reactive with the two surface proteins MV-F or MV-H.  
 
The sera were also tested by ELISA to confirm that the constructs induced antibodies. 
Fig 58: Response of the mice sera to the Me asles virus. 
The graphs show the OD values at 405nm of the 5 individual mice of each group compared with 
the different blood samples. Pre-bl, bl1, bl2 and bl3 stand respectively for pre-bleeding, bleeding 
after boost 1, bleeding after boost 2 and bleeding after boost3 
 
Fig 58 shows that the sera obtained after immunization with ABMVH1 react strongly with coated 
measles virus. Sera obtained with ABNP1-7 reacted weakly after the third boost. This suggests that 
either the FACS experiment was not very sensitive or that the ELISA detected antibodies directed 
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against the nucleoprotein. The construct ABNP1-7, that stimulated T cell proliferation, also induced 
detectable amounts of anti-MV antibodies. Although construct ABMVH1 gave only very weak 
reactions in the T cell assay, the mouse sera reacted with the antigen lysate in ELISA. 
 
The above results showed that although overall expression of the constructs in bacteria was 
probably low, some chimeric proteins induced antibodies that cross-reacted with coated measles  
virus in ELISA. However, when the same sera were tested against measles virus budding from the 
surface, they were negative. These two results can be reconciled if one considers that a high 
proportion of the coated MV in ELISA is denatured (Worldwide vaccines, 2002) and it is probably 
this fraction that is recognized. 
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IV. DISCUSSION   
 
IV.1 Secondary immune response in adults with low levels of antibodies 
 
There are different manifestations after contact with wild-type measles depending on the pre-
existing immune status (Aaby et al, 1986; Pedersen et al, 1989). Seronegative people generally 
develop clinical measles. While seropositivity normally protects against disease, this study 
demonstrates that a SIR occurs in individuals protected by wild-type virus induced immunity. 
Among 45 fully protected, measles late convalescent parents reexposed to measles, 4 developed 
an asymptomatic SIR with a significant increase in MV-specific IgG. Mainly the IgG1 subtype was 
boosted, which is also the predominant subclass during primary infection (Mathiesen et al. 1990). 
SIR included antibodies against MV-H and against MV-NP, which are also the main antibody 
targets during primary response (Norrby et al, 1981). SIR was sometimes associated with a weak 
IgM response as reported before (Murray and Lynch, 1988; Sekla et al, 1988). Higher and more 
transient increases of IgM may have been missed in sera which were drawn later after exposure. 
 
SIR was only found in individuals with a pre-exposure IgG level below a well defined threshold 
which was determined in this study to be IgG<780-850 mO.D., NT<1:25.5-26.5, HI<1:26.5-27. Above 
this threshold none of the parents developed a reaction to MV after exposure. SIR seems to be an 
“all or none response” where the magnitude of increase in specific IgG, NT and HI is independent 
of pre-exposure antibody levels as long as these are below a certain threshold (Muller et al. 1996). 
However, a single serological parameter may not be sufficient for the assessment of SIR 
susceptibility. The four parents with SIR were the only individuals which were below the threshold 
for the three parameters, suggesting that only low specific IgG combined with low NT and HI titers 
predispose for SIR. 
 
Another observation was that antibody levels tended to decrease again after exposure. Antibodies 
persisted, however, long enough that an IgG increase would not have been missed in the other 
sera taken 4.6-6 weeks after exposure. This observation suggests that the low antibody levels 
found in these individuals are not caused by an insufficient MV contact, but rather to a low-
responder status, which may be genetically defined as has been suggested (Poland et al, 1995; 
Hayney et al, 1997). Consenting individuals with short-lived SIR could potentially be useful for the 
surveillance of circulating virus. A similar short-lived antibody increase was also observed in 
vaccinees after booster immunisations with live measles vaccine (Markowitz et al, 1992).  
 
Several observations indicate that measles virus can circulate among seropositive persons 
(Pedersen et al, 1989; Gustafson et al, 1987). In a secluded population of seropositive vaccinees, 
most experienced an increase in measles titers several years after vaccination. In the absence of 
clinically overt measles, this suggested that the virus circulated also in healthy vaccinated 
individuals which could potentially transmit disease to seronegative people (Pedersen et al, 1989). 
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It is likely that this requires a transient viraemia. People undergoing a clinically inapparent SIR are 
the most likely candidates to support such a transmission of virus. In this context, the transient 
nature of the SIR seems to indicate that such individuals can be efficiently protected from disease 
but not necessarily from infection. The frequency of SIR during measles outbreak was about 5% 
(Ozanne et al, 1992; Edmonson et al, 1990), however, the number of susceptibles to SIR may be 
considerably higher. Our data can be used to estimate the frequency of susceptibles on the basis 
of their pre-existing IgG, NT and HI levels. Such estimates may become important, since after 
vaccination antibody titers are lower and more likely to wane than after wild-type infection (Weibel 
et al, 1980; Krugman, 1983; Pedersen et al, 1986; Christenson and Böttiger, 1994). Therefore, with 
more and older vaccinated people the number of susceptibles to SIR is likely to increase in the 
future.  
 
Our study suggests that a subset of individuals which may be transiently contagious, can be 
serologically identified on the basis of their pre-existing immunity and that the estimation of their 
frequency could be relevant for future MV epidemiology and vaccination strategies. In only one 
case, wild-type virus has been isolated from individuals with asymptomatic secondary immune 
response (Kreis and Schoub, 1998), possibly because they are poorly defined. But direct case 
confirmation of unapparent secondary immune response is also complicated by the need of 
documented measles virus contact as well as pre- and post-re-exposure serum samples. It is 
therefore difficult to obtain direct estimates of the frequency of persons susceptible to 
asymptomatic secondary immune response. 
 
In this view, the study of other representative populations could shed light on the percentage of 
SIR-susceptibility in the population. We assessed here the fraction of individuals which would 
undergo SIR when in contact with a measles patient. This estimate is based on the pre-reexposure 
serology of parents from measles children undergoing an asymptomatic SIR with concomitant 
increase in specific IgG, NT and HI titers defined earlier. 
 
In a population of 277 adults with natural immunity after measles infection, 3.2-3.9% exhibited the 
pre-reexposure serological characteristics of the SIR-competent parents. Among vaccinated 
children, up to one-third (22.2-33.2%) seemed susceptible to develop SIR upon contact with a 
measles patient, no matter if they were vaccinated once or twice. Christenson and Böttinger (1994) 
showed that specific titers can be boosted by revaccination, while boosting late convalescent 
individuals was not possible, demonstrating that vaccines are more likely to undergo vaccine-
induced secondary immune response than late convalescents. In our study, SIR susceptibility was 
not reduced by a second vaccination, although revaccination reduces susceptibility to measles 
(Hutchins et al, 1990; Robertson et al, 1992; Tulchinsky et al, 1993). 
 
SIR may present with unspecific symptoms, mild or even typical measles (symptomatic SIR) (Aaby 
et al, 1986; Edmonson et al, 1990) or it may remain clinically silent (Pedersen et al, 1989). It 
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appears that asymptomatic SIR may be a serological reaction to MV re-exposure detected in 
seropositive individuals protected against disease.  
 
 SIR Susceptibility  
Cohorts Minimum (%) Maximum (%) 
Early convalescents 0 0 
Late Convalescents 3.2 3.9 
Vaccinated once 22.2 33.2 
Vaccinated twice 32.6 32.6 
Table 12: Estimated frequency of SIR-susceptibles among early and late convalescent donors and 
vaccinated high school children. 
 
The above estimates include seronegative individuals susceptible to disease and those prone to 
develop asymptomatic SIR. 
 
In the first instance, among the vaccinated children 3-4% were seronegative by ELISA, but less 
than half of these were also negative for HI and NT. Such seronegative vaccinees correspond to 
primary vaccine failures and must not be counted as susceptible to SIR, since they would develop 
disease upon measles exposure. These values are in agreement with the primary vaccine failure 
rates of other studies (Miller et al, 1995). In the late convalescent cohort, <1% is seronegative, i.e 
susceptible to clinical measles.  
 
Symptomatic SIR is mainly seen as secondary vaccine failure and is only rarely found in measles 
convalescents (Aaby et al, 1986; Edmonston et al, 1990; Miller et al, 1995). Most estimates of 
secondary vaccine failure range from 0% (Gustafson et al, 1987; Anders et al, 1996) to about 5% 
of either the measles patients or the vaccines (Edmonston et al, 1990; Ozanne and d’Halewin, 
1992). Measurements of symptomatic SIR susceptibility in a population largely depend on MV 
exposure and on the sampling method. 
 
Even when primary and secondary vaccine failures are taken into account, our data still suggest 
that a large proportion of vaccinees is susceptible to asymptomatic SIR. Susceptibility to 
unapparent SIR may be 5 to 8 times higher than to symptomatic SIR.  In a fully vaccinated 
population asymptomatic SIR was found to be as high as 66% (Pedersen et al, 1989). That study 
describes a population with a high risk for SIR, in which viral replication could potentially be studied 
after measles exposure. Moreover, serological follow-up of voluntary contacts between SIR-
susceptibles and accidentally measles exposed secondary immune response susceptibles could 
shed light on the potential infectivity of individuals undergoing secondary immune response. 
 
As a result of sustained vaccination programs, measles immunity will wane in the general 
population and will eventually fall to the level of vaccine-induced immunity.  
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A simple estimation (Fig 59) shows the status of the population and the evolution of SIR 
susceptibility in a population. If we consider that in 1975, the whole population was protected by 
natural infection, the proportion of SIR susceptible would be equal to the late convalescent cohort 
(approx 3.2 – 3.9%). A population that is protected only by vaccine-induced immunity (100%) would 
have a proportion of SIR equal to the cohort of vaccinated children (22.2 – 33.2%). As the 
percentage of individuals protected by vaccination in the Luxemburgish population is about 32%, 
we could postulate, using a linear relation, that the current proportion of SIR susceptible is about 
10%. 
 
 
 
Fig 59: Estimation of the fraction of SIR susceptible in the population 
 
Moreover, in the elderly, vaccine-induced immunity wanes faster than natural immunity (Markowitz 
et al, 1990; Christenson and Böttiger, 1994), meaning that the proportion of SIR susceptible in a 
population vaccinated to 100% could be potentially much higher that in our estimation. A study 
based on a similar data set (Mossong et al, 1999) has used a mathematical model to determine 
that after 25 years, 50% of seroconverted vaccinees would have an antibody titer below protective 
level. This means that 80% of all vaccinees will eventually loose protective levels of antibodies. In 
this case, elimination of measles virus cannot be achieved by a single-dose routine vaccination 
strategy if the basic reproduction number of vaccinated SIR-susceptibles exceeds 1.24 (Mossong 
et al, 1999). 
 
If SIR susceptibility plays a role in the epidemiology of measles, this role is likely to grow in fully 
vaccinated populations where SIR could affect 30 % or more. Vaccination strategies as well as 
global eradication programs may have to consider the increasing number of SIR susceptibility in 
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highly vaccinated populations, and this in addition to enhanced susceptibility due to waning 
immunity. 
 
The duration of the “booster effect”, the antibody increase detected in the SIR parents, can also be 
an issue in the development of further strategies. Indeed, 30±1 week after MV-reexposure, 10-25% 
of the increase in specific antibody was already lost, with similar decrease in HI and NT. This 
demonstrates that the booster effect was only transient. Although none of the parents have already 
recovered their pre-exposure immune status, the antibody titers are coming close to the threshold 
values (780-870mOD) and are still decreasing 4 years after exposure. It is possible that the SIR 
parents may become SIR-susceptible again and therefore could again be transiently infected by 
measles virus. 
 
IV.2 The vaccine strategies 
 
Our concept of a subunit vaccine consists in the design of a recombinant protein containing 
immunologically relevant peptide sequences derived from one or several pathogens.  
 
Two complementary strategies, which differ mainly by the size of the pathogen-derived peptide 
sequences, have been used. One is based on the use of minimal epitopes allowing the 
incorporation of a maximal number of immunologically relevant peptides into a small protein, but 
using no human T-cell epitopes to prevent any risks of atypical disease. The other strategy uses 
larger pathogen protein fragments, containing BCE and TCE in their natural local sequence 
environment, with the objective to boost the immunity of vaccinated individuals. 
 
In both cases, DNA fragments, encoding the BCE and TCE peptides, are assembled using 
molecular biology techniques to generate artificial genes encoding recombinant proteins differing 
by the order, orientation and nature of the subunits. These DNA constructs will subsequently be 
expressed in eukaryotic or prokaryotic cells. The recombinant proteins will be isolated and used for 
testing their antigenicity and immunogenicity. We designed our polyepitopic constructs by 
molecular biology techniques, because this technique allows to create longer constructs than with 
peptide synthesis. Moreover, as the constructs are made of linear epitopes or mimotopes, they 
may not require a defined tridimensional structure for recognition by immunoglobulins. Therefore, 
these artificial proteins may have the advantage of being more stable.  
 
IV.2.1 Polyepitopes based on mimotopes 
Routine vaccination against measles in young infants is performed at 15 months of age in the 
developed countries and at 9 months in the developing world. Earlier vaccination is usually 
associated with a low seroconversion rate due to persisting transplacentally transferred maternal 
antibodies (Albrecht et al, 1977). These antibodies neutralize the low dose of live viruses 
contained in the attenuated vaccine. Another mechanism by which pre-existing antibodies 
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complexed with viral antigen may inhibit the activation of specific B cells is by cross-linking specific 
surface immunoglobulins and Fc-gamma receptors (Sarkar et al, 1996).  But even in the absence 
of maternal antibodies, the immaturity of the immune system of infants early after birth precludes a 
high seroconversion rate (Gans et al, 2001), although the T cell reponse may be adequate 
(Siegrist, 2001).  
In developing countries maternal antibodies seem to wane faster than thought until now. In a 
cross-sectional study from our own laboratory with Nigerian infants up to 9 months of age the 
overall prevalence of measles antibodies was 45 % with only 32% of the 3 months old and 2% of 
the 6-9 months old infants protected (Hartter et al, 2000). Other investigations also demonstrated 
an early loss of maternal measles antibodies in children from different developing countries with 
low national per-capita income. Seronegativity at 4 months of age was 52% in Brazzaville, Congo 
(Dabis et al, 1989),  54% in Kenya (Collaborative study by the Ministry of health of Kenya and 
WHO,1977),  and 90% in Libreville, Gabon (Gendrel et al, 1986); at five months of age it was as 
high as 88% in Bangladesh (de Francisco et al, 1998) and 88% at six to seven months of age in 
South Africa (Kiepiela et al, 1991) and 93% in Ilorin, Nigeria (Babaniyi et al, 1995). In many of 
these studies, mothers were immune as a result of wild-type infection. In the first section of this 
study, we showed that vaccinees have considerably lower antibody titers than those protected by 
wild-type immunity (Damien et al, 1998). Therefore in the future, vaccinated mothers will transfer 
even less antibodies onto their babies. Moreover, some strains have been reported, that seem to 
be less susceptible to neutralization by vaccine induced antibodies (Klingle et al, 2000). Thus a 
number of factors contribute to a further reduction of child protection by maternal antibodies and to 
a widening of the “window of susceptibility” which delimits the time between the end of the 
protective immunity by maternal antibodies and the age at which the child is routinely vaccinated. 
This window of susceptibility is a period of high-risk for the child to develop complicated measles. 
 
The development of new vaccines for vaccination of young infants during this period of enhanced 
susceptibility has been hampered by the concern for atypical measles, a severe form of measles 
with unusual clinical features that was observed after vaccination with the early killed vaccine 
(Brodsky, 1972). Although the exact mechanism leading to this disease is still unclear, several 
hypotheses have been produced. Initial studies of the immune response to killed measles vaccine, 
have shown that recipients developed antibodies to the H protein but little to the F or N proteins 
(Norrby et al, 1975; Norrby and Gollmar, 1975), indicating that the immune response against other 
proteins than H may be needed. With a better understanding of mechanisms of antigen 
presentation and T cell activation it seems more likely that an inadequate T cell response may be 
the cause of atypical measles. The cytotoxic class I restricted response is probably reduced after 
vaccination with killed vaccine. Moreover, an imbalance in cytokine production leading to a biased 
Th2 response is another suspected reason (Ward and Griffin, 1993).  In monkeys, diseases 
mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting 
antibody were observed (Polack et al, 1999). A similar model was also proposed to explain 
enhanced disease after vaccination with killed RSV virus (Openshaw et al, 2002). However, the 
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Th1/2 imbalance is not generally accepted, and some authors defend the possibility that the 
atypical measles could be caused by the absence or a marginal T cell reaction after immunization 
with a killed virus (Griffin D., personal communication).  
 
While the latter hypothesis emphasizes the importance of strong T cell epitopes in an 
experimental vaccine, the Th1/Th2 imbalance suggests that no priming of MV-specific T cells may 
be the best approach. Our set of polyepitopes was constructed to take these views into account. 
 
MV-specific antibodies are sufficient to protect against disease. For instance, 
hyperimmunoglobuline infusions protect until several days after infection (CDC, 1996; Gupta et al, 
2001). Also infants are solely protected by maternal antibodies, highlighting the role of antibodies 
(Bromberg et al, 1994). The vaccine proposed here, is designed to induce antibodies against 
measles without priming for MV-specific T cells. The induction of an efficient immune response 
requires a T cell epitope. Therefore a broadly reactive promiscus T cell epitope of the tetanus 
toxoid, that activates T cells in the framework of most human MHC class II restriction elements 
was included in our sequence for priming in humans, along with a mouse (H2d restricted) T cell 
epitope demonstrated as very potent in our animal model (Brons et al, 1996), for experimental 
testing. It is very unlikely that such mouse short epitope sequence would also be a T cell epitope 
in many humans. 
 
The B cell epitope is a mimotope, which does not share sequence homology with the measles 
protein, but mimicks a neutralising and protective conformational epitope of the fusion protein. 
One such mimotope has been described by Stewart et al (1995). The mimotope was selected with 
a monoclonal antibody directed against the fusion protein. The selection was performed using a 
library of randomly synthesized 8mer oligopeptides. The study from Stewart et al (1995) showed 
that the selected mimotope induced protective antibodies in the mouse model. The vaccine 
containing such mimotope would induce MV-specific neutralizing antibodies, but avoiding the 
induction of MV-specific T cell epitopes, thus preventing priming of the aberrant Th pathway that 
may be responsible for atypical measles.  
 
As a result, polyepitopes based on the described epitopes should be able to induce the production 
of MV-specific antibodies without containing any MV-specific sequence, thus avoiding the 
induction of MV-specific T cells in human. Such setup would induce protective antibodies without 
being neutralized by remaining maternal antibodies and with limited risk of atypical measles. 
 
The distance of antigenic regions, the importance of number, order and orientation of these 
epitopes have been discussed in the literature (Hathaway et al, 1995; El Kasmi et al, 1999). These 
factors play an important role in the efficiency of the immune response. In the presented 
approach, we have combined the mimotope and the T cell epitopes into a set of permutational 
polymimotope constructs with the intention to investigate the importance of the protein size, the 
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copy number and the relative position of the different subunits with respect to the antigenic and 
immunogenic properties of the recombinant protein. Adjacent or overlapping B and T cell epitopes 
have been observed in influenza hemagglutinin (Barnett et al, 1989), Plasmodium falciparum  
antigen Pf155/RESA (Troye-Blomberg et al, 1988) and other pathogens (Celada and Sercarz, 
1988). In natural immunity, pairing of T and B cell epitopes uses a mechanism, which allows 
preferential processing and presentation of T cell epitopes adjacent to the antibody binding site. 
Through differential binding to epitopes of the same antigen, B cells could define the B cell epitope 
and can directly process (Davidson and Watts, 1989) and select the peptide fragment mediating T 
cell help as proposed by the concept of directional help (Celada and Sercarz, 1988). This requires 
an important role of B cells as antigen processing cells (APCs). B cells are directly involved as 
APCs, particularly when memory cells have already been established (Lanzavecchia, 1985).  
 
A strategy similar to the one described here has already been developed by our laboratory by El 
Kasmi et al (2000) using peptides mimicking sequential MV-epitopes. El Kasmi et al. used the 
HNE and NE epitopes from the H protein to induce a neutralizing antibody response. These 
peptides actively induced virus-neutralizing antibodies even in the presence of protective levels of 
anti-MV antibodies. These same epitopes were also used to generate permutational polyepitopes 
(Theisen et al, 2000). At least one of these polyepitopes gave high neutralizing antibody titers 
(Bouche et al. submitted). Since in the latter studies peptides and polyepitopes were based on 
BCE derived from sequences of the MV, they potentially contain a T cell epitope active in a 
fraction of the human population. In contrast, the present approach completely avoids to include 
MV sequences as B cell epitopes. 
 
Our constructs using the M2 epitope were produced in eukaryotic cells. T cell experiments showed 
that the constructs were able to stimulate T cells. This also indicated that the constructs were 
produced in the expression system. However, the mab did not detect any sizeable amounts of the 
construct in ELISA. Therefore, it was tested whether the Leu-Asp spacer (resulting from the 
restriction sites) between the mimotopes may have precluded recognition. An ELISA test with 
synthetic peptides and the monoclonal antibody F7-21 showed that the antibody recognized the 
Mimotope-Gly-Gly-Gly-Mimotope but did not detect the Mimotope-Leu-Asp-Mimotope peptide. 
This result suggested that the Leu-Asp spacer perturbs the secondary structure of the BCE in the 
synthetic peptide, preventing recognition by the antibody. The presence of the Leu-Asp amino 
acids flanking each subunit may explain the non-detection of the BCE in the recombinant protein 
and suggests that the spacer amino acids may also be responsible of a modified epitope 
conformation in the recombinant proteins. Numerous examples in the literature showed that the 
flanking regions of an epitope change its crossreactive-immunogenicity (Manca et al, 1993; 
Stittelaar et al, 2001; Hudecz, 2001) and it is very difficult to predict such changes. 
Furthermore, the sera obtained with the Mimotope-Leu-Asp-Mimotope peptide did not show a 
significant titer of antibodies, indicating that the peptide was probably poorly immunogenic. 
Alternatively, it is possible that ionic interactions between the aspartic acid (Asp) situated in the 
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spacer and a positively charged amino acid (lysine or arginine) in the mimotope may have 
influenced its conformation in vivo, differently than in vitro. Cumulatively, these results suggest 
that the spacer used is not compatible with suitable crossreactive immunogenicity of the 
mimotope.   
 
In studies by Steward and colleagues (Steward et al,1995; Obeid et al, 1995; Olszewska et al, 
2000) the mimotope was described to induce antibodies that protected mice against an 
intracranial challenge with a rodent adapted measles virus. Therefore, this mimotope was 
considered as a possible candidate for a linear B cell epitope able to elicit neutralizing antibodies 
against the measles virus. However, when the F7-21 mab was tested for virus neutralising activi ty, 
it came to a surprise that the antibody did not neutralise the virus, casting some serious doubts on 
the protective capacity of both the antibody and the mimotope.  
Steward et al (1995) obtained a neutralising mimotope from a non-neutralizing antibody. However, 
the literature shows that in vivo protection by antibodies, which do not neutralize in vitro is possible 
(McCullough et al, 1986; Gould et al, 1986; Harty et al, 1987; Burns et al, 1996). One notable 
example is the linear epitope of the G glycoprotein of the respiratory syncytial virus (RSV), 
described by Trudel et al (1991). However, this dichotomy has never been reported for the 
measles virus. Whether in the case of the F7-21 mab this could be explained by complement-
mediated effector mechanisms or antibody-dependent cellular cytotoxicity (ADCC) and/or immune 
phagocytosis  (Mochizuki et al, 1990) or the synergistic neutralising effect of several non-
neutralising antibodies (Verrier et al, 2001) remains an open question.  
 
Although a similar study from our laboratory with polyepitopes based on linear epitopes of MV 
gave some very promising results (El Kasmi et al, 2000; El Kasmi et al, 1999; Bouche et al, 
submitted), the present study showed that the mimotope M2 is not suitable for incorporation into 
such constructs possibly because of conformational incompatibility with the LD-spacer and 
possibly for other reasons too.  
 
For futures projects, the current cloning strategie will still be used unchanged since we have not 
noticed a similar interference of the spacing amino acids with the desired conformation of other 
recombinant constructs in our laboratory. The effect impeding the recognition of mimotopes with 
Leu-Asp spacer by antibodies may therefore be related to the sequence particularities of the M2 
mimotope only. Nonetheless these results illustrate that the neighboring amino acid environment 
can introduce important conformational modifications in the structure of a specific minimal epitope 
and the use of larger peptide fragments, presenting the core epitope in their natural sequence 
environment appears to be an interesting alternative to ensure the presentation of the desired 
epitope conformation in a recombinant protein. 
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IV.2.2 Polyepitopes derived from antigenic regions of the measles virus 
As already discussed in the Chapter IV.1, the level of immunity of vaccinees is less robust than in 
individuals protected by wild-type immunity. This is certainly true when the comparison between 
vaccinees and late convalescents is based on antibody levels: antibody levels are both lower 
(Damien et al, 1998) and less durable in vaccinees (Mossong et al, 2000). At this point the 
significance of waning antibodies both for the protection of individuals and for the future 
epidemiology of measles virus remains unclear. While some authors are concerned by the loss of 
antibodies (Mossong et al, 2000) others expect that vaccinees with waning antibodies may still be 
protected by a more durable T cell immunity (Weidinger et al, 2000).  For instance, it was observed 
that monkeys immunized with BCG expressing were substantially protected from lung inflammation 
by T cell immunity, in the absence of anti-MV antibodies (Zhu et al, 1997). Although T cells may 
prolong protections by vaccination beyond the prevalence of antibodies, the waning of immunity in 
vaccinees may develop into a major problem with respect to the WHO target of measles 
eradication. In the future, when the proportion of vaccinees with waning immunity is going to 
increase, there may be a need for revaccination of these individuals as well as those that are 
susceptible to secondary immune responses. 
 
A strategy is proposed here for routine revaccination of vaccinees with waning immunity. In the 
absence of prior testing, antibody levels in these vaccinees are normally not known. Since these 
individuals may have variable levels of antibodies, the vaccine should also be efficient in the 
presence of antibodies. Ideally a vaccine designed for boosting vaccinees should be resistant to 
residual virus neutralising antibodies. Our vaccine strategy is based on the boosting of the T cell 
response by MV sequences of the main immunogenic viral proteins. Such a vaccine must include 
a large number of T cell epitopes and, at the same time, exclude functional neutralizing B cell 
epitopes. The vaccine is based on a polyepitope containing a large selection of known or putative 
CD4 and CD8 epitopes, many of them in their natural environments, facilitating the uptake and 
processing as described by Celada and Sercarz (1988). The large number of CD4+ T cell epitopes 
should ensure efficacy in the human population with polymorphic MHCs. Mice TCE were also 
included for ensuring testing in an animal model. Thus, selected sequences were assembled into 
single proteins, which have little or now resemblance with the 3D structure of the viral proteins. We 
expect that these chimeric proteins or polyepitopes would resist antibodies but boost the residual T 
cell response. The presence of numerous TCEs in the vaccine would also help to make the 
vaccine more resistant to immunological pressure and the generation of escape mutants.  
 
Unlike the previous strategy, we used fragments from the N protein from measles. This protein 
carries a large number of CD4+ and CD8+ TCE (Nanan et al, 1995; Hickman et al, 1997; 
Beauverger et al, 1993; Fournier et al, 1996; Giraudon  et al, 1988). Several studies suggested that 
recombinant proteins based on N protein epitopes alone may be protective although the N protein 
does not induce neutralizing antibodies. Bankamp et al (1991) have shown protection in Lewis rats 
against neurotropic MV, vaccinated with recombinant vaccinia virus expressing the nucleocapsid 
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protein. Immunized rats revealed polyclonal but not neutralizing antibodies to the N protein as well 
as an N protein-specific proliferative lymphocyte response. This study concluded that a CD4+ cell-
mediated immune response specific for the N protein could be sufficient to control measles 
infections of the central nervous system (Bankamp et al, 1991). In this context, it is interesting to 
note that N protein has been reported to induce primarily antibodies of the IgG2a subclass after 
intraperitoneal injection, indicating a Th1 response (Cardoso et al, 1996; Olszewska et al, 2001). 
Similarly, other studies have shown that recombinant N protein was able to induce T cell responses 
and low levels of neutralizing antibody as well as considerably reducing the virus titer recovered 
from brain homogenates of mice (Fennelly et al, 1995). 
 
Cytotoxic T-lymphocytes (CTL) against measles virus are thought to play an important role in 
recovery from disease (van Binnendijk et al, 1990). An and Whitton (1997) found that an isolated 
CTL epitope may confer protection against a lethal dose of a virus. In measles immunity, the major 
protein for CTL activity is the N protein and such CTL epitopes play an important role in the control 
of virus infection (Schadeck et al, 1999). However, other authors reported no reduction of virus 
titers in rats after immunization with N protein. (Schlereth et al, 2000b). These authors suggested 
that additional neutralizing epitopes may be required to overcome viral infection completely.  
 
Some studies report that MV and CDV share an antigenically similar nucleoprotein which allows 
the MVN protein to protect dogs from distemper virus (Wild et al, 1993). Such vaccine containing 
numerous TCE from the N protein may also help to negate the selective pressure induced by 
current life-attenuated vaccine because of the high homology of the nucleoprotein between 
different strains or even different host species, preventing the emergence of resistant clades.  
 
In the previous mimotope strategy, the spacers that resulted from the restriction sites were 
detrimental for antibody recognition, probably because of their influence on conformation. In the 
present strategy, virus-crossreactive antibodies were undesired. Therefore, the spacers may 
actually contribute by perturbing the conformation of the constructs.  Since it is difficult to predict 
the effect of the spacer on processing, in particular, of class II-restricted TCEs, the same cloning 
strategies used for the construction of the polymimotopes was also utilized for the assembly of the 
polyepitope construct based on immunogenic sequences of the MV.  
 
In this strategy, we have used the T7 prokaryotic expression system, hoping to increase the 
quantity of produced protein along with some experimental simplification. This expression system 
has been designed to produce high levels of recombinant proteins. It has been used in combination 
with a large variety of genes. However, sometimes proteins were produced in disappointingly small 
amounts, for reasons that were obvious in some cases and obscure in others (pET system manual, 
Novagen). By following the protocol recommended by the manufacturer, only low levels of 
recombinant protein were detected and considerable improvements were needed. In the case of 
the polyepitopes several reasons for the low expression must be considered: (I) low expression 
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efficiency of the T7 system for these randomly assembled proteins, or (ii) low stability and/or rapid 
degradation of the chimeric proteins, or (iii) a low sensitivity of the detection system.  
 
IV.2.2.1 Optimization of the induction 
The induction protocol provided by the manufacturer was recommended for generic proteins of 
smaller sizes (pET system manual, Novagen) than those of our constructs. Therefore, the protocol 
provided by the manufacturer may have been less optimal for larger constructs. Several attempts 
were made to improve the output of the induction process. The duration of induction was 
investigated and we showed that maximal levels of proteins were already obtained within 4 hours 
of induction. Induction times over 12 hours seemed to decrease the overal efficiency of the 
induction. 
Different concentrations of IPTG were also experimented to find the best compromise between 
good induction and best cell growth. In addition, different experiments were made on the kinetics of 
delivery of IPTG. The best overall efficacy was obtained with a delivery of 1mM IPTG every 2 
hours, during 4 hours. The fine-tuning of the purification method provided some amount of partially 
purified recombinant protein, sufficient to perform down-stream experiments. 
 
Once the induction protocol was improved to produce the best overal performance, the obtained 
raw protein batch could be purified using a Nickel column connected on a HPLC. 
 
IV.2.2.2 Protein stability 
Some factors were described to influence the stability of the recombinant proteins such as the 
nature of the amino acid immediately following the N-terminal methionine (penultimate amino-
acid).The amino-acid at this position determines the removal of the N-terminal fMet 
(formylmethionyl). This process is catalysed by a methionyl aminopeptidase and its rate decreases 
as the size of the penultimate amino acid side chain increases (Hirel et al, 1989; Lathrop et al, 
1992). Little or no processing was observed by these authors when the following amino-acid 
occupied the penultimate position: His, Gln, Glu, Phe, Met, Lys, Tyr, Trp, Arg. Processing ranged 
from 16% to 97% when the other amino-acids occupied their critical position. In our cassette, the N 
terminal amino-acid sequence is the same for all constructs: The sequence, corresponding to the 
nucleotides running from the NcoI site (containing the ATG) to the Xba I site (first cloning site used 
during our cloning step) is Met - Ala - Ile - Leu – Ala, meaning that we have amino-acids with a 
relatively short side-chain, leading to a potentially high rate of removal of the fMet that may induce 
protein degradation. 
 
Tobias et al (1991) have determined the relationship between a protein’s amino-terminal amino 
acid and its stability in bacteria, i.e., the N-end rule. They reported protein half-lives of only 2 
minutes when the following amino-acids were present at the amino-terminus: Arg, Lys, Phe, Leu, 
Trp and Tyr. In contrast, all other N-terminal amino acids conferred half-lives of >10 hours. As none 
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of these amino-acids are present in the immediate N-terminal end of our recombinant proteins, this 
suggests that our protein may have a relatively long half life. 
 
The above studies suggest that for instance Leu in the penultimate position would be a poor 
choice, because it would likely be exposed by fMet processing and then be targeted for rapid 
degradation (Lathrop et al, 1992). Therefore, when an NdeI site is used for the production of 
unfused target proteins from pET vectors, Leu codons in the penultimate position should be 
avoided. Having always the same sequence at the beginning our our polyepitopes ensure the 
same treatment for all the proteins, along with a N-terminal region free of amino-acid inducing short 
half-life. Moreover, Leu codons in the penultimate position cannot be generated in our strategy 
because we used NcoI as the cloning site, where the penultimate codon must begin with a G. 
 
Other factors that may also influence the expression level of target proteins include: mRNA 
secondary structure that may interfere with the ribosome binding site or the initiation codon 
(Tessier et al, 1984; Lee et al, 1987), or an excessive occurrence of rare codons in the target gene 
(Zhang et al, 1991; Sorensen et al, 1989), inducing the synthesis of truncated proteins. The codon 
usage of the constructs were compared for expression in human and bacteria and revealed no 
obvious incompatibilities. 
 
IV.2.2.3 T Cell experiments 
The T-cell experiments showed that the construct ABNP1-7 containing the epitope 185-199 of the 
nucleoprotein stimulated IL2 secretion of the corresponding T cell hybridomas. These experiments 
showed that at least one of the constructs was produced in detectable amounts (ABNP1-7). The 
lower stimulation induced by other constructs with the same NP fragment could be explained 
either by a lower expression efficiency possibly as a result of its larger size (ABNP1-7 is 444aa 
long and ABMVH1 is 729aa long) or by a perturbation by the MVH fragment that interfered with 
antigen processing. 
IV.2.2.4 Antigenicity and immunogenicity studies 
To detect the constructs produced in bacteria, monoclonal antibodies, which recognize both the 
native and the denatured H were used. Both antibodies are specific of the sequence 381-400 of the 
H protein; BH216 recognises the loop-shaped native form, whereas BH195 binds to the linear 
denatured form of the H protein. BH195 reacted with all constructs containing the related BCE, 
whereas the detection by BH216 was much weaker in the same constructs, indicating a poor 
conservation of the three-dimensional structure of this BCE (data not shown).  Although, some of 
the proteins could be purified to some extend, human sera could not be used to test whether the 
constructs were recognized, because of a high background generated by contamination from 
residual bacterial components. Therefore, selected constructs were injected into mice and sera 
were tested for crossreactivity with the viral proteins. In ELISA, the constructs ABMVH1 and to a 
lesser extend ABNP1-7 induced sera that were able to bind denatured MV. When the same sera 
were tested against WMPT cells superinfected with MV, no binding above background levels was 
 135 
observed. These cells are MV-infected and express native F and H proteins on the cell surface.  
The fact that the sera were positive in ELISA but not by flow cytometry, indicated that the epitopes 
recognized were not present on the cell surface-expressed MV proteins. This can be interpreted in 
either one of two ways: (I) the sera crossreacted with N protein, which is not detectable on the cell 
surface. It is very unlikely that the short distinct TCEs embedded in an unnatural environment 
mimic natural epitopes of the N protein. (ii) The sera react with denatured epitopes in the ELISA 
and do not recognize native epitopes of the MV on the cell surface of infected cells. This is the 
more likely interpretation of these results, although we can see that the AB MVH1 signal is much 
stronger than the AB NP1-7, indicating that the MVH1 fragment may play a direct or indirect role in 
the immune response. 
ABMVH1 contained short sequences of the N protein, a relatively short central sequence of the F 
protein and a N- and –C terminally truncated domain of the H protein in the case of the construct. 
As expected these short sequence domains may not share conformational epitopes with the 
native full-length proteins, as was also indicated by the poor recognition of the BH216 antibodies. 
Alternatively, eukaryotic proteins produced in bacteria may undergo no or different post-
translational modifications than those required for the immunogenicity of such proteins, including 
disulfide bonds formation, proteolytic processing of precursor proteins, failure to add chemical 
groups (e.g. glycosylation) or adding undesired groups (myristylation, palmitoylation, 
carboxylation, hydroxylation). Little is known about the effect of such groups on the protein 
structure.  
These factors are of course more important in the case of conformation dependent B cell epitopes, 
as inadequate post-translational modifications may be less critical when they affect T cell 
epitopes. Although some glycopeptide antigens are presented by the MHC, the generation of 
peptide antigens from glycoproteins may require enzymatic removal of sugars before the protein 
can be cleaved (Rudd et al, 2001), therefore being less critical for T cell epitopes.  
Some authors have already demonstrated the importance of the H protein sequence and structure 
for binding of monoclonal antibodies. It was shown that the absence of disulphide bonds impaired 
the capacity of the protein to react with mAbs specific for the discontinuous epitopes and thus its 
immunogenicity (Wilcox et al, 1988; Hu and Norrby, 1994). For the H protein, Hu et al (1994a) has 
suggested that two of the four individual carbohydrate side-chains have a large influence on the 
antigenicity of the molecule.Other studies have indicated that a large part of the maturation and 
processing of the H protein takes place in the ER (Hu et al, 1994b), suggesting that a part of the 
maturation process happening in the ER may not be reproducible in a bacterial environment.  
Recent studies have also demonstrated that the uses of pET system with pelB leader sequence 
has led to the production of functionally and structurally conserved proteins, but the proteins 
needed further renaturation and oxidation (Ribo et al, 1996), thus generating more constraints to 
structurally sensible proteins, as the MV-H protein.  
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It has become clear that prokaryotes (Archaea and Bacteria) are capable of glycosylation of 
proteins (Moens and Vanderleyden, 1997), but only in a few cases is structural information 
available. Many different structures have been observed that display much more variation than 
that observed in eukaryotes. Due to their different cell structure, prokaryotes have to use 
glycosylation mechanisms different from those found in eukaryotes. Despite some similarities with 
the eukaryotic system, these differences may result in substantial differences in glycosylation 
patterns, with important consequences for the structure and immunogencity of proteins (Adeyefa 
et al, 1997; Jaskiewicz et al, 1994; Delmas and Laude, 1991; Caust et al, 1987). 
 
Proof of principle of a strategy of vaccination in the presence of MV antibodies comes from our 
own laboratory, although in relation to another setting. El Kasmi et al. (2001) demonstrated that 
peptides that escape recognition by passively acquired anti-whole virus antibodies could 
potentially be used as components of a 'pre-vaccine' that could be given during early childhood 
irrespective of persisting maternal antibodies. Unlike vaccines based on recombinant proteins, 
such epitope-based peptide vaccines can be designed to be compatible with a subsequent boost 
with the standard life-attenuated vaccine. The same author demonstrates that MV wild-type 
isolates can be neutralized using synthetic peptides which are not recognized by neutralizing 
passive antibodies (El Kasmi et al, 2000; El Kasmi et al, 1999).  
 
Experiments to test this in the presence of passively induced mouse antibodies against MV would 
not be conclusive: from other experiments in our laboratory, we know that MV preparations 
contain sufficient amount of denatured virus to induce antibodies against denaturated virus and 
therefore which cross-reacts with the constructs described here. Thus this can only be tested in 
animals in which the virus can replicate, such as the cotton rat or monkeys. Although, we did not 
have access to a monkey colony at the present time, collaborations to perform these experiments 
are now being seeked.  
 
In summary, the chimeric constructs were designed to boost the measles specific T cell response 
in vaccinees with waning immunity. The above antigenicity and immunogenicity studies suggest 
that the constructs are most likely not recognized by anti-MV antibodies persisting in vaccinees. 
We have further demonstrated that our set of constructs was able to be adequately processed to 
generate the desired T cell epitopes and to stimulate T cells. This suggests that our T cell vaccine 
should be able to boost the T cell reponse in vaccinees without being neutralized by persisting 
antibodies, which would suppress the immune response to the vaccine.  
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V. Conclusions and perspectives 
 
Before the introduction of a vaccine, 8 million people worldwide died each year from measles and 
there were an estimated 130 million cases. The use of the live, attenuated vaccine decreased the 
mortality by 88% within years. At present days, the WHO estimates that over 40 millions cases still 
occur worldwide each year, contributing to about 800.000 deaths, with the largest proportion of 
cases reported to occur in children under the age of 5 years. 
 
Recovery from measles normally results in life-long protection (Panum, 1940) but, despite having 
reached high level of global vaccination against measles, outbreaks continue to occur in 
developing and developed countries (Frank et al, 1985; Gustafson et al, 1987), because the virus 
continues to circulate in seronegative individuals. However, there is also evidence that measles 
virus can circulate in seropositive populations (Pedersen et al, 1989; Gustafson et al, 1987; 
Ozanne and d’Halewyn, 1992; Pedersen et al, 1992). Secondary immune responses (SIR) against 
measles have been observed in fully immunized populations (Gustafson et al, 1987). It is 
reasonable to assume that people undergoing a clinically unapparent SIR after reexposure to 
measles are the most likely seropositive candidates to support transmission of the virus. It is 
therefore important to study the role of SIR-susceptibles for the epidemiology of measles. 
 
In this study, we have characterized SIR in parents exposed to children with measles during an 
outbreak in 1996 (Muller et al, 1996a). Forty-five fully protected, measles late convalescent parents 
reexposed to measles, 4 (9%) developed an asymptomatic SIR with a significant increase in MV-
specific IgG. SIR was only found in individuals with a pre-exposure IgG level below a well defined 
threshold and no individuals with immunity over that threshold seemed to be SIR susceptible. 
Moreover, such immunity increase was shown to be only transient, as the IgG levels of the 4 SIR 
individuals tends to return to original values 5 years after contact. 
 
On the basis of the characteristics of SIR-susceptibles, we have estimated the frequency of SIR-
susceptibles among individuals with natural and vaccine-induced immunity to define a high-risk 
population in which asymptomatic viral transmission could potentially be investigated. Such 
estimates may become important, since after vaccination antibody titers are lower and more likely 
to wane than after wild-type infection (Weibel et al, 1980; Krugman, 1983; Pedersen et al, 1986; 
Christenson and Böttiger, 1994).  
 
Our study suggests that a subset of individuals which may be transiently contagious, can be 
serologically identified on the basis of their pre-existing immunity and that the estimation of their 
frequency could be relevant for future MV epidemiology and vaccination strategies. Other 
representatives populations have been investigated using the defined thresholds. Our study has 
demonstrated that vaccinated population had a much higher risk of being SIR susceptible (22.2-
33.2% of the population) than individuals protected by natural immunity (3.2-3.9%).  
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Moreover, the vaccine-induced immunity of the older population wanes faster than natural immunity 
(Markowitz et al, 1990; Christenson and Böttiger, 1994), meaning that the proportion of SIR 
susceptible in a population where measles immunity is acquired only by vaccination could be 
potentially much higher that in our estimation. A study from Mossong et al (1999) demonstrated 
that after 25 years, 50% of seroconverted vaccinees would have an antibody titer below protective 
level. If the basic reproduction number of vaccinated SIR-susceptibles exceeds 1.24, elimination of 
measles would be made impossible using the current single-dose vaccination strategy (Mossong et 
al, 1999). 
 
The role of SIR is therefore likely to grow in fully vaccinated populations where SIR could affect 30 
% or more. Vaccination strategies as well as global eradication programs may have to consider the 
increasing number of SIR susceptibility in highly vaccinated populations, and this in addition to 
enhanced susceptibility due to waning immunity. 
 
Therefore, the current research priorities of the WHO with respect to measles include, amongst 
others, the characterization of the immunobiology of the measles virus infection and immunization. 
This goal can be reached by studies of the protective immunity responses including the study of 
humoral and cell-mediated immunity in animals and man, the identification of the B and T cell 
epitopes of protective antigens and to investigate the immune response and characteristics of the 
infection during natural MV infection and immunization. 
 
In our study, we have investigated two strategies aimed at two emerging problems of the current 
vaccination strategy. One is the window of susceptibility in young infants. More and more children 
became infected by measles before the age of vaccination. Earlier vaccination is complicated by 
the presence of maternal antibodies and there is a need for a vaccine that would be able to protect 
the seronegative children until vaccination age. The second strategy is aimed at vaccinees with 
waning immunity. With the increasing proportion of vaccinees in the population, the role of SIR is 
likely to grow. In this strategy, we proposed a set of designer proteins that should boost the T cell 
immunity without being neutralized by residual anti-MV antibodies. 
 
The majority of infants are susceptible to measles by the age of 6-9 months in developing countries 
and 9-12 months in industrialized countries. Therefore, measles-related death is frequent (>50%) 
with children between 6 and 12 month (Aaby et al, 1990). 
 
Current vaccination strategies recommend measles vaccination at 15 months of age in the 
developed countries and at 9 months in the developing world. The development of new vaccines 
for vaccination at earlier age is hampered by persisting transplacentally transferred maternal 
antibodies that neutralize the low dose of live viruses contained in the attenuated vaccine 
(Albrecht et al, 1977) and by the risks of atypical measles (Brodsky, 1972). 
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In this study, we demonstrated that vaccinees have considerably lower antibody titers than those 
protected by wild-type immunity (Damien et al, 1998). We can therefore suggest that vaccinated 
mothers will transfer even less antibodies onto their babies, leading to potentially higher measles-
related mortality in infants below 9 months. 
 
Such factors contribute to a further reduction of child protection by maternal antibodies and to a 
widening of the “window of susceptibility” which delimits the time between the end of the protective 
immunity by maternal antibodies and the age at which the child is routinely vaccinated.  
 
Therefore, there is a need for a “pre-vaccine” that could be administered to young infants before 
the age of routine vaccination. The pre-vaccine proposed here was designed to be restistant to 
maternal antibodies, because it did not include any target sequence for measles neutralizing 
maternal antibodies. It was also supposed to be safe, with respect to atypical measles, because it 
did not include measles-specific human T cell epitopes. The B cell epitope of our construct was a 
mimotope, which does not share sequence homology with the measles protein, but mimicked a 
neutralizing and protective conformational epitope of the fusion protein.  
The candidate vaccine was designed to induce MV-specific neutralizing antibodies, but avoiding 
the induction of MV-specific T cell epitopes. As a result, polyepitopes based on the described 
epitopes should be able to induce protective antibodies without being neutralized by residual 
antibodies and with limited risk of atypical measles. 
 
Unfortunately, immunogenicity studies indicated that the spacer included in our polyepitopes 
induced conformational changes that prevented recognition by the monoclonal antibody used for 
the selection of the mimotope. Numerous examples in the literature showed that the flanking 
regions of an epitope could change its crossreactive immunogenicity (Manca et al, 1993; Stittelaar 
et al, 2001; Hudecz, 2001). Furthermore, the sera obtained with the immunization of mimotope 
peptide indicated that the peptide was not immunogenic, in contrast to the studies by Steward and 
colleagues (Steward et al, 1995; Obeid et al, 1995; Olszewska et al, 2000). In the studies from 
Steward et al (1995), the antibody used to select the mimotope was unable to neutralize the virus. 
Non-neutralizing antibodies can sometimes confer protection but this has not been reported for the 
measles virus. As the spacer used in our constructs rendered our constructs non-immunogenic 
and that the mimotope used was a questionable neutralizing epitope, it was decided to stop the 
study. This series of experiment served as a test bed for further series of experiments and 
demonstrated the importance of the flanking regions in the design of recombinant protein used as 
potential vaccines.   
 
As demonstrated in our study, the level of immunity of vaccinees is less robust than in individuals 
protected by wild-type immunity. Antibody levels are both lower (Damien et al, 1998) and less 
durable in vaccinees (Mossong et al, 2000), although T cells may prolong protections by 
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vaccination beyond the prevalence of antibodies. The waning of immunity in vaccinees may 
become a major problem when the proportion of vaccinees in the population will increase, with 
respect to the WHO target of measles eradication.  
 
Therefore, we also proposed a candidate vaccine designed for the revaccination of vaccinated 
individual with waning immunity as well as for individuals that are susceptible to secondary immune 
responses. 
 
Ideally, a vaccine designed for boosting vaccinees should be resistant to residual virus 
neutralizing antibodies. Unlike our previous strategy, there is no risk of atypical measles in 
boosting the immunity of vaccinees, since they already have the correct T cell priming from their 
first vaccination. Our vaccine strategy is therefore based on the boosting of the T cell response by 
a large number of T cell epitopes of the main immunogenic viral proteins of MV by a protein that 
will not include functional neutralizing B cell epitopes. In this way, we expected that these chimeric 
proteins or polyepitopes would resist antibodies but boost the residual T cell response. The 
presence of numerous TCEs in the vaccine would also help to make the vaccine more resistant to 
immunological pressure and the generation of escape mutants by negating the selective pressure 
induced by current life-attenuated vaccine because of the high homology of the nucleoprotein 
between different strains or even different host species. 
 
The selected constructs were injected into mice and sera were tested for crossreactivity with the 
viral proteins. Two constructs (ABMVH1 and to a lesser extend ABNP1-7) were shown to be able 
to induce MV cross-reactive sera. Such sera were unable to recognize H and F protein present on 
the surface of the WMPT cells superinfected with MV. This suggested that either the sera 
crossreacted with N protein in ELISA, which is not detectable on the cell surface of the WMPT 
proteins, or that the sera reacted with denatured epitopes in the ELISA and is in fact unable to 
recognize native epitopes of the MV.  
 
Experiments to validate one of the two possibilities will require experiments in animal models were 
the virus can replicate. In such models, we would be able to test the eventual T cell proliferation 
generated by our construct and to investigate the presence of eventual anti-NP antibodies induced 
by our candidate vaccine.  
The collected data suggests that the constructs are most likely not recognized by anti-MV 
neutralizing antibodies persisting in vaccinees. We have also shown T cell experiments where our 
constructs were adequately processed and stimulated specific T cell lines. This suggests that our 
T cell vaccine should be able to boost the T cell response in vaccinees without being neutralized 
by persisting antibodies, which would suppress the immune response to the vaccine.  
 
With this series of studies, we have developed two possible strategies of design for candidates 
vaccines aimed at some of the limitation of the current vaccine strategy. These experimental 
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vaccines are trying to offer a long-term solution to the emerging problems of the current measles 
control campaign. 
 
The future of vaccine development sits in the design of improved vaccines, designed using the 
techniques of molecular biology, based on viral or bacterial subunits. Novel vaccines should offer 
high sero-conversion rate and a long term protection along with low vaccine-related side-effects. 
Such vaccine should have a better heat-stability than life-attenuated measles vaccines, should be 
more resistant to maternal antibodies and could be more appropriate for revaccinating vaccinees 
that have lost protection as a result of waning immunity. Such vaccine should also have a long 
shelf-life, be easily administered, be eventually combined with vaccines of other diseases. They 
could explore alternative routes of immunization, for example oral administration, that would not 
require the involvement of trained health workers and avoid the risks of infection associated with 
needles injections.  
 
The fulfillment of all those objectives will require many more years of research before usable 
vaccine candidates can be tested clinically. With this study, the authors hope to have made a small 
contribution towards this long term goal. 
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Design of an immunization strategy based on recombinant proteins of the measles virus  
in the context of a changing epidemiology 
Benjamin DAMIEN – Laboratoire national de Santé - Luxembourg 
 
Recovery from measles normally results in life-long protection, but despite having reached high level 
of global vaccination against measles, outbreaks continue to occur in developing and developed 
countries, because the virus continues to circulate in seronegative individuals. However, there is also 
evidence that measles virus can circulate in seropositive populations. Secondary immune responses 
(SIR) against measles have been observed in fully immunized populations and it is reasonable to 
assume that people undergoing a clinically unapparent SIR after reexposure to measles are the most 
likely seropositive candidates to support transmission of the virus. 
 
Amongst 45 fully protected, measles late convalescent parents reexposed to measles, 4 (9%) 
developed an asymptomatic SIR with a significant increase in MV-specific IgG. SIR was only found in 
individuals with a pre-exposure IgG level below a well defined threshold. Moreover, such immunity 
increase was shown to be only transient. In combination with pre-exposure neutralizing and 
haemagglutination inhibiting titers, a threshold was defined below which SIR is likely to occur. 
 
Our study suggests that a subset of individuals which may be transiently contagious, can be 
serologically identified on the basis of their pre-existing immunity and that the estimation of their 
frequency could be relevant for future MV epidemiology and vaccination strategies. Other 
representatives populations have been investigated using the defined thresholds. Our study shows 
that vaccinated population had a much higher risk of being SIR susceptible (22.2-33.2% of the 
population) than individuals protected by natural immunity (3.2-3.9%). Although viral transmission 
between protected individuals has never been directly demonstrated, the data describe a population in 
which protected but infections persons could potentially be of epidemiological importance. 
 
In our study, we have investigated two strategies aimed at two emerging problems of the current 
vaccination strategy. One is the window of susceptibility in young infants.  Vaccination before 9 
months is made difficult by the presence of maternal antibodies and there is a need for a vaccine that 
would be able to protect the seronegative children until vaccination age, without risks of atypical 
measles. Our developed pre-vaccine was designed to be resistant to maternal antibodies, because it 
did not include any target sequence for measles neutralizing maternal antibodies. It was also 
supposed to be safe, with respect to atypical measles, because it did not include measles-specific 
human T cell epitopes. The B cell epitope of our construct was a mimotope, which does not share 
sequence homology with the measles protein, but mimicked a neutralizing and protective 
conformational epitope of the fusion protein. Unfortunately, immunogenicity studies indicated that the 
spacer included in our polyepitopes induced conformational changes that prevented recognition by the 
monoclonal antibody used for the selection of the mimotope. Furthermore, the sera obtained with the 
immunization of mimotope peptide indicated that the peptide was unable to induce neutralizing 
antibodies.  
 
In a second part of our study, we proposed a candidate vaccine designed for the revaccination of 
vaccinated individual with waning immunity as well as for individuals that are susceptible to secondary 
immune responses. Our vaccine strategy was therefore based on the boosting of the T cell response 
by a large number of T cell epitopes of the main immunogenic viral proteins of MV by a protein that will 
not include functional neutralizing B cell epitopes, to prevent neutralization by remaining antibodies. 
Two constructs were shown to be able to induce MV cross-reactive but not neutralizing sera.  We have 
also shown T cell experiments where our constructs were adequately processed and stimulated 
specific T cell lines. This suggests that our T cell vaccine should be able to boost the T cell response 
in vaccinees without being neutralized by persisting antibodies, which would suppress the immune 
response to the vaccine.  
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Mise au point d’une stratégie d’immunisation basée sur des protéines recombinants du virus 
de la rougeole, dans le contexte d’une épidémiologie changeante 
Benjamin DAMIEN – Laboratoire national de Santé - Luxembourg 
 
La guérison de la rougeole résulte normalement en une protection à vie, mais, malgré avoir atteint de 
hauts niveaux de vaccination contre la rougeole dans le monde, des épidémies continuent à 
apparaître aussi bien dans les pays en voie de développement que dans les pays développés, 
principalement parce que le virus continue de circuler grâce aux individus séronégatifs. Néanmoins, il 
y a également des preuves que le virus peut circuler dans le sang d’individus séropositifs. Des 
réponses immunitaires secondaires (RIS) contre la rougeole ont déjà été observées dans des 
populations totalement immunisées et on peut penser que des individus qui subissent une réponse 
immunitaire secondaire asymptomatique après réexposition à la rougeole sont les plus sérieux 
candidats séropositifs pouvant être responsables de la transmission du virus. 
 
Parmi 45 parents protégés, ayant contracté la rougeole dans leur jeunesse, 4 (9%) ont développé une 
RIS avec une augmentation significative de leurs IgG spécifiques à la rougeole. Cette RIS a été 
détectée uniquement chez des individus avec un niveau d’IgG avant exposition inférieur à une limite 
bien définie. De plus, cette croissance du niveau de leur immunité était seulement temporaire. En 
combinant IgG, titres de neutralisation et d’inhibition d’hémagglutination, un niveau a été défini, en 
dessous duquel une RIS était susceptible de se produire. 
 
Notre étude suggère qu’un groupe d’individus, qui peut être temporairement contagieux, peut être 
défini sérologiquement sur base de leur niveau d’immunité à la rougeole et que l’estimation de leur 
susceptibilité à la RIS pourrait être importante pour de futures études épidémiologiques de la rougeole 
et pour l’élaboration de stratégies de vaccination. D’autres populations représentatives ont été 
étudiées en utilisant les limites définies précédemment. Notre étude montre qu’une population 
vaccinée a un risque plus élevé de susceptibilité à la RIS (22.2-33.2% de la population) que des 
individus qui ont acquis leur immunité naturellement (3.2-3.9%). Bien que la transmission virale entre 
individus immunisés n’ait jamais été prouvée, nos données décrivent une population dans laquelle des 
individus protégés mais potentiellement infectieux pourraient avoir une importance du point de vue 
épidémiologique. 
 
Dans la suite de notre étude, nous avons expérimenté deux stratégies visant deux problèmes 
émergents des stratégies de vaccinations actuelles. L’un est la fenêtre de susceptibilité chez les 
jeunes enfants. La vaccination avant l’âge de 9 mois est rendue difficile par la présence d’anticorps 
maternels, et il y a donc un besoin pour un vaccin capable de protéger ces enfants séronégatifs 
jusqu'à l’âge de vaccination, sans risques de provoquer une rougeole atypique. Le pré-vaccin que 
nous avons développé a été étudié pour être résistant aux anticorps maternels car il n’inclut pas 
d’épitopes étant la cible d’anticorps neutralisants. Il est également supposé être sûr, du point de vue 
de la rougeole atypique, car il ne comporte pas d’épitopes T humains spécifiques de la rougeole. 
L’épitope B utilisé dans nos épitopes était un mimotope, qui n’a pas de séquence commune avec des 
protéines du virus de la rougeole, mais qui imite la conformation tridimensionnelle d’un épitope 
conformationnel décrit comme neutralisant et protecteur. Malheureusement, nos études 
immunologiques nous ont indiqué que l’élément espaceur utilise dans nos constructions provoquait 
des changements de conformation et empêchait sa reconnaissance par notre anticorps monoclonal 
utilisé pour la sélection du mimotope. De plus, le sérum obtenu par l’immunisation du mimotope nous 
a permis de démontrer que ce peptide était incapable d’induire la production d’anticorps neutralisants.  
 
Dans une seconde partie de notre étude, nous avons proposé un candidat vaccin destiné à la 
revaccination d’individus vaccinés et ayant perdu leur immunité, ainsi que pour des individus 
susceptibles de faire une RIS. Notre stratégie de vaccination était donc basée sur la restimulation de 
leur réponse lymphocytaire T par une protéine recombinante contenant un grand nombre d’épitopes T 
provenant des protéines de rougeole les plus immunogènes, mais pas d’épitope B fonctionnel. Deux 
protéines recombinantes ont montré qu’elles étaient capables d’induire des anticorps qui réagissaient 
également avec la rougeole mais sans être neutralisants. Nous avons également montré dans une 
expérience de prolifération de lymphocytes T que nos protéines recombinantes étaient correctement 
traitées et stimulaient des lignées de lymphocytes T spécifiques. Cela suggère que notre vaccin à 
lymphocyte T devrait être capable de restimuler la réponse lymphocytaire T des vaccinés mais sans 
être neutralisé par les anticorps restants, ce qui éliminerait toute réponse possible contre le vaccin.  
 
